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Abstract 
RAL proteins (RALA and RALB) are small GTPases that operate downstream 
of the proto-oncogene RAS. They are known to activate a signalling network 
controlling membrane trafficking, cell migration and gene transcription. Whilst 
RAL isoforms are recognised as having overlapping but non-redundant 
functions, despite their high degree of structure homology, in general the 
isoform specific contributions of RAL signalling remain poorly understood.  
Most of our understanding of RAL biology has derived from ectopic expression 
studies. However, the general consensus is that studying endogenous protein 
levels is highly advantageous. Here, the generation of a panel of gene edited 
colorectal cancer cell lines, harbouring different RAS mutations, enabled 
profiling of the wider network responses influenced by each RAL isoform as 
an effector of RAS. 
Using RNA sequencing, the transcriptome of isoform specific RAL knockout 
isogenic cell lines was characterised. A subset of genes expressed in both cell 
lines that showed differential expression was identified. In order to infer likely 
protein expression differences as a result of RAL isoform loss, the RNA 
sequencing analysis was integrated with proteomic data obtained from RPPA 
technology. The combination of these two methodologies highlighted RAL 
responsive proteins that provide evidence the RALGEF/RAL pathway is 
involved in crosstalk between the other well-known RAS effector pathways, 
particularly proteins involved in MAPK signalling. This also extended to 
expression changes in proteins involved in RAS-driven processes such as cell 
proliferation. 
Turning attention to RAL itself, activity assays revealed an increase in activity 
levels of the remaining RAL isoform in the knockout clones, compared to the 
parental, with significant RALB activity increases recorded in the RALA 
knockout clones across all the RAS mutant cell lines tested. It is likely that this 
compensatory activity results in functional redundancy for both proteins. In 
addition to RAL activity levels, combining targeting SRM-based proteomics 
with an isotope-labelled protein standard strategy enabled the most accurate 
measurement of cellular RAL isoform abundance to date. On the whole, this 
panel of colorectal cancer cell lines require sufficient levels of both RAL 
isoforms for proper signalling, with RALB expression being slightly more 
dominant than RALA. This again supports the idea of high levels of signalling 
compensation between the two isoforms in colorectal cancer, with any 
differences in RAL isoform function likely extending from different subcellular 
locations. Using genome-wide and protein expression/activity analysis 
techniques has allowed large scale profiling of isoform specific RAL signalling. 
Together, the data presented in this thesis provides a novel insight into RAL 
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Chapter 1: Introduction 
1.1 RAL small GTPases 
1.1.1 Evolutionary Biology and Structure of RAL 
To date, over 250 small GTPases have been identified as being part of the 
RAS superfamily (Cox and Der, 2010). Differences in the sequence, structure 
and function of these small GTPases allow them to be divided into five main 
groups, one of which is the RAS family. The RAL small GTPases are members 
of this RAS branch (Figure 1.1A) and due to the high degree of sequence 
similarity, are the closest relative of the RAS proteins, hence the basis for their 
names RAL (RAS-like). 
The RAL gene was first identified in 1986 during a search for genes related to 
RAS in a simian cDNA library established from immortalised B-lymphocytes 
(Chardin and Tavitian, 1986). Three years later, the human RAL orthologs; 
RALA and RALB were identified using the simian RAL cDNA as an 
oligonucleotide probe in a human cDNA library (Chardin and Tavitian, 1989). 
Since then, RALA and RALB isoforms have been found in all vertebrate 
species (van Dam, Bos and Snel, 2011), as well as single RAL genes present 
in C. elegans (RAL-1) and Drosophila (RALA) (Frische et al., 2007) (Figure 
1.1A). 
Despite the genes for RALA and RALB residing on different chromosomes, 
chromosome 7 and 2 respectively, the isoforms share >80% overall amino 
acid sequence identity (Figure 1.1B) (Gentry et al., 2014). The tertiary 
structure of both proteins consists of an 11-amino acid N-terminal followed by 
a G-domain, containing two switch regions, and a C-terminal membrane 
targeting sequence (Figure 1.1C). Whilst the switch I (SI) and switch II (SII) 
regions of the G-domain, responsible for regulator and effector interactions, 
share almost 100% sequence identity, the C- terminals differ considerably, 
with only 50% similarity. This hypervariable region contains important post-
translational phosphorylation sites that play an essential role in membrane 
association and localisation and consequent effector interaction. 
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Figure 1.1 Conservation of RAL small GTPases.  
A) RAL is part of the RAS branch of the RAS small GTPase superfamily. RALA and RALB 
isoforms are shown here alongside the four key RAS proteins and other members of the RAS 
family. RAL isoforms are found in all vertebrate species, whilst only a single RAL ortholog is 
present in D. melanogaster (Dm) and C. elegans (Ce). B) Human and invertebrate RAL 
orthologs display strong sequence identity. C) Schematic of RAL small GTPases and the 
amino acid differences between the two isoforms RALA and RALB. The G domains of the 
RAL isoforms share 88% sequence identity. The C-terminal hypervariable region contains key 
phosphorylation sites (red) that regulate isoform subcellular location and effector interaction. 
Thus, they exhibit only 50% sequence identity. Dendrograms and sequence identities were 







1.1.2 RAL activation and regulation 
Like other small GTPases, RAL cycles between a GTP-bound active state and 
GDP-bound inactive state (Figure 1.2A) (Gentry et al., 2014). As mentioned 
previously, the SI and SII regions of the G-domain are involved in regulator 
and effector recognition and the conservation of these two switch sequences 
can be found in the RAL proteins of C. elegans and Drosophila, supporting the 
interaction of RAL with conserved regulator and effector proteins. 
Similar to RAS, the intrinsic GTPase activity of the RAL proteins is very weak 
(Goody, Frech and Wittinghofer, 1991). Therefore, GDP-GTP exchange and 
GTP hydrolysis is accelerated by the presence of RAL guanine nucleotide 
exchange factors (RALGEFs) and RAL GTPase activating proteins 
(RALGAPs). With the intracellular levels of GTP ~10 times higher than GDP 
(Goody, Frech and Wittinghofer, 1991), the formation of RAL-GTP is favoured 
by RALGEFs, that subsequently stimulate the exchange of GDP for GTP. 




Currently, there are seven known RALGEFs that can be divided into two 
groups (Figure 1.2B). The first group includes RALGDS, RGL1, RGL2, and 
RGL3. These proteins rely on RAS activation by binding directly to the effector 
binding region of active RAS. Whereas the second group (RGL4, RALGPS1 
and RALGPS2) can be activated in a RAS-independent manner (Gentry et al., 
2014). 
RAL guanine nucleotide dissociation stimulator (RALGDS) was discovered in 





Figure 1.2 Small GTPase RAL GDP-GTP cycle.  
A) Regulation of RAL is carried out by selective GEFs and GAPs that accelerate GTP 
hydrolysis, which promotes the formation of active GTP bound and inactive GDP bound RAL. 









(Albright et al., 1993; Hofer et al., 1994). RALGDS was the first RALGEF to be 
identified and therefore the most characterised. It has been shown to be RAL 
specific (Albright et al., 1993), catalysing nucleotide exchange on both RALA 
and RALB but not on other small GTPases. Further yeast two-hybrid library 
screen studies identified three more RALGEF proteins named RGL1 
(RALGDS-like), RGL2 and RGL3 (Kikuchi et al., 1994; Isomura et al., 1996; 
Shao and Andres, 2000; Wolthuis et al., 1996). These RALGEFs were found 
to contain a similar domain architecture that includes a RAS exchanger motif 
(REM) domain at the N-terminal, followed by a CDC25 homology domain and 
a C-terminal RAS-association (RA) domain (Ferro and Trabalzini, 2010). The 
CDC25 homology domain and the catalytic domains of RASGEFs share 
sequence identity, allowing activated RAS to recruit RALGEFs onto the 
plasma membrane and deliver them to RALA and RALB (van Dam, Bos and 
Snel, 2011). As well as HRAS, KRAS and NRAS, other RAS family small 
GTPases are able to bind and activate RALGEFs through the RA domain 
(Rodriguez-Viciana, Sabatier and McCormick, 2004). Furthermore, a 
complementary mechanism of RALGEF activation, specifically RALGDS, has 
been shown to occur through the more familiar RAS target protein, PI3K (Tian 
et al., 2002). The activation of PI3K promotes the binding of the PDK1 protein 
kinase to the N-terminus of RALGDS, which subsequently alleviates the 
inhibitory effect of the N-terminus on its catalytic domain allowing it to bind to 
RAL. 
The second group of RALGEFs, RGL4, RALGPS1 and RALGPS2 also contain 
the CDC25 homology domain but lack the REM and RA domains, uncoupling 
them from association with RAS and the RAS family of small GTPases 
(D'Adamo et al., 1997; de Bruyn et al., 2000; Rebhun, Chen and Quilliam, 
2000). Instead, RALGPS1 and RALGPS2 contain a C-terminal pleckstrin 
homology (PH) domain that has been shown to be involved in membrane 
targeting and RAL activation (Rebhun, Chen and Quilliam, 2000). Whilst RGL4 
does contain this CDC25 homology domain, a well-defined RA or PH domain 
is absent and its activation mechanism is still poorly understood. Although the 
RALGEFs mentioned previously are highly selective RAL activators, RGL4 is 




Like RALGEFs, RALGAP activity was also reported in the early 1990s (Emkey, 
Freedman and Feig, 1991). However, molecular identification of these proteins 
has only recently been achieved. Using a GTPase-deficient, constitutively 
active RALA mutant for affinity chromatography, two RALGAP complexes, 
RALGAP1 and RALGAP2 were identified from brain cytosol (Shirakawa et al., 
2009). RALGAPs (Figure 1.2B) are heterodimers each consisting of a 
RALGAPβ regulatory subunit and one of two RALGAPα1 and α2 catalytic 
subunits (Chen et al. 2011) (Chen et al., 2011b). As with the RALGEFs, 
RALGAPs are RAL specific, only accelerating the GTPase activity of both 
RALA and RALB but no other small GTPases (Shirakawa et al., 2009; Chen 
et al., 2011b; Martin et al., 2014). Relatively little is known about these RAL 
specific GAP proteins. However, the subunit RALGAPβ was found to play an 
important role in RAL-mediated spindle formation regulation during mitosis 
(Personnic et al., 2014) and RALGAPα2 (previously known as AS250; AKT 
substrate of 250 kDa) is known to undergo phosphorylation by AKT, reducing 
its interaction with RALA (Chen et al. 2011). 
 
Post-translational modification 
RALA and RALB exhibit the most significant sequence divergence in their C-
terminal hypervariable region (Figure 1.1C). Like RAS, RALA and RALB 
terminate in a CAAX motif sequence (C = cysteine, A = aliphatic amino acid, 
X= any amino acid), which undergoes a series of posttranslational 
modifications that are necessary for membrane association (Gentry et al., 
2015). The terminal X residue at the end of the CAAX motif, determines protein 
prenyltransferase specificity. The CAAX motif are CCIL and CCLL for RALA 
and RALB respectively.  In the case of both RAL isoforms, the presence of the 
leucine (L) residue signals for the addition of an isoprenoid lipid to the first 
cysteine (C), which is carried out by geranylgeranyltransferase type I 
(GGTase-I). Modifications of the CAAX motif are critical for normal RAL 
function and mutation of the cysteine residue preventing these necessary 
changes, disrupts RAL association with the plasma membrane (Falsetti et al., 
2007). Whilst both isoforms can be found at the plasma membrane and 
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endomembranes of the cell, this sequence divergence results in distinct 
subcellular localisation that subsequently contributes to functional difference 
between the two proteins.  
In addition to the prenylation of the CAAX motif, RAL subcellular location is 
also regulated by reversible post-translational modifications through 
phosphorylation of RAL at the C-terminal region with distinct protein kinases. 
Aurora-A kinases and protein kinase A (PKA) were found to phosphorylate 
RALA at residue S194 (Wu et al., 2005; Lim et al., 2010), with 
dephosphorylation at the same residue carried out by protein phosphatase 2A 
(Sablina et al., 2007). Phosphorylation of RALA at S194 by Aurora A alters 
subcellular location of RALA from the plasma membrane to internal 
membranes, allowing for enhanced interaction with the effector RALBP1 (Lim 
et al., 2010). Aurora A phosphorylation of RALA also promotes translocation 
to the mitochondrial outer membrane, where it again recruits RALBP1 to 
stimulate mitochondrial fission (Kashatus et al., 2011). 
Studies have revealed RALB is similarly regulated through phosphorylation of 
residue S198 by protein kinase C alpha (PKCα), relocating it from the plasma 
membrane to the endocytic vesicles (Martin et al., 2012; Wang et al., 2010). 
In addition to changes in subcellular location, phosphorylation of both isoforms 
is associated with a change in effector utilisation. Unphosphorylated RALB 
preferentially binds to the effector Sec5, whilst S198 phosphorylation leads to 
preferential association with RALBP1 (Gentry et al., 2014). Together, 
alteration of RALs GTP and GDP bound state by GEFs and GAPs, C-terminal 
posttranslational modifications and phosphorylation provide spatial and 
temporal regulation of RAL and allow cells to respond to different stimuli in 








1.2 RAL function  
1.2.1 RAL effectors 
Following activation, GTP bound RAL carries out various biological functions, 
such as cytoskeleton organisation, membrane trafficking, transcription 
regulation and kinase signalling (Figure 1.3), via different effector binding 
proteins. Since RALA and RALB are regulated by the same set of proteins and 
have the same enzymology, they are able to interact with the same set of 
effectors. The best characterised proteins being RALBP1/RLIP76 and the 
Sec5/Exoc2 and Exo84/Exoc8 subunits of the octameric exocyst complex. As 
described earlier, a combination of regulatory processes leads to differences 
in subcellular localisation. Therefore, even though the effector proteins are the 
same, distinct functions can arise. 
 
RALBP1/RLIP76 
RAL binding protein 1 (RALBP1) was the first effector of RAL to be discovered 
in screens searching for proteins that preferentially bound to RALA (Cantor, 
Urano and Feig, 1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995). 
The most extensively studied effector of RAL, RALBP1 is a 76 kDa protein that 
includes a binding domain that is able to bind to both switch regions of GTP-
RAL (Fenwick et al., 2010). RALBP1 itself binds to a diverse group of proteins 
and bears RHOGAP activity for CDC42 and RAC1 (members of the RHO 
branch of the RAS superfamily) small GTPases (Wennerberg, Rossman and 
Der, 2005). These proteins are involved in cytoskeletal changes such as actin 
dynamics, filopodia and lamellipodia formation and membrane ruffling (Park 
and Weinberg, 1995). Overexpression of RALBP1 has also been found in 
different human cancers, with RALBP1 suppression impairing tumourigenic 
growth in vivo (Singhal et al., 2007), regulating oral cancer cells via AKT 
(Ieong, Ma and Lai, 2019) and inducing resistance to apoptosis in breast and 
prostate cancer (Singhal et al., 2019; Yang et al., 2015). However, it should 
be noted that any phenotypes attributed to RALBP1, are not necessarily linked 
with RAL signalling. 
RALBP1 has additional functions that regulate endocytosis and signal 
transduction. The N-terminus of RALBP1 can associate with the AP2 adaptor 
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complex, a regulator of clathrin-mediated endocytosis (Jullien-Flores et al., 
2000), whilst the C-terminal region interacts with Reps1 and Reps2 
(Yamaguchi et al., 1997; Ikeda et al., 1998; Nakashima et al., 1999). These 
are important proteins involved in receptor tyrosine kinase-regulated 
endocytosis (Cullis et al., 2002; Morinaka et al., 1999). Prevention of 
endocytosis during mitosis has also been linked with the RALA induced 
activation of RALBP1 (Rossé et al., 2003). The C-terminus of RALBP1 
associates with cyclin B1 and subsequently form complexes with CDK1, which 




Figure 1.3 RAL and its effectors and effector functions.  
RAS activated RAL can regulate a variety of downstream effectors that modulate numerous 
cellular processes. Cell cycle progression is regulated through PLD cytokinesis, and gene 
transcription through ZONAB. RAL associates with the subunits Sec5 and Exo84 to regulate 
exocyst processes while cytoskeletal changes are modulated by Filamin. RALBP1 acts as a 
scaffold for proteins involved in endocytosis.  
 10 
Several other RAL-driven processes require RALBP1 as a key effector. Many 
of these studies utilise RAL isoforms that have selective mutations impairing 
effector interaction to determine protein function. For example, the D49N 
substitution impairs RAL-RALBP1 but not RAL-Sec5/Exo84 binding, whereas 
a D49E mutation results in the opposite effect (Cantor, Urano and Feig, 1995; 
Moskalenko et al., 2002; Moskalenko et al., 2003). Consequently a D49E 
mutation was important in discovering that RALBP1 was a critical effector for 
the RALB-specific function of invadopodia formation, after rescuing the loss of 
endogenous RALB following shRNA silencing (Neel et al., 2012). 
RALA inhibits TGFβ-mediated growth arrest in epithelial cell through the 
mislocalisation of the cyclin-dependent kinase inhibitor p27 KIP1 (Tazat et al., 
2013). This process appears to rely on the RHOGAP domain of RALBP1. 
Recruitment of RALBP1 by RALA to the mitochondria is required for 
mitochondrial fission during mitosis (Kashatus et al., 2011). Fission is 
necessary for the proper distribution of mitochondria to daughter cells during 
cell division and is controlled by the GTPase DRP1 present on the outer 
mitochondrial membrane. Once recruited, RALBP1 acts as a scaffold that 
facilitates the phosphorylation of DRP1 by cyclin B/CDK1 complexes. Loss of 
mitochondrial fission was observed following suppression of either RALA or 
RALBP1. 
 
The Sec5 and Exo84 subunits of the exocyst  
Both Sec5(Exoc2) and Exo84(Exoc8) are key subunits of the exocyst 
complex, which plays an essential role in the generation of exosomes and cell 
migration. This multiprotein complex is responsible for trafficking various 
secretory vesicles to specific regions of the plasma membrane (He and Guo, 
2009). 
The association of these two subunits with RAL has been found to be 
important in exocytosis (Moskalenko et al., 2002; Moskalenko et al., 2003; 
Sugihara et al., 2002; Camonis and White, 2005). Sec5 binds to the switch I 
region of RAL (Fukai et al., 2003) and mediates the delivery of membrane 
proteins in epithelial cells as well as vesicle secretion in neuronal cells 
following direct binding to RALA (Moskalenko et al., 2002). The Exo84 subunit 
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binds to both switch regions of activated RAL (Jin et al., 2005) and is essential 
for RAL-mediated assembly of the hetero-octameric exocyst complex 
(Moskalenko et al., 2003). The subcellular localisation of the exocyst is 
regulated by RAL promoting Sec5-paxillin interactions and the subsequent 
assembly of the whole exocyst complex including Exo84 (Spiczka and 
Yeaman, 2008). 
RAL is also capable of interaction with Sec5 and Exo84 to regulate cellular 
processes that are independent of their roles in exocytosis. The employment 
of Sec5 by RALB is important in activating the innate immune response (Chien 
et al., 2006). The interaction between RALB and Sec5 results in Sec5 binding 
with the protein kinase TBK1, which is known to regulate NF-κB signalling. 
On the other hand, during nutrient starvation or the presence double-stranded 
DNA, RALB engages with the EXO84 subunit and the exocyst, which in turn 
upregulates autophagosome formation (Shi et al., 2012; Bodemann et al., 
2011). The interaction between RALB and EXO84 triggers the assembly of the 
serine/threonine kinase ULK1 and the Beclin1-Vps34 autophagy initiation 
complex. This differential interaction between RALB and either Sec5 or Exo84 
is achieved molecularly by ubiquitylation of RALB at Lysine 47, which is 
controlled by the deubiquitylase USP33 (Simicek et al., 2013). Here, 
ubiquitination inhibits EXO84 binding and facilitates SEC5 interaction. These 
data suggest that RALB in association with different exocyst subunits acts as 
a regulatory hub that trigger specific cellular responses supporting systemic 
pathogen recognition and removal. 
 
Transcription Factors and other effectors 
RAL also has other lesser-characterised effectors, one of which is 
phospholipase D1 (PLD1) (Luo et al., 1998; Kim et al., 1998). Unlike other 
effectors, the association of PLD1 with RAL is not GTP dependent. Instead of 
the effector binding domain, the association is with the N-terminus of RAL. 
PLD1 is an important second messenger protein involved in the conversion of 
phosphotidylcholine to phosphatidic acid and choline following G-protein 
coupled receptor (GPCR) stimulation. RALA-PLD1 binding is also important in 
the localisation of p27; a cyclin-dependent kinase inhibitor, thus promoting 
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proper TGFβ signalling (Tazat et al., 2013). Additionally, RALA is necessary 
for PLD1-mediated activation of mTORC1 signalling (Xu et al., 2011). 
Filamin is an important protein of the cytoskeleton, playing a role in actin 
crosslinking and the formation of lamellipodia. RALA was found to interact with 
filamin and induce filopodia formation in Swiss-3T3 cells (Ohta et al., 1999). 
Lastly, RAL has been shown to engage with several transcription factors. At 
high cell densities, RALA engages with ZONAB (zonula occludens 1-
associated nucleic acid binding protein), unlocking ZONAB targets for 
transcription in MDCK cells (Frankel et al., 2005). 
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Other examples of transcription factor regulation by RAL, include the 
phosphorylation of c-JUN through JNK (de Ruiter et al., 2000), ROS-induced, 
JNK-dependent regulation of FOXO (forkhead box O) transcription factors by 
promotion of a JIP1 scaffold complex (van den Berg et al., 2016), STAT3 
activation following EGF stimulation through the non-receptor tyrosine kinase 
SRC (Goi et al., 2000) and B cell receptor (BCR)-controlled activation of 
JUN/ATF2 and NFAT (de Gorter et al., 2007). 
Although RALA and RALB are structurally similar and are known to bind to the 
same set of effector proteins, they have been observed as having isoform-
specific functions (Table 1.1). Nonetheless, it seems that both RAL proteins 
are involved in a wide variety of biological processes. Whilst these studies 
have greatly assisted in determining the role of RAL under normal cellular 
physiology, it should be noted that all interactions and observations of RAL 
were determined following the use of gene knockdown and gene 
overexpression techniques. Although the use of RNAi, is a direct approach to 
gene disruption and loss of function, off-target effects are a growing concern. 
The siRNA induced silencing of non-target mRNA transcripts is particularly an 
issue (Carthew and Sontheimer, 2009), as potentially hundreds of transcripts 
(Sigoillot and King, 2011) can be repressed resulting in phenotypes that 
dominate over the intended target phenotype (Franceschini et al., 2014). 
Overexpression of proteins poses its own problems and limitations, such as 
the burden protein production puts on the cellular resources, stoichiometric 
imbalance, promiscuous protein interaction and pathway modulation (Moriya, 











1.2.2 RAL and cancer 
Since RALGEFs act as direct downstream effectors of activated RAS, it was 
suggested that RAL signalling may contribute to RAS-driven tumourigenesis. 
Perhaps surprisingly, early studies in NIH 3T3 mouse fibroblasts found that 
only the RAF effector pathway and not RAL was sufficient to mediate RAS-
driven cellular transformation (Urano, Emkey and Feig, 1996). However, later 
studies exploring the role of RAL in RAS-dependent transformation in 
immortalised human cell supported a more significant role for RAL GTPases 
as effectors of RAS in human cancers (Hamad et al., 2002). Following 
depletion of either RAL isoform via RNAi, it was further demonstrated that 
RALA but not RALB is necessary for anchorage-independent growth of cancer 
cells whereas RALB is required for tumour cell survival (Chien and White, 
2003). 
It should be noted that since RALGEFs can be activated and regulated by RAS 
independent mechanism, any involvement of RAL GTPases in cancers, where 
RAS mutations are not present is not surprising. Indeed, a critical role for RAL 
in both tumourigenesis and metastasis in many types of human cancer has 
been established. 
 
Pancreatic ductal adenocarcinoma (PDAC) 
Pancreatic cancer is one of the most popular models for studying the role that 
RAL plays in human cancer, due to the high frequency of activating KRAS 
mutations present (>90%, COSMIC database) and the activation of RAL seen 
in both tissue samples and tumour cell lines (Jones et al., 2008; Lim et al., 
2005; Lim et al., 2006). Within these studies, activation of RAL was found to 
be more common than that of either ERK or AKT, suggesting a key role for 
RAL signalling downstream of oncogenic KRAS besides the RAF and PI3K 
effector pathways. 
Stable shRNA suppression of RALA, but not RALB, in established primary 
tumours resulted in tumour regression, indicating persistent RALA signalling 
is necessary for PDAC tumour maintenance in addition to tumour initiation 
(Lim et al., 2006). Distinct roles of RAL in RAS-driven cancers has been 
confirmed by another study showing active KRAS signalling to RALB but not 
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RALA is involved in invadopodia formation in human pancreatic cancer cells 
(Neel et al., 2012). This supports the idea of a role for RALB in metastasis, 
since invadopodia are known to be involved in the secretion of matrix 
metalloproteases (MMPs) during tumour cell invasion. 
Other members of the RAL pathway have been found to play a role in PDAC. 
The RALGEF protein RGL2 is overexpressed in patient tumours and has been 
shown to be a requisite for anchorage independent growth and invasion of 
PDAC tumour cells (Vigil et al., 2010). Indeed, RNAi-mediated depletion of 
RGL2 led to a significant decrease in both RAL isoform activation. It should be 
highlighted that involvement of RAL regulators in cancer progression does not 
necessarily require RAL itself and interestingly, expression of constitutively 
active RALA did not rescue soft agar growth after the loss of RGL2. This may 
be due to RGL2 having non-RAL dependent regulatory functions or that the 
interaction between RALA and RGL2 is critical for the regulation of anchorage-
independent growth that was observed (Vigil et al., 2010). The idea of different 
roles carried out by RAL isoforms in cancer is supported by the co-localisation 
of RGL2 with RALB but not RALA at the leading edge of CFPac-1 PDAC cells 
during migration. Again, loss of RGL2 is accompanied by loss of RALB from 
the leading edge, suggesting that PDAC migration and invasion may rely on 
RGL2/RALB signalling. 
As well as consistent hyperactivity of RALA and RALB seen across pancreatic 
cell lines and tumour samples, loss of RAL control was found to be a risk factor 
for pancreatic cancer development in vivo (Beel et al., 2020). Here, 
deregulation of the GTPases κB-RAS1 and κB-RAS2 (NF- κB inhibitor 
interacting RAS-like protein 1/2) results in upregulation of RAL activity through 
the loss of RALGAP function, promoting acinar-to-ductal metaplasia (ADM) 
during tumour initiation and progression. 
 
Colorectal carcinoma 
As in pancreatic cancer, a high frequency of oncogenic KRAS mutations are 
present in colorectal cancer (CRC) tumours (45%, COSMIC database). 
Proliferation of KRAS mutated colorectal cancer cell lines was found to be 
significantly reduced following RALA knockdown (Győrffy et al., 2015). 
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Furthermore, identification of a RALA-responsive gene expression signature 
from these cell lines, correlated with progression-free survival of colorectal 
cancer patients in five independent data sets. 
RALA and RALB have been found to be upregulated in both colorectal cancer 
cell lines and patient samples (Martin et al., 2011). Knockdown of RALA 
resulted in a decrease in soft agar colony growth, whereas RALB knockdown 
had the opposite effect and led to enhancement of anchorage-independent 
growth of cancer cells. This contrasting phenotype was found to be attributed 
to the differential use of common RAL effector proteins. Both RAL isoforms 
required interaction with RALBP1 but with different subunits of the exocyst. 
RALA binds to Exo84, whereas RALB interacts with Sec5 to carry out their 




In contrast to colorectal and pancreatic cancer, RALA and RALB have been 
found to have redundant effects on the growth of non-small cell lung cancer 
(NSCLC) tumour cells. Depletion of both RALA and RALB or either one alone, 
reduced anchorage independent growth in KRAS mutant NSCLC cell lines 
(Ihle et al., 2012). Analysis of RAL expression in NSCLC patient tumours found 
that both RAL isoforms had higher expression in those with a KRAS mutation 
and was associated with poor survival (Guin et al., 2013). However, only RALA 
activity levels were found to be elevated in KRAS-mutant NSCLC cell lines, 
suggesting it’s RALA that plays a role in tumour growth. Interestingly, a 
relationship between KRAS mutation and RAL dependence has been 
established across many NSCLC cells, where KRAS G12C or G12V mutations 
have been found to carry an increased sensitivity to RAL depletion, supporting 
the importance of RAL signalling for tumour growth downstream of RAS (Ihle 
et al., 2012). 
 
Other cancers 
Increased activation of RALA and RALB has been detected in human bladder 
cancer cell lines (Smith et al., 2007; Saito et al., 2013), with similar tumour 
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growth functions but opposite roles in motility found in the KRAS mutant 
UMUC3 line (Oxford et al., 2005). This motility promoting function of RALB 
was found to be dependent on its post-translational phosphorylation 
modification by protein kinase C (Wang et al., 2010). 
RALA was recorded as being significantly overactivated in hepatocellular 
carcinoma (HCC) cells and tissues, with suppression of expression leading to 
a decrease in viability and invasiveness of HCC cells (Ezzeldin et al., 2014). 
Analysis of RAL activation in human melanoma cells showed a consistent 
increase in total and activated levels of RALA and were shown to be necessary 
for the tumourigenic growth of melanomas (Zipfel et al., 2010). Ectopic 
expression of the RALGEF RGL2, mutated to mimic RAS activation, 
sufficiently promoted anchorage independent growth of melanocytes, whilst 
the expression of a RALB mutant, that blocks RALGEF function, impaired the 
growth of transformed melanocytes (Mishra et al., 2010). 
Elevated RAL expression has also been observed in malignant peripheral 
nerve sheath tumours (Bodempudi et al., 2009), prostate cancer (Yin et al., 
2007) and medulloblastomas (Ginn et al., 2016). Squamous cell carcinoma 
(SCC) is one exception, where RALA was found to suppress rather than 
promote tumour progression in SCC cell lines (Sowalsky et al., 2010) and a 
RALA gene expression signature supporting this tumour suppressor function 
was downregulated in cancer tissues (Smith et al., 2012). 
 
Together, these studies provide increasing evidence of RAL GTPases playing 
a key role in cancer cell growth. Across most cancer types examined, the 
expression and activation levels of RALA and RALB was increased in patient 
tumour samples compared with normal tissue. Studies utilising human cancer 
cell lines have established that, in general, RALA is required for anchorage-
independent growth, whereas RALB is important in tumour survival and 
invasion. Consequently, the idea that RAL may contribute to oncogenic RAS 
function should not be discounted and when it comes to identifying 
pharmacologic approaches for correcting aberrant RAL function, both isoforms 
should be targeted simultaneously. 
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1.3 Targeting RAL signalling 
1.3.1 Efforts to target RAL directly 
When it comes to targeting RAL, like RAS, there are several issues that hinder 
the development of compounds that directly bind to and inhibit RAL activity. 
First, the high concentration of GTP/GDP in cells, along with the high affinity 
of RAL for guanine nucleotides make the development of a molecule that can 
compete with GTP/GDP binding extremely difficult (Cox et al., 2014). Second, 
the protein-protein interactions in the RAL signalling cascade are harder to 
target in comparison to the enzymatic activity of protein kinases (Arkin, Tang 
and Wells, 2014). Lastly, activated RAL (GTP-RAL) has a very “smooth” 
surface with no deep hydrophobic pockets suitable for tight binding of small 
molecules (Yan and Theodorescu, 2018). Fortunately, unlike RAS, the 
presence of RAL mutations in cancer are extremely rare, which allows more 
options for targeting (Ostrem et al., 2013). Furthermore, advances in structure-
based drug discovery have helped shed light on small GTPases such as RAS 
and RAL, allowing for development of inhibitors. 
Structure-based drug discovery is based on understanding the three-
dimensional structure of the target protein, which is usually determined 
through either X-ray crystallography  or nuclear magnetic resonance (NMR), 
both of which have drawbacks when it comes to structure determination (Chen 
et al., 2012). For instance, X-ray crystallography traps the target molecule in 
a single low-energy confirmation, which might not be physiologically relevant, 
whilst NMR structure determination is restricted to small proteins usually less 
than 30 kDa (Gauto et al., 2019). Additionally, the idea that small GTPases 
exist solely in either an inactive GDP-bound or active GTP-bound state was 
disproved when NMR studies of HRAS uncovered the existence of at least two 
conformations of the active form (Shima et al., 2010; Shima et al., 2013). The 
concurrence of a more dynamic conformational status of small GTPases has 
led to several breakthroughs in developing small molecule compounds, such 
as the two KRAS inhibitors DACI and VU0460009 (Maurer et al., 2012; Sun et 
al., 2012). Fragment-based drug design, used to develop drugs such as these 
two KRAS inhibitors, is based on identifying chemical fragments that are 
capable of binding to small pockets on the target protein and then growing or 
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linking them together to produce a lead compound with a higher affinity. This 
approach is particularly promising for targeting small GTPases such as RAL 
(Zhao et al., 2017). 
Another breakthrough in structure-based drug design is the idea of a “stapled 
peptide”. This approach is based on mimicking the α-helices present in protein 
binding domains and applying a constrained in the form of a covalent linkage 
or “staple” (Walensky and Bird, 2014). The introduction of a synthetic brace 
(staple) aids in locking a small peptide into a specific conformation. This helps 
increase stability, cell permeability and target affinity of the peptide.  
This technique has been applied to target RAL, in which the binding domain 
of the RAL effector RALBP1 was used as a template (Thomas et al., 2016). 
The designed peptides can bind selectively to the switch I and II regions of 
GTP-RALB, blocking downstream effector signalling of RAL. Recent efforts to 
improve binding of these stapled peptides to RAL proteins has been achieved 
through affinity maturation of the RALBP1 binding domain (Hurd et al., 2020). 
Several sequence substitutions were identified and used to design second-
generation stapled peptides that exhibited improved selectivity for RAL 
GTPases. Although these stapled peptides are able to successfully compete 
with multiple RAL effectors, because these peptides do not bind to the inactive 
GDP-bound RAL, they are unable to prevent RALGEF binding and are 
therefore unable to inhibit RAL activation. 
Another structure-based approach has led to the development of allosteric 
inhibitors capable of binding to inactive GDP-RAL. Using a virtual chemical 
library screen, small ligands that bound to an allosteric binding site on the 
surface of RAL were identified. Since these ligands lock RAL in the inactive 
GDP-bound form, they are able to break up the GTP-GDP cycle and block 
RAL signalling. In fact, the first of these developed RAL compounds inhibited 
the growth of human NSCLC cell lines both in vitro and in vivo (Yan et al., 
2014). 
Finally, in an effort to target RAL GTPases directly, the formation of a covalent 
bond at a tyrosine residue (Tyr-82), inhibits RALGEF RGL2-mediated 
nucleotide exchange of RAL (Bum-Erdene et al., 2020). Although these 
covalent inhibitors are not considered suitable for therapeutic drug use, they 
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serve as valuable probes to uncover possible binding sites for future drug 
development. 
1.3.2 Targeting RAL localisation 
In order for RAL proteins to carry out their biological functions, they must be 
correctly localised to the inner surface of the plasma membrane. As discussed 
earlier, both RAL proteins have a CAAX motif C-terminal sequence that 
requires modification to allow for appropriate localisation. When it comes to 
posttranslational modifications of RAL, unlike RAS which primarily undergoes 
prenylation by farnesyltransferase (FTase), RAL proteins can act as 
substrates for geranylgeranyltransferase (GGTase I) (Kinsella, Erdman and 
Maltese, 1991) and will not be subjected to prenylation following GGTI inhibitor 
treatment (Falsetti et al., 2007). The inhibition of GGTase I and its effect on 
RAL signalling has been evaluated in the human pancreatic cancer cell line 
Mia PaCa-2 (Falsetti et al., 2007). Both RAL isoforms were involved in the 
inhibition of anchorage-independent growth as well as cell cycle progression 
in these cells. The growth inhibition effect of GGTIs within RALB signalling, 
has also been confirmed in squamous cell carcinoma (Hamada et al., 2011) 
and other cancer types such as glioma (Song et al., 2015). A potential problem 
with targeting RAL through GGTase inhibition is that many other RAS family 
small GTPases are also substrates for GGTase I. This lack of specificity could 
result in toxicity in normal tissues. Fortunately, the inhibitor GGTI-2418 used 
in a phase I clinical trial (Ullah, Mansha and Casey, 2016) seemed to be well 
tolerated and the use of GGTIs for targeting RAL may still be a feasible 
approach. 
1.3.3 Targeting the RALGEF/RAL pathway 
Instead of targeting RAL itself, another logical approach would be to develop 
inhibitors directed at other members of the RAL pathway involved in 
regulation. The majority of RALGEFs mediate the activation of RAL in a RAS-
dependent manner. Therefore, targeting RALGEFs should be as effective as 
inhibiting RAL directly, as long as the RAL signalling is a result of RAS 
activation. Unfortunately, targeting any GEF protein of the small GTPases is a 
challenge as it requires targeting protein-protein interactions. Whilst inhibitors 
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have been developed that target GEFs of the small GTPases, ARF, RHO and 
RAC1 (Schmidt et al., 2002; Renault, Guibert and Cherfils, 2003; Gao et al., 
2004), structural information for RALGEFs is limited and making it difficult for 
them to be used as feasible therapeutic targets. 
Another option to interfere with RAL signalling is to target downstream effector 
proteins that directly bind to active RAL. Currently, specific inhibitors for most 
RAL effectors are not available but targeting these downstream protein 
interactions is a sound approach that may aid in the development of novel 
inhibitors of RAL signalling. 
 
1.4 Genome Editing 
1.4.1 Targeted genome editing development 
In order to study RAL function, generating appropriate gene “knockout” or 
“knock-in” cell lines through genome editing is highly desirable. Through the 
loss/gain of function of a target gene, protein interactors and signalling 
pathways can be identified and studied. Conventional gene targeting was 
initially achieved through the addition of a donor DNA template containing the 
gene of interest or mutation that would be incorporated at the target site 
through homologous recombination (HR) (Capecchi, 1989). Whilst HR has 
been used to successfully generate knockout murine embryonic stem cells 
(Capecchi, 2005), the rate at which it occurs is low and lower still in other cell 
types, making it an inefficient process to utilise exclusively.  
Over recent years, there has been extensive advancements in genome editing 
technologies that enable precise modification of a specific locus within the 
genome through the introduction of a double-stranded break (DSB). The idea 
that DSBs could boost the efficiency of HR was first shown in yeast (Haber et 
al., 1988) and at later dates in mammalian cells (Rouet, Smih and Jasin, 1994). 
Furthermore, the discovery that DNA cleavage triggers the cell’s natural repair 
mechanism, known as non-homologous end joining (NHEJ), a donor DNA 
template is no longer required to disrupt the gene of interest and produce a 
“knockout” cell line (Wake et al., 1984). 
The introduction of a break in the DNA is carried out by the targeted delivery 
of a nuclease, with zinc finger nucleases (ZFNs) being the first to be used in 
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this manner (Kim, Cha and Chandrasegaran, 1996). ZFNs are endonucleases 
that consist of a DNA-binding domain of a zinc finger protein transcription 
factor, fused to a separate DNA-cleavage domain (Carroll, 2011). Here, DNA 
binding specificity can be provided through the customisation of the zinc finger 
protein to target any user-defined sequence. Transcription activator-like 
effector nucleases (TALENs) were the next nuclease to be developed (Miller 
et al., 2011). Like ZFNs, TALENs contain an endonuclease domain, this time 
linked to two DNA-binding motifs instead of one (Joung and Sander, 2013). 
Whilst there are structural similarities, TALENs have an advantage over other 
nucleases in that the DNA recognition code can be easily engineered to target 
almost any sequence (Boch et al., 2009). However, the substantial size of 
TALENs presents a challenge when it comes to packaging and delivery into 
cells and is especially problematic in applications that must be delivered in 
viral vectors (Gupta and Musunuru, 2014). Finally, the current gold-standard 
of genome editing, and precise modification is the CRISPR/Cas system.  
1.4.2 CRISPR/Cas system 
Clustered regulatory interspaced palindromic repeats (CRISPR) and the 
CRISPR-associated (Cas) nucleases were initially discovered as part of the 
bacterial adaptive immune system (Fineran and Charpentier, 2012). Any 
invading foreign genetic material detected by the bacteria is catalogued and 
incorporated into their own genome as “protospacers” and expressed as short 
guide RNAs (gRNAs). The CRISPR/Cas system uses a combination of these 
short RNAs to guide Cas nucleases to target and cleave specific foreign DNA 
(Barrangou et al., 2007). 
Various CRISPR/Cas systems are available for use as a gene editing tool but 
the most comprehensively studied is the type II system from the bacterial 
species Streptococcus pyogenes (Cong et al., 2013; Mali et al., 2013; Jinek et 
al., 2012; Cho et al., 2013). The CRISPR gene loci, present in both bacterial 
plasmid and chromosomal DNA, is comprised of gRNA(s) along with a Cas9 
nuclease (Mojica et al., 2005). This CRISPR/Cas system has been harnessed 
to facilitate human genome editing through human optimisation of the Cas9 
nuclease, in addition to design of the relevant gRNA components. This 
includes fusing a trans-activating CRISPR RNA to the 20 base pair sequence 
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gRNA through a linker loop region to form the final single gRNA (Kim and Kim, 
2014) (Figure 1.4). 
Directly upstream of the Cas9 nuclease binding site on the target DNA strand 
is a small base pair sequence known as the protospacer adjacent motif (PAM). 
Different CRISPR/Cas9 systems have discrete PAM requirements, with the 
PAM sequence in this particular system being a 5'-NGG sequence, where ‘N’ 
is any random nucleotide (Jiang et al., 2013). The gRNA recognises and 
hybridises to the matching part of the genome, leading to a Cas9-induced DSB 
three base pairs downstream of the PAM. Importantly, cleavage will only occur 
if a PAM sequence is present (Ding et al., 2016). 
As previously mentioned, subsequent repair of these DNA breaks occurs 
through the cellular process NHEJ (Figure 1.4). This process is highly error 
prone and can be exploited to introduce insertion/deletion (indel) mutations, 
potentially knocking out the gene, leading to premature truncation of the 
protein (Gupta and Musunuru, 2014). Alternatively, homology directed repair 
(HDR) can be utilised  with the addition of a repair template, to insert a specific 
mutation, allowing for precise repair and the option of knock-in gene editing 
(Chapman, Taylor and Boulton, 2012).  
1.4.3 CRISPR and RAL 
CRISPR can also be used to conduct large-scale genetic loss of function 
experiments (Poirier, 2017). This technique known as CRISPR screening, 
facilitates the discovery of key genes that elicit a specific phenotype for a cell 
type, such as drug resistance/sensitivity (Shalem et al., 2014), susceptibility to 
environmental toxins (Koike-Yusa et al., 2014) as well as leading to a particular 
disease state (Chen et al., 2015). The basic idea of a CRISPR screen uses 
precise DSBs to knockout every gene but only one gene per cell, so the 
resulting population has a different gene knocked out. Following a period of 
time in which some cells will die, and some will become the predominant cell 
type, next-generation sequencing is carried out to determine individual gene 
level changes. This allows the identification of genetic sequences that are 





Figure 1.4 The CRISPR/Cas9 system.  
Schematic of the CRISPR/Cas9 system including gRNA with 20 base pair target sequence 
and Cas9 nuclease that generates double strand breaks in the DNA. The two methods of 
repair are also depicted, NHEJ and HDR. crRNA = CRISPR RNA, tracrRNA = trans-activating 












Out of 1007 and 1001 CRISPR screens conducted in human cell lines, 13 and 
7 of them identified RALA and RALB as hits respectively (BioGRID ORCS). 
One screen focusing on a peptide accumulation phenotype in an embryonic 
kidney cell line found that RALA may act as a suppressor of ER stress-induced 
apoptosis (Panganiban et al., 2019). Eleven screens, focused on changes in 
cell proliferation, with RALA recorded as being a hit in a range of cell types 
including large B-cell lymphoma, neuroblastoma and endometrial cancer 
(Behan et al., 2019), neural stem cells and glioblastoma (MacLeod et al., 
2019), B-cell non-Hodgkin Lymphoma (Reddy et al., 2017) and chronic 
myeloid leukaemia cell line (Zhuang, Veltri and Long, 2019). One of these 
screens involved 33 cancer cell lines, many of which harbour active RAS 
mutations (Aguirre et al., 2016). Another specifically looked at the protein 
interactomes of RAS isoforms with regards to proliferation behaviour changes 
(Adhikari and Counter, 2018). For RALB, 3 out of those 7 screens observed 
cell proliferation changes in a chronic myeloid leukaemia cell line (Liu et al., 
2019), glioblastoma cell line (MacLeod et al., 2019) and a B-cell non-Hodgkin 
lymphoma cell line (Reddy et al., 2017). Interestingly, RALB was also found to 
be a significant hit in a chronic myeloid leukaemia cell line that noted vesicle 
distribution had been affected (Lu et al., 2018). 
 
1.5 Aims and objectives 
The RALGEF/RAL signalling pathway has emerged as being critically 
important in normal cell physiology. RAL proteins themselves have been 
implicated in many biological processes and whilst structurally and 
biochemically RALA and RALB are similar, they have been observed as 
having very distinct functions. Whether this is simply a reflection of spatially 
distinct interaction with the same set of effector proteins or that there are 
isoform specific effectors that remain to be discovered has yet to be 
determined. What’s more, whilst RAL has been implicated in neoplastic cell 
growth and oncogenic RAS is known to be involved in the dysregulation of 
cellular growth and survival through MAPK signalling pathways, how and 
indeed if RAL also contributes to RAS-dependent tumourigenesis remains 
unclear. Furthermore, whilst a great deal has been learnt from studies on how 
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the RAL signalling network regulates biological and pathological processes, 
the approach of many has been to utilise knockdown techniques and/or 
overexpression of RAL, both of which have multiple drawbacks. Finally, 
although a few null and conditional RAL knockout mice have been generated, 
at the beginning of my project there were no available studies targeting and 
investigating RAL at the endogenous level in an appropriate human cell model. 
For this reason, isoform specific RAL knockouts, in a panel human colorectal 
cancer cell lines, harbouring different KRAS mutations will be generated. Tools 
needed to insert mutations at the endogenous loci, that express a 
constitutively active version of RAL, creating knock-in lines in the same cell 
panel will also be developed. These cell lines will be created using the 
CRISPR/Cas9 system and will allow the characterisation of RAL signalling at 
an endogenous level, thus build a detailed profile of RAL biology. 
 
AIM: 




• Quantify the absolute protein abundance contribution for each isoform. 
• Build a detailed profile of the transcriptome and proteome involved in 
the RAL GTPase signalling network. 












Chapter 2: Materials & Methods 
2.1 Cell Biology 
2.1.1 Materials & Reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM) (#31966-021), Dulbecco’s 
Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM/F-12) (#31331-
028), McCoy’s 5A Modified Medium (36600-021), Minimum Essential Medium 
(MEM) (#11095-080), Opti-MEM reduced serum medium (#31985-070), 
Trypsin 0.5% EDTA 10X (#15400-054) and Fetal Bovine Serum (FBS) 
(#10270106) were all purchased from Invitrogen (Paisley, UK). StemPro 
Accutase Dissociation Reagent (#A11105-01) was obtained from Fisher 
Scientific (Loughborough, UK). JetPEI transfection reagent (#101-01) was 
obtained from Polyplus Transfection (France). Lipofectamine LTX and PLUS 
reagent (#15338100) and Lipofectamine RNAiMAX transfection reagent 
(#10601435) were all purchased from Invitrogen. ON-TARGETplus Human 
RALA (5898) siRNA – SMARTpool, 5 nmol and ON-TARGETplus Human 
RALB (5899) siRNA – SMARTpool, 5 nmol were obtained from Dharmacon, 
Horizon Discover (Cambridge, UK). Puromycin dihydrochloride (#P7255) was 
purchased from Sigma-Aldrich, Merck (Poole, UK). All plasticware used for 
cell culture were obtained from Corning Inc. (NY, USA).  
2.1.2 Cell culture 
A panel of colorectal cancer cell lines were obtained for use in this study. Cell 
name, source and culture conditions are specified in Table 2.1. All cells were 
cultured in a 5% CO2 atmosphere at 37°C. Confluent cells (~70%) were split 
every 3 days with an appropriate dissociation reagent, such as 1X trypsin- 
0.5% EDTA and ready to use StemPro Accutase (400-600 units/mL). Any 







Table 2.1 Colorectal cancer cell line information. 








CaCo2 ATCC/ HTB-37 MEM + 20% FBS Accutase/ 1:3 
DLD-1 ATCC/ CCL-221 RPMI + 10% FBS Trypsin-EDTA/ 
1:5 
HCT116 In-house stock DMEM +10% FBS Trypsin-EDTA/ 
1:10 
LoVo ATCC/ CCL-229 RPMI + 10% FBS Trypsin-EDTA/ 
1:5 
SW48 In-house stock McCoy’s + 10% FBS Accutase/ 1:3 
SW403 ATCC/ CCL-230 DMEM/F-12 + 10% 
FBS 
Accutase/ 1:5 
SW620 ATCC/ CCL-227 DMEM + 10% FBS Trypsin-EDTA/ 
1:6 


















McCoy’s + 10% FBS Accutase/ 1:3 SW48   
RALA KO 
- 





































2.1.3 DNA transfection 
Different methods and reagents were tested to determine optimal transfection 
for both transient expression and gene editing in the chosen cell lines. 
Lipid based reagents displayed similar transfection efficiency, with JetPEI and 
Lipofectamine LTX being the most effective. For transfections using JetPEI, 
cells were seeded in a 6-well plate at a density of 2x105 and incubated 
overnight at 37°C. The following day cells were transfected using JetPEI 
following manufacturer’s instructions. Each reaction contained 4 µL JetPEI in 
96 μL 150 mM NaCl, added to a solution of 1 µg of DNA diluted in 100 µL NaCl 
and mixed gently by vortexing. Combined solutions were incubated for 20 
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minutes at room temperature and added dropwise to the cells. Plates were 
incubated at 37°C for 72 hours before harvesting.  
For Lipofectamine LTX, cells were seeded in a 6-well plate at a density of 
2x105 and incubated overnight at 37°C. The following day cells were 
transfected using Lipofectamine LTX following manufacturer’s instructions. 
Each reaction contained 6 µL LTX in 200 µl Opti-MEM, added to a solution of 
1 µg of DNA and 2 µL PLUS reagent diluted in 200 µL Opti-MEM and mixed 
gently by vortexing. Combined solutions were incubated for 10 minutes at 
room temperature and added dropwise to 1800 µL of fresh medium on the 
cells. Plates were incubated at 37°C for 72 hours before harvesting. 
2.1.4 siRNA knockdown 
For a 40nM single siRNA knockdown experiment, cells were typically seeded 
at a density of 1.5x105 cells per well in a 6-well plate and incubated overnight 
at 37°C. Cells were then transfected using Lipofectamine RNAiMAX according 
to manufacturer’s instructions. Each reaction contained 2 µL siRNA (20 µL 
stock) (Table 2.2) in 83 µL Opti-MEM added to a solution of 2 µL RNAiMAX in 
83 µL Opti-MEM. Combined solutions were incubated at room temperature for 
20 minutes and added to 830 µL fresh medium in each well. Media was 
exchanged for 2 mL fresh medium after 6 hours at 37°C. For a double 
knockdown, RNAiMax was doubled to 4 µL and the Opti-MEM reduced so 












Table 2.2 siRNA oligo sequences used for transfection. 
siRNA 
 Target sequence Mol. Wt. (G/MOL) 









2.1.5 Antibiotic treatment 
Transfected cells were treated with two separate concentrations of puromycin 
(1 and 2 µg/mL), 48 hours post-transfection to select the cells which had 
successfully taken up plasmids with a puromycin selection marker. Cell death 
was monitored over the following 4 days, with 70-80% cell death usually 
observed by day 2. If no visible cell death occurred after the second day, a 
second higher dose was added in fresh media. Any resultant colonies were 
grown and expanded into two new 6-well plates before single cell dilutions.  
2.1.6 Virus production in HEK293T cells 
For viral transduction, a combination of a retrovirus system and a 2nd 
generation lentiviral system was used depending on the transfer plasmid being 
utilised. The retroviral system involved a plasmid encoding the gene(s) of 
interest and the retrovirus packaging plasmid (pCL-10A1) that encodes both 
the packaging and envelope elements required for virus particle production. 
Whereas the 3 plasmids necessary for lentivirus production are one envelope 
plasmid encoding VSV-G (pMD2.G), one packaging plasmid (psPAX2 or 




For any viral production, two 10 cm dishes were seeded with 3.5x106 
HEK293T cells and grown to reach 70% confluency. Culture medium was 
exchanged 4 hours prior to transient transfection (section 2.1.3). 
For stable transfection and expression of WT and mutant RAL isoforms, a total 
of 2 µg of DNA (1 µg pCL-10A1 packaging vector, 1 µg pBabe-Puro transfer 
vector) was required per dish. 
For the CRISPR/Cas9 knock-in cell lines, the psPAX2-D64V (Supplementary 
Supplementary Figure 7.1) is preferred over the psPAX2 plasmid. This plasmid 
generates integrase deficient lentiviral vectors due to a point mutation in the 
integrase gene. This stops any fluorescent markers from the transfer plasmid 
inserting into the target genome which would prevent any future assays 
involving fluorescent analysis. In total, 4 µg of transfer plasmid and 2 µg of 
each envelope and packaging plasmid plasmids was required per dish.  
Following addition of transfection mixture, medium was changed the next 
morning and the supernatant harvested 48- and 72-hours post transfection. 
Viral particles were concentrated on day of harvest and were resuspended in 
PBS and stored at -80°C following flash freezing. 
2.1.7 Viral Transduction 
Six well plates were set up with 4x105 cells. Polybrene at a final concentration 
of 8 µg/mL and 100 µL of unconcentrated virus were added to each well and 
the plates spinoculated for one hour at 1000 x g. Following incubation 
overnight at 37°C, medium was replaced, and the cells incubated for a further 










2.2 Molecular Biology 
2.2.1 Reagents 
Primers were ordered from Eurofins (Ebersberg, Germany) or IDT (Leuven, 
Belgium). OneTag Hot Start DNA Polymerase (#M0481S), Phusion High-
Fidelity DNA Polymerase (#M0530S), Q5 High-Fidelity DNA Polymerase 
(#M0491S), Deoxynucleotide (dNTP) Solution Mix (#N0447S), Quick Ligation 
Kit (#M2200S), T4 Polynucleotide Kinase (#M0201S) and all restriction 
enzymes were purchased from New England Biolabs (NEB) (Hertfordshire, 
UK).  Stable (#C3040I) and 5-alpha (#C2987I) competent cells were obtained 
from NEB. Auxotrophic E. coli AT713 bacteria were from The Yale Coli Genetic 
Stock Center (New Haven, USA). L-lysine-U-13C6-15N2 (#608041) and L-
arginine-U-13C6-15N4 (#608033) and SOC medium (#S1797) was purchased 
from Sigma Aldrich-Merck (Poole, UK). Carbenicillin (#10163193), Ampicillin 
(#10419313) and TRIzol Reagent (#15596026) were purchased from Fisher 
Scientific (Loughborough, UK). QIAprep Spin Miniprep Kit (#27106), HiSpeed 
Plasmid Maxi Kit (#12663) and QIAquick Gel Extraction Kit (#28704) were 
from QIAGEN (Crawley, UK). Wizard™ SV Gel and PCR clean up system 
(#A9281) was purchased from Promega (Southampton, UK). Ultrapure 
Agarose powder (#15510-019) was obtained from Invitrogen (Paisley, UK) and 
the TAE buffer from National Diagnostics (Hull, UK). All DNA markers, 1kb 
(#N3232) and 100bp (#N3231) were purchased from NEB. All chemicals used, 
were obtained from Sigma Aldrich-Merck unless otherwise stated. 
2.2.2 RNA extraction and integrity checks 
Cells were grown to 70-80% confluency in 6 cm dishes. Cells were lysed using 
1 mL Trizol directly into the dish before transferring cell lysate to 1.5 mL tube. 
In the fume hood, 200 µL of chloroform was added and each tube shaken 
vigorously for 15 seconds. The samples were incubated at room temperature 
for 3 minutes before centrifugation at 12,000 x g at 4°C for 15 minutes. The 
RNA present in the clear upper aqueous phase was pipetted into a new tube 
and incubated at room temperature for 10 minutes with 0.5 mL RNase free 
isopropanol. Samples were centrifuged at 12,000 x g at 4°C for 10 minutes. 
The RNA pellet was washed once with 1 mL 75% ethanol before centrifugation 
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at 7500 x g at 4°C for 5 minutes. The supernatant was removed by pouring 
and the RNA pellets left to air dry for 10 minutes before resuspension in 25-
50 µL of RNase free H2O. RNA concentration was quantified on a NanoDrop® 
1000 Spectrophotometer and the integrity verified on an Agilent 2100 
Bioanalyzer. Each sample was given an RNA integrity number (RIN) between 
1-10, with 10 being of the highest quality. All samples scored 9-10/10 (data 
not shown) and were taken forward for RNA sequencing analysis. 
 
2.2.3 RNA sequencing data and analysis 
Following RNA extraction, all samples were sent to BGI Genomics 
(https://www.bgi.com/global/sequencing-services/rna-sequencing-
solutions/transcriptome-sequencing/) to undergo RNA transcriptome 
sequencing using DNBSEQ technology. Initial analysis and bioinformatics 
were also carried out by BGI Genomics. Differentially Expressed Genes 
(DEGs) were detected with DEseq2 and Poisson distribution. DEseq2 was 
based on the negative binomial distribution, as described in (Love, Huber and 
Anders, 2014). Poisson distribution was performed as described in (Audic and 
Claverie, 1997).  
Once this dataset was received from BGI, further evaluation of DEGs was 
carried out using a collection of data including the gene expression value, log2 
fold change and adjusted p-value. This summary data file was filtered to show 
only those genes that were classed as a DEG (fold change ≥2.00 and adjusted 
P value ≤0.05). The log2 fold change was then used to generate a visual 
representation of gene expression changes for RAL KO vs parental samples 
for each cell line in the form of heatmaps. These were created using 
Cytoscape and Multiple Experiment Viewer (MeV) software. 
2.2.4 Cloning 
The following pBabePuro-RAL plasmids (Supplementary Supplementary 
Figure 7.2) were obtained for transient/stable isoform specific expression or 
RAL recombinant protein production. Plasmids pBabePuro-RALA(Q72L), 
pBabePuro-RALB(Q72L) and pBabePuro-RALB(G23V) were kindly sent from 
Professor Chris Counter at Duke University Medical Center, Durham. pBabe-
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Puro-RALA-wt was a gift from William Hahn (Addgene plasmid #15251). 
pBabe-Puro-RALA-V23 was a gift from William Hahn (Addgene plasmid 
#15252). pBabe puro RALB wt was a gift from Channing Der (Addgene 
plasmid #19720).  
2.2.5 Bacterial transformation 
Ligations were transformed into competent E. coli via heat shock. Briefly, 5 µL 
of the ligation was added to 50 µL of bacteria and incubated on ice for 20 
minutes. Bacteria were then heat-shocked for 1 minute at 42°C, then allowed 
to recover on ice for 2 minutes. Following this, 350 µL of SOC medium (Luria 
Broth with 10 mM MgCl2, 10 mM MgSO4, 2.5 mM KCl and 20 mM glucose) was 
added and incubated at 37°C, 245 rpm for 1 hour. Bacteria were then plated 
onto LB-Agar plates containing the appropriate antibiotic and grown at 37°C 
overnight. 
Single colonies were grown in 5 mL LB broth supplemented with antibiotic 
overnight at 37°C, 245 rpm. Isolation of plasmid DNA was performed 
according to the manufacturer’s instructions using the QIAprep Spin Miniprep 
Kit. Purified DNA was test digested and potential positive samples were sent 
for sequencing at the DNA Sequencing Service at University of Dundee, UK. 
Verified plasmids were expanded into 250 mL LB medium from glycerol stock 
scrapings and the DNA extracted using the Qiagen MaxiPrep Kit. 
 
Table 2.3 Plasmid information. 
Name Product Selection 
marker 
Purpose 
pBabe-Puro-RALA WT RALA Puromycin 
Protein 
expression 
pBabe-Puro-RALA-V23 G23V RALA Puromycin 
Protein 
expression 
pBabePuro-RALA(Q72L) Q72L RALA Puromycin 
Protein 
expression 




pBabePuro-RALB(G23V) G23V RALB Puromycin 
Protein 
expression 
pBabePuro-RALB(Q72L) Q72L RALB Puromycin 
Protein 
expression 
ptrcHis-A-RALA His-RALA (wt) - PSAQ 
ptrcHis-A-RALB His-RALB (wt) - PSAQ 








































pEGFP-C1 EGFP Neomycin 
Transfection 
optimisation 
*All plasmids are ampicillin resistant except LentiCRISPR(V2)-SFFV which 










Table 2.4 A typical double restriction test digest reaction. 
Component Amount 
10X Buffer 5 µL (1X) 
Restriction Enzyme 1 1 µL 
Restriction Enzyme 2 1 µL 
DNA (1 µg) X µL 
DNase/RNase-free water Up to 50 µL 
 
2.2.6 Glycerol stocks 
500 µL of 5 mL overnight bacterial culture was mixed with a 50% solution of 
glycerol and gently vortexed before being placed directly in -80°C for long-
term storage. 
2.2.7 Restriction digest 
A typical test digest was set up as shown in Table 2.4. In general, 1 µg of DNA 
was used with the chosen enzyme/s (most restriction enzymes used were 
20,000 units/mL) and the mixture incubated for 1 hour at 37°C. 
2.2.8 Genomic DNA extraction 
Following DNA transfection, cells were scraped, washed with PBS and 
pelleted by centrifugation at 1000 x g for 5 minutes. Cells for DNA isolation 
were lysed in 300 µL tail lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5  
mM EDTA, 0.1% sodium dodecyl sulphate) with 2 µL RNAase A (200 mg/mL) 
and 6 µL proteinase K (10 mg/mL) and incubated overnight at 55°C. Cell 
lysates were heated at 95°C for 10 minutes, followed by the addition of 1 µL 
glycogen (20 mg/mL) and 400 µL of isopropanol to precipitate the DNA. 
Samples were incubated on ice for 30 minutes before centrifugation for 20 
minutes (14,000 x g). Resulting pellets were washed with 70% ethanol before 
finally being resuspended in nuclease free water. 
2.2.9 Polymerase Chain Reaction (PCR) screen 
DNA amplification by PCR was performed to identify correct gene editing by 
CRISPR/Cas9. OneTaq DNA polymerase was used to amplify the targeting 
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Exon 1 region in both RAL isoforms. Each PCR reaction was set up as shown 
in Table 2.5. 
2.2.10 Agarose gel electrophoresis 
Agarose gels were prepared with electrophoresis grade agarose and 1X TAE 
buffer (40 mM Tris-acetate, 1 mM Na2-EDTA) and heated in a microwave until 
the agarose had fully dissolved, approximately 4 minutes. Ethidium Bromide 
was added at a final concentration of 0.5 µg/mL to allow visualisation of DNA 
using an ultraviolet light source. The mixture was then poured into a cassette 
and left to solidify at room temperature. Prior to loading, a 1:6 dilution of 6X 
gel loading dye, no SDS was added to each sample. 10 µL of either a 100 bp 
or 1 kb DNA ladder standard was loaded alongside the samples. DNA was 
resolved using 1X TAE buffer in an electrophoresis tank at 130 V for 30 
minutes. DNA bands were confirmed under a uvidoc (uvitec). 
 
 
Table 2.5 A typical PCR reaction for gene editing screen. 
Component Amount 
OneTaq 5 µL 
Forward and Reverse Primers (10 µM) 1 µL 
DNA (200 ng) 1 µL 
DNase/RNase-free water 8 µL 
 
Table 2.6 Thermal cycler programme for general PCR. 
 Step No. of Cycles Temperature Time 
1 Initial Denaturation 1 95°C 2 minutes 
2 Denaturation 25 95°C 30 seconds 
Annealing 58°C 30 seconds 
Extension 68°C 30 seconds 





2.2.11 Recombinant RALA & RALB standard production  
To generate N-terminal His-tagged RALA and RALB recombinant proteins, 
WT RALA and WT RALB sequences were subcloned into the ptrcHis-A 
construct (Supplementary Supplementary Figure 7.3). 
WT RALA and WT RALB were gel extracted from pBabe-Puro-RALA-wt 
(Addgene plasmid # 15251) and pBabe puro RALB wt (Addgene plasmid # 
19720) following a two-hour restriction digest with BamHI plus SalI (RALA) 
and BamHI plus XhoI (RALB) and subsequently ligated into a ptrcHis-A 
construct following digestion with the same enzymes.  
Auxotrophic E. coli AT713 bacteria were used as this bacterial strain is suitable 
to generate isotope-labelled, full- length proteins due to its inability to 
synthesize arginine and lysine as a result of mutations present at argA21 and 
lysA21 (Taylor, 1970). Following ligation, all plasmids were transformed into 
AT713 bacteria and glycerol stocks (2.2.4) produced and stored at -80°C. 
Samples were sent for sequencing with a T7 forward (5’- 
















2.3 CRISPR/Cas9 Gene Editing 
For generation of knockout cells, a double gRNA approach was selected 
(Figure 2.1). This strategy uses a LentiCRISPR plasmid containing two gRNAs 
and the Cas9 enzyme. 
 
 
Figure 2.1 Strategy for generating isoform specific knockout cell lines. 
A double guideRNA approach was used for generating knockout clones. This involved two 
gRNA inserted into one LentiCRISPR plasmid. Following targeted DNA cleavage by Cas9, 
the deletion of the sequence between the two gRNAs can be detected through the 
amplification of a smaller PCR product compared to the unedited cells. 
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2.3.1 Phosphorylation of guide oligonucleotides and ligation into 
LentiCRISPR 
All gRNAs complimentary oligonucleotides with appropriate overhangs are 
shown in Table 2.7 with an additional G at the front of the 20-nucleotide 
sequence if absent. 
Guide oligonucleotides were resuspended in DNase-free water at 100 µM and 
phosphorylated using T4 polynucleotide kinase at 37°C for 1h to allow for 
successful ligation. Oligonucleotides were annealed by heating at 95°C for 10 
minutes, allowed to cool to room temperature, then diluted at 1:25 ready for 
ligation. For the ligation, 4 µL of the annealed oligonucleotides was mixed with 
50 ng of BsmBI digested LentiCRISPR(V2)-SFFV vector (Supplementary 
Supplementary Figure 7.4), 1 µL 10X T4 Ligase buffer, and 0.5 µL T4 Ligase, 
made up to 10 µL final volume. Ligations were incubated at 4°C overnight 
before transformation into Stable E. coli onto LB agar/carbenicillin plates (100 
µg/mL). 
 




 Forward (5'>3') Reverse (5'>3') 
1 CACC-GTAAAACAAGCCTATGACTCA AAAC-TGAGTCATAGGCTTGTTTTA-C 
2 CACC-GAATGAAGTATGCTCACTTAG AAAC-CTAAGTGAGCATACTTCATT-C 
3 CACC-GTTTACACAAAGTCATCATGG AAAC-CCATGATGACTTTGTGTAAA-C 
4 CACC-GAAAGTCATCATGGTGGGCAG AAAC-CTGCCCACCATGATGACTTT-C 




 Forward (5'>3') Reverse (5'>3') 
1 CACC-GTGTCATCAGCAGCTCTTCAG AAAC-CTGAAGAGCTGCTGATGACA- C 
2 CACC-GTCATCAGCAGCTCTTCAGT AAAC-ACTGAAGAGCTGCTGATGA-C 
3 CACC-GAAGGTGATCATGGTTGGCAG AAAC-CTGCCAACCATGATCACCTT-C 




2.3.2 Colony screening  
Single colonies were picked and screened by polymerase chain reaction 
(PCR) using OneTaq DNA polymerase mix using a U6 promoter forward 
primer and the reverse primer for the corresponding guide. PCR positive 
colonies were identified by agarose gel electrophoresis and were cultured in 5 
mL of LB supplemented with 100 µg/mL of Carbenicillin. Isolation of plasmid 
DNA was performed according to manufacturer’s instruction using the 
QIAprep Spin Miniprep Kit. Clones were then sent for sequencing with a U6 
promoter primer to the MRC PPU DNA Sequencing and Services in Dundee 
prior to larger scale DNA preparation (maxiprep).  
 
Table 2.8 A typical PCR reaction for colony screen. 
Component Amount 
OneTaq 5 µL 
Forward and Reverse Primers (10 µM) 1 µL 
DNase/RNase-free water 9 µL 
Colony scraping 1 
 
2.3.3 Assessing gRNA targeting and Cas9 cleavage. 
Each gRNA targeting efficiency was assessed by co-transfection into 
HEK293T cells (section 2.1.3), the genomic DNA extracted (section 2.2.7) and 
screened for successful Cas9 cleavage, Indel formation and production of a 
smaller PCR product. Genotyping primer sequences are shown in Table 2.9 
and one pair for each isoform selected following verification of efficiency (in 
this case that’s Gen 1F + Gen1R for both isoforms). PCR amplification was 








Table 2.9 Genotyping primer sequences for PCR screen. 
Genotyping Primers (sequence 5'-3') 
RALA 
Gen 1F (genotyping forward 1) GCTGATACCCCATTATTGTCAGC 
Gen 2F (genotyping forward 2) GTCAGCATGCAGTTGTACTGGG 
Gen 1R (genotyping reverse 1) AATCAAGTTATGTACAGATGGCTC 
Gen 2R (genotyping reverse 2) CCATAAGTTTCCTGATTTGTAAAATC 
 
RALB 
Gen 1F (genotyping forward 1) GTGACTTCCAGAGTTGTTGG 
Gen 2F (genotyping forward 2) GAGGGCTCGCATGTCTGC 
Gen 1R (genotyping reverse 1) CGATGCAAGCAGAGATCTCTC 
Gen 2R (genotyping reverse 2) TAACAATGGAAACGATGCAAG 
 
2.3.4 Duplexed gRNA LentiCRISPR cloning 
The knockout cell lines generated require two gRNA for successful gene 
editing. Following validation of each gRNA by co-transfection as single 
LentiCRISPR plasmids, gRNA#2 and gRNA#4 for RALA and RALB were 
chosen for future experiments. 
To ensure both gRNAs are taken up into the cell, a single LentiCRISPR 
plasmid containing both gRNAs is preferred over two separate single gRNA 
plasmids. To create this double or “duplexed” construct, gRNA#4 with 
adjoining U6 promoter from LentiCRISPR-gRNA#4 was amplified by PCR, 
with the addition of a linker sequence. This enabled ligation into the previously 
verified LentiCRISPR-gRNA#2 plasmid, resulting in a single plasmid with two 
gRNAs each with their own U6 promoter.  
PCR amplification was carried out using Q5 High-Fidelity DNA Polymerase 
with forward primer 5’-CGGAATTCGTTTTAGAGCTAGAAATAGCAAG 
TTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCCAATTCTGCAGACAAATGGCT
CTAGAGAGGGCCTATTTCCCATGATTCC-3’ and reverse primer 5’- 
GCGAATTCAAAAAAGCACCGACTCGG-3’. The PCR reaction was set up as 
show in Table 2.10 and run according to the thermal cycler programme 
described in Table 2.6. The amplified insert (U6 promoter + gRNA#4 + gRNA 
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linker) was cut from a 1.5% agarose gel using a Qiagen extraction kit, eluted 
and digested with restriction enzyme EcoRI for 2 hours at 37°C. A total of 4 µg 
of each RAL construct LentiCRISPR-gRNA#2 was digested with EcoRI for 2 
hours at 37°C. The digested vector was gel extracted and purified using the 
Wizard™ SV Gel and PCR clean up system. The digested inserts were ligated 
into their corresponding RAL LentiCRISPR-gRNA#2 vectors overnight at 4°C 
before transformation into Stable competent cells. Positive colonies were 
identified as previously described and the isolated plasmid DNA transfected 
into HEK293T cells. 
 
Table 2.10 A typical PCR reaction using Q5 high-fidelity DNA polymerase. 
Component Amount 
Q5 polymerase 0.5 µL 
dNTPs (10 µM) 1 µL 
Forward and Reverse Primers (10 µM) 5 µL 
5X buffer 10 µL 
DNA (200 ng) X µL 
DNase/RNase-free water X µL 
total 50 µL 
 
2.3.5 Doxycyclin inducible Cas9 cells 
To generate inducible Cas9 cells, target cell lines were transduced (section 
2.1.7) using a lentivirus containing the pCW-Cas9-Blast lentiviral vector 
(Supplementary Supplementary Figure 7.5). This construct contains the 
sequences for expression of doxycycline inducible Cas9 and constitutive 
expression of the selectable antibiotic marker, blasticidin. 
Following positive selection with 1 µg/mL blasticidin for 5 days, cells were left 
to recover and expanded into duplicate 6-well plates before cell lysis to 
determine Cas9 expression by western blot. Cells were treated 24 hours with 




2.3.6 Insertion of gRNA#4 into pLeGO-EGFP/2A-Puro for knock-in 
For generating knock-in cell lines, using a virus is the most effective way to 
ensure both CRISPR components (a single gRNA and HDR DNA template) 
get into a cell population (Figure 2.2). Since the Cas9 enzyme is already 
present in the chosen cell lines (section 2.3.4), gRNA#4 was subcloned from 
the verified LentiCRISPR(V2)-SFFV plasmids into a new pLeGO-EGFP/2A-
Puro construct (Supplementary Supplementary Figure 7.6). This approach 
overcomes the problems associated with packaging the Cas9, gRNA and long 
HDR template into a single plasmid for virus production. It also offers the 
benefit of two positive selection markers, puromycin and enhanced GFP, to 
allow for easy detection of transduction efficacy.  
 
PCR amplification of gRNA#4 for RALA and RALB was carried out using Q5 
High-Fidelity DNA Polymerase with forward primer 5'-TAAGGTA 
CCGAGGGCCTATTTCCC-3' and reverse primer 5'-CTAGAGCTAGCGAAT 
TCAAAAAAAGCAC-3'. The PCR reaction was set up as show in Table 2.10 
and run according to the thermal cycler programme described in Table 2.6. 
The amplified product was cut from a 1.5% agarose gel using a Qiagen 
extraction kit, eluted and digested with restriction enzyme KpnI for 1 hour at 
37°C. A total of 4 µg of the construct pLeGO-EGFP/2A-Puro (gifted from Dr 
Nicholas Harper, University of Liverpool) was digested with KpnI and PmeI for 
2 hours at 37°C. The digested vector was gel extracted and purified using the 
Wizard™ SV Gel and PCR clean up system. Each digested gRNA#4 insert 
was ligated into a pLeGO vector overnight at 4°C before transformation into 
Stable competent cells. Positive colonies were identified as previously 
described (2.3.4) and the isolated plasmid DNA transfected into HEK293T 
cells along with a LentiCRISPR-gRNA#2 to validate cutting efficiency. 




Figure 2.2 Strategy for generating knock-in cell lines. 
Knock-in cell lines will be generated using a lentivirus approach. This will involve the 
transduction of target Cas9-inducible cells with a plasmid containing a single gRNA and an 
HDR template including the desired mutation and additional silent mutations. Following 
positive selection through GFP/puromycin, cells will be screened by PCR using mutant 
specific primers. 
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2.3.7 G23V HDR template 
For homology directed repair to take place following a double stranded DNA 
break, as well as a gRNA, a DNA template including the desired mutation must 
be included (Table 2.11). For both RALA and RALB the glycine at amino acid 
23 was changed for a valine to produce constitutively active RALA/B knock-in 
cell lines. As well as this specific mutation, other “silent” mutations were 
introduced into the template to aid the screening process following HDR. 
 
Table 2.11 HDR DNA templates for RALA and RALB. 



















DNA templates were produced in 2 parts before ligation into the pLeGO-
EGFP/2A-Puro that already contains gRNA#4 (section 2.3.5). Both parts were 
amplified using Q5 High-Fidelity DNA Polymerase with the reaction set up as 
outlined in Table 2.10, using primers specified in Table 2.12. Part 1 was 
amplified using normal PCR thermal cycler steps (Table 2.6), whilst part 2 was 
amplified by tail PCR (Table 2.13). Both parts were identified by agarose gel 
electrophoresis and extracted and eluted into 20 µL DNase/RNase-free water 
(section 2.2.9). 
Using 15 µL of each template part, an overlap PCR reaction (Table 2.14) was 
set up with Q5 High-Fidelity DNA Polymerase and run for 15 cycles without 
primers (template parts will act as primers with each other). The PCR reaction 
was briefly paused and 5 µL of forward primer 5’-
AAGGAAAAAAGCGGCCGCGTCAGCATGCAGTTGTACTGGG-3’ and reverse 
primer 5’-CTAGCTAGCCTTGTGATCTGCCTGTCTTGG-3’ for RALA and 
forward primer 5’-AAGGAAAAAAGCGGCCGCG AGGAGTAAAGCTAAAGAGCTGG-
3’ and reverse primer 5’-CTAGCTAGCGCTTTACCTTGCCGCACG-3’ for RALB 


















Table 2.12 Primers for amplification of HDR template parts 1 + 2. 
 PART 1 





HDR Overlap - 
TGATGACTTTGTGTAAAGCCAAAG 
RALB 
HDR NotI – 
AAGGAAAAAAGCGGCCGCGAGG 
AGTAAAGCTAAAGAGCTGG 
HDR Overlap –  
GCTCTGGCCCTTACTCTTG 
 
 PART 2 
 Forward (5'>3') Reverse (5'>3') 
RALA 




















HDR NheI - 
CTAGCTAGCGCTTTACCTTGCCGC 
ACG 
The HDR template for both isoforms were generated in two parts. Restriction 






Table 2.13 Thermal cycler programme for tail PCR. 
 Step No. of Cycles Temperature Time 
1 Initial Denaturation 1 94°C	 3 minutes 
2 Denaturation 
13 
94°C 20 seconds 
3 Annealing 63°C 1 minute 
4 Extension 72°C 1 minute 
5 Denaturation 94°C 20 seconds 
6 Annealing 61°C 1 minute 
7 Extension 72°C 1 minute 
8 Denaturation 94°C 20 seconds 
9 Annealing 61°C 1 minute 
10 Extension 72°C 1 minute 
11 Denaturation 94°C 20 seconds 
12 Annealing 50°C 1 minute 
13 Extension 72°C 1 minute 
14 Final Extension 1 72°C 5 minutes 
 
 
Overlap PCR reactions were run on a 1% agarose gel and each complete 
template was extracted before digestion with NheI and NotI and subsequent 
ligation into the NheI/NotI pre-digested pLeGO-EGFP/2A-Puro. 
To confirm successful ligation of the HDR DNA template into the vector, a PCR 
reaction was set up using 25 ng of plasmid DNA and 2 different primer pairs 
for double verification (Table 2.15). Correct plasmids were subsequently 
transformed into STABLE competent cells prior to larger scale DNA 




Table 2.14 Thermal cycler programme for overlap PCR. 
 Step No. of Cycles Temperature Time 
1 Initial Denaturation 1 95°C 15 minutes 
2 Denaturation 35 94°C 1 minute 
Annealing 55°C - 61°C 1 minute 
Extension 72°C 1 minute 
3 Final Extension 1 72°C 10 minutes 
 
 









G23V mutant - 
GACTTGCCAACTCCAACGG 
2 
G23V mutant - 
GTGGGCTCCGTTGGAGTTG 
HDR NheI - 
CTAGCTAGCCTTGTGATCT 
GCCTGTCTTGG 




 Forward (5'>3') Reverse (5'>3') 
1 
HDR NotI - 
AAGGAAAAAAGCGGCCGCGAGG 
AGTAAAGCTAAAGAGCTGG 
G23V mutant - 
ACGCCTACACTACCCACC 
2 
G23V mutant - 
ATGGTGGGTAGTGTAGGC 
HDR NheI - 
CTAGCTAGCGCTTTACCTTG 
CCGCACG 






2.3.8 PCR screen for knock-in 
Due to time constraints, screening for knock-in clones was not carried out. 
However, the following protocol can be used to detect HDR template insertion 
and successful integration of mutations. 
Following Cas9 induction by doxycycline treatment in conjunction with viral 
transduction (section 2.1.7) with either pLeGO-EGFP/2A-Puro-gRNA#4-RALA 
or pLeGO-EGFP/2A-Puro-gRNA#4-RALB, initial verification of successful 
transduction is confirmed through positive GFP expression. Transduced cells 
undergo antibiotic selection (section 2.1.5) before single cell isolation into a 
96-well plate. After cell expansion and colonies formation, the plate is split into 
two new 96-well plates: one for knock-in cell line expansion and one for 
genotyping. Genomic DNA is extracted from one plate using a NaOH lysis 
method (Wang, Qi and Cutler, 1993). Briefly, 200 µL of 0.5 M NaOH is added 
to each well. Once mixed with the cells, 5 µL of the suspension is diluted in 
495 µL 100 mM Tris-HCl, pH 8.0 and then 1 µL of the dilution is used as 
template DNA for PCR amplification. 
To screen for a successful knock-in of the desired HDR template, isolated DNA 
undergoes genotyping PCR using primers situated in Exon 1 in combination 
with primers designed to bind to the mutated sequence only (Table 2.16). 
Once CRISPR/Cas9 gene edited cells have been identified and verified by 
PCR (and immunoblotting for knockout cell lines), they are sent off for 
sequence verification along with the genotyping primers listed in Table 2.17 















 Forward (5'>3') Reverse (5'>3') 
1 GCTGATACCCCATTATTGTCAGC GACTTGCCAACTCCAACGG 
2 GTGGGCTCCGTTGGAGTTG AATCAAGTTATGTACAGATGGCTC 




 Forward (5'>3') Reverse (5'>3') 
1 GTGACTTCCAGAGTTGTTGG ACGCCTACACTACCCACC 
2 ATGGTGGGTAGTGTAGGC CGATGCAAGCAGCGATGTCTC 




Table 2.17 Genotyping primers for sequencing EXON 1. 
Genotyping Primers (sequence 5'>3') 
RALA 
Gen 1F (genotyping forward 1) AGATCCTTTAGCCTGCTTTCG  
Gen 2F (genotyping forward 2) CGTATCTGTGTGGACATATTGC  
Gen 1R (genotyping reverse 1) AATTTTAGTGACTTGGCCTGC  
Gen 2R (genotyping reverse 2) CATGCCAAACACACAATAAACG 
 
RALB 
Gen 1F (genotyping forward 1) GTGAGCATGTGTGTGAATGTGG 
Gen 2F (genotyping forward 2) CATGTGTGAGTGTGTTAGTGACC 
Gen 1R (genotyping reverse 1) GCCCACAGTAGGCTAAGTATCC 








2.4 Protein Biochemistry 
2.4.1 Reagents 
Lysozyme (#L6876), PhosSTOP phosphatase inhibitor tablets 
(#04906837001) and all chemicals used were purchased from Sigma-Aldrich, 
Merck (Poole, UK) unless otherwise stated. Pierce™ BCA Protein Assay Kit 
(#23225), Pierce™ 660 nm Protein Assay Kit (#22662), full range rainbow 
molecular weight protein marker (#11580684) and GE Healthcare Glutathione 
Sepharose™ 4B Media (#11594935) were obtained from Fisher Scientific. 
NuPAGE 4-12% gradient Bis-Tris gels (10 well 1 mm #NP0321BOX, 15 well 
1.5 mm #NP0303BOX), NuPAGE MES buffer (#NP0002-02), SimplyBlue 
SafeStain (#LC6060) were purchased from Invitrogen. Marvel skimmed milk 
powder was purchased from Premier brands, UK. Amersham™ nitrocellulose 
western blotting membrane (#GE10600002), GSTrap™ High Performance 
columns (#GE17-5281-01) and HisTrap™ High Performance columns 
(#GE17-5247-01) and Amicon® Ultra Ultra Centrifugal filters (#UFC900) were 
obtained from Sigma-Aldrich, Merck.  
2.4.2 Cell lysis 
Samples for isolation of protein were washed 3 times with ice cold 1X PBS 
and resuspended in 150 µL RIPA lysis buffer (10 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.1% SDS, 1% sodium deoxycholate and 1% Triton X-100) 
containing 1X protease inhibitor cocktail and PhosSTOP phosphatase inhibitor 
cocktail. Plates were left rocking on ice for 10 minutes before lysates were 
collected into Eppendorfs and sonicated for 3 x 10 seconds. Samples 
underwent centrifugation at 13,000 g for 20 minutes at 4°C. Supernatants were 
transferred to a new tube and protein concentration quantified using a protein 
assay kit. Lysates were then stored at -20°C until use. 
2.4.3 Concentration determination 
The Pierce BCA protein assay kit was used to determine protein concentration 
of cell lysates. Bovine IgG was used for the standard curve concentrations. 
The kit was used according to manufacturer’s instructions with a typical BCA 
protein assay depicted below. Samples were read on a Multiskan Spectrum 
plate reader at A562 following 30 minutes incubation at 37°C. The Pierce 660 
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nm protein assay kit was used to determine the concentration of recombinant 
proteins. A typical 660 nm protein assay is depicted below, and samples were 
read on a Multiskan Spectrum plate reader immediately after the addition of 
Reagent B. 








































Sample - 13 - 2 200 
*BCA mixture was made with 50 parts BCA Reagent A with 1-part 
Reagent B. 
Final sample concentration (mg/mL) is calculated from the µg/well 
standard curve and divided by the volume of test sample. 
 












































Sample - - 5 5 
150 µL of Reagent B was added to each well 
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2.4.4 Sodium Dodecyl Sulphate polyacrylamide electrophoresis (SDS-
PAGE) 
Protein samples were resolved by SDS-PAGE using precast NuPAGE 4-12% 
Bis-Tris gels. Protein lysates harvested in RIPA or NP-40 buffer were 
resuspended in 5X sample buffer (310 mM Tris-HCl pH 6.8, 50% w/v glycerol, 
16% w/v 2-Mercaptoethanol, 15% w/v SDS, 0.05% w/v Bromophenol Blue) 
and boiled at 98°C for 5 minutes. Bacterial pellets or “hot lysates” were 
resuspended in 10X hot lysis buffer (1M DTT, 1% Bromophenol Blue) and 
boiled at 110°C for 5 minutes before loading onto the gel. Depending on the 
concentration of cell lysate collected, 10-20 µg of protein was usually loaded 
into each well.  
Precast NuPAGE 4-12% gradient Bis-Tris gels in a XCell SureLock Mini-Cell 
System (10, 15 and 20 wells) were used for most experiments. MES buffer 
was used to separate lower molecular weight proteins with the gels run at 150 
V for 90 minutes. 
2.4.5 Western blot 
Following electrophoresis, proteins were transferred to a nitrocellulose 
membrane for 1 hour at 100 V. Each membrane was blocked with 5% milk in 
1X TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 2 hours 
at room temperature. Blots were washed three times with 1X TBST and 
incubated with primary antibodies (Table 2.20) diluted in 5% milk/ 1X TBST 
overnight at 4°C. Unbound antibodies were washed off 3 times with 1X TBST, 
changing the TBST every 5 minutes. Membranes were then incubated with a 
secondary antibody (Table 2.21) for 45 minutes at room temperature. 
Membranes were washed with 1X TBST for 15 minutes as previously 
described and results visualised on an Odyssey CLx LI-COR. 
Quantification of protein expression was carried out using Image Studio Lite 
software and statistical analysis using Welch’s Analysis of Variance (ANOVA) 
parametric test was conducted on GraphPad PRISM software. The Welch’s 




Table 2.20 Primary antibodies for western blotting. 
Antibody Name Target Protein Species Source Dilution 











R CST, 2914 1:1000 
Cas9 (7A9-3A3) Cas9 M CST, 14697 1:1000 
DUSP4 
[EPR19881] DUSP4 R Abcam, ab216576 1:1000 
DUSP5 
[EPR19684] DUSP5 R Abcam, ab200708 1:1000 












R CST, 14069 1:1000 
Exoc2 
[EPR9420] Sec5 R Abcam, ab140620 1:1000 
Exoc8 Exo84 R Abcam, ab106121 1:500 
KRAS KRAS M LSBio, C175665 1:2000 
His Tag His M Amersham, 27471001 1:3000 
P44/42 MAPK 











PKCa/b II R CST, 9375 1:1000 
RALA RALA R CST, 3526 1:1000 
RALB RALB R CST, 3523 1:1000 
RALBP1 RALBP1 R Abcam, ab33446 1:500 
RALGDS RALGDS R Abcam, ab65204 1:1000 
WEE1 WEE1 R CST, 4936 1:1000 





Table 2.21 Secondary antibodies for western blotting. 
Secondary Antibody Catalogue No. Dilution 
IRDye® 680RD Donkey 
anti-Rabbit 
926-68073 1:15,000 
IRDye® 680CW Donkey 
anti-Mouse 
926-68072 1:15,000 
IRDye® 800CW Donkey 
anti-Rabbit 
926-32213 1:15,000 





2.4.6 GST-RALBD protein production 
Construct pGEX-GST-RALBD was a gift from Dr Ignacio Rubio. GST-RALBD 
contains amino acids 397-518 of the binding domain of RAL effector RALBP1 
(RAL binding protein/RLIP76). Following transformation into DH5-alpha 
competent cells, single colonies were grown overnight in 5 mL LB media with 
100 μg/mL Ampicillin and glycerol stocks made the following day. 
Scrapings from each glycerol stock were grown separately in 5 mL LB broth 
for 6 hours at 37°C at 245 rpm. 100 μL of each culture was transferred to 100 
mL of LB broth plus ampicillin and grown overnight under the same conditions. 
All the overnight culture was spiked into 900 mL of fresh LB broth and grown 
to an OD600 of 0.6, before induction with isopropyl B-D-
1thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Bacteria were 
incubated for overnight at 20°C, and the bacteria collected by centrifugation at 
3000 x g, 15 minutes. Pellets were washed once with ice cold 1X PBS and 








2.4.7 GST-RALBD protein purification 
Bacterial pellets were resuspended in ice- cold IMAC20 (20 mM Tris-HCl, pH 
7.4, 0.5 M NaCl) 5 mL per 1 g of bacteria, supplemented with bacterial 
protease inhibitors (1:500, #P8465, Sigma-Aldrich). Lysozyme was added to 
a final concentration of 1 mg/mL and incubated on ice for 30 minutes with 
regular agitation. The bacterial lysate underwent sonication 5 x 10 seconds 
with 30 second intervals on ice, ahead of centrifugation at 82,000 x g for 30 
minutes at 4°C. The supernatant was collected and filtered using a 0.2 µm 
syringe filter before purification on the ÄKTA purifier system equipped with 
Frac950 and UPC900 (GE Healthcare, Buckinghamshire, UK) using a GSTrap 
HP columns according to manufacturer’s instructions. Data was analysed on 
Unicorn 5.31 software.  
 
Table 2.22 Buffers for GST-protein purification. 
GST-RALBD purification buffers for ÄKTA 
 Reagent Final Concentration 













2.4.8 Protein concentration and storage 
Purity of GST-RALBD protein was checked by subjecting 20 µL from each 
elution well to SDS-PAGE, using 4-12% bis-tris NuPAGE gel, before colloidal 
blue staining. 
GST-RALBD protein was concentrated and eluted using an Amicon Ultra 30-
kDa MWCO filter at 3000 x g with wash and store buffer (10% glycerol, 50 mM 
Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) until the total 
volume reduced to ~0.5 mL. Concentration was determined by BCA assay and 
Pierce 660 nm (Table 2.18 and Table 2.19) before being flash frozen in liquid 




2.4.9 RAL activity assays 
Cell Preparation and Lysis 
PAR and RAL KO cell lines were seeded in 10 cm dishes to be at least 80% 
confluent for all activity assays. Following overnight serum starvation, all 
media was exchanged for fresh medium supplemented with 10% FBS and 50 
ng/mL EGF to stimulate the RAL pathway. Treatment time was determined 
following an EGF time course (0-20 minutes) on a parental clone from each 
cell type. Dishes were immediately placed on ice, washed once with ice cold 
1X PBS and 150-300 μl of cell lysis buffer (25 mM Tris-HCl pH 7.5, 5 mM 
MgCl2, 0.25 M NaCl and 2% Igepal CA-630 (Nonidet P-40) was added to each 
dish for at least 30 seconds before scraping into a 1.5 mL eppendorf. Cell 
lysates underwent centrifugation at 1000 x g for 2 minutes at 4°C before the 
supernatant was transferred to a new LoBind Eppendorf and flash frozen in 
liquid nitrogen. A small volume of lysate was left with the pellet for use in a 
BCA assay to determine concentration. Treated cell lysates were stored at -
80°C until use. 
 
RALA/B Pulldown 
Previously treated lysates were defrosted in a water bath at room temperature 
and made up to 1 mg/mL in cell lysis buffer. 400 μl (400 μg) of each lysate was 
added to a new 1.5 mL tube already containing 10 μg of Glutathione 
Sepharose beads pre-mixed with 10 μg of GST-RALBD in 200 μL cell lysis 
buffer (600 μL total in tube). Samples were incubated with rotation at 4°C for 
1 hour. Following centrifugation at 1000 x g for 2 minutes at 4°C, supernatant 
was carefully removed with gel loading tips to avoid disturbing the beads and 
washed once with wash buffer (25 mM Tris-HCl pH 7.5, 30 mM MgCl2, 40 mM 
NaCl) and resuspended in 16 μL 4X loading buffer and heated at 95°C for 5 
minutes. 8 μL was loaded in duplicate onto a 4-12% Bis-Tris gel for separate 
RALA and RALB probing by western blot. 20 μg of total cell lysate was run 
alongside each pulldown to probe for total RALA/B and actin. Quantification of 
active RALA and RALB was performed using Image Studio Lite software and 
normalised to actin expression across 3 separate repeats. 
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2.4.10 Reverse Phase Protein Array (RPPA) analysis 
Cell pellet samples were collected and sent to the Functional Proteomics 
RPPA Core Facility at the MD Anderson Cancer Center 
(https://www.mdanderson.org/research/research-resources/core-
facilities/functional-proteomics-rppa-core/rppa-process.html). Cell pellets 
were lysed using RPPA buffer and protein extracted. Lysates were serially 
diluted in 5 two-fold dilutions and using an Aushon Biosystems 2470 arrayer, 
applied onto nitrocellulose-coated slides. The slides were probed with 466 
previously validated primary antibodies followed by detection with secondary 
antibodies. Samples were then visualised by DAB colourimetric reaction to 
produce stained slides and scanned on a Huron TissueScope scanner. 
Primary data analysis conducted at the facility generated normalised linear 
data values for protein expression and modification. Once this dataset was 
received, a correlation analysis was conducted between cell lines. A 
correlation coefficient value was generated using the CORRELL function in 
Microsoft excel. Perfect correlation between two samples is indicated by a 
coefficient of +1, whereas -1 indicates an inverse relation and lack of 
expression similarity. 
To determine the expression fold change for KO vs PAR, the normalised linear 
values for each RAL status within a cell line were averaged (PAR1+PAR2, 
AKO1+AKO2, BKO1+BKO2) and a ratio for AKO/PAR and BKO/PAR were 
generated. Each ratio was subsequently turned into a log ratio for visualisation 
of fold change.  
To allow for comparison of isoform specific knockout verses parental protein 
expression, log2 fold change of ±0.5 were used to generate heatmaps in 







2.5 Protein Standard Absolute Quantification (PSAQ) 
The PSAQ method described below was optimised throughout my project and 
adapted from: Hood FE, Sahraoui YM, Jenkins, RE and Prior IA. Absolute 
quantitation of GTPase protein abundance. Methods in Molecular Biology 
(2021) in press. 
2.5.1 Production of heavy labelled His tagged RAL standards 
Scrapings from ptrcHis-A-RALA and ptrcHis-A-RALB glycerol stocks were 
grown separately in 5 mL LB broth for 6 hours at 37°C at 245 rpm. 100 μl of 
each culture was transferred to 100 mL of 1X M9 minimal media (Table 2.23) 
and grown overnight under the same conditions. All the overnight culture was 
spiked into 900 mL of fresh 1X M9 minimal media and grown to an OD600 of 
0.6, before induction with isopropyl B-D-1thiogalactopyranoside (IPTG) to a 
final concentration of 1 mM. Bacteria were incubated for a further 3 hours, and 
the bacteria collected by centrifugation at 3000 x g, 15 minutes. Pellets were 
washed once with ice cold 1X PBS and pelleted again before storing at -80°C.  
2.5.2Affinity purification using His-Trap columns 
Bacterial pellets were prepared as outlined in section 2.4.7 before purification 
on the ÄKTA purifier system using the following steps:  
1. Wash the His-Trap column at 1 mL/min with 5 column volumes (CVs) 
of Binding Buffer (20 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 20 mM 
Imidazole), then 5 CVs of Elution Buffer (20 mM Tris-HCl, pH 7.4, 0.5 
M NaCl, 500 mM Imidazole) 
2. Equilibrate the His-Trap column with 10 CVs of Binding Buffer. 
3. Batch load the filtered lysate supernatant onto the HisTrap column 
through a 5 mL loop using a 5 mL syringe. 
4. Equilibrate the His-Trap column with 10-15 CVs of Binding Buffer. 
5. Run the imidazole gradient: 
a. Monitor protein elution by reading absorbance at 280 nm using a 
UV module throughout 
b. 1 mL/min flow rate throughout 
c. 0-60% Elution Buffer (20-300 mM imidazole) over 21.5 CVs 
d. 0.25 mL elution fractions 
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e. 3 mLs gradient delay 
2.5.3 Purification check 
For the filtered lysate and flow-through samples (40 µL each), 40 µL of hot 
lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol) was added and 
the samples boiled at 110°C for 15 minutes with frequent vortexing. Following 
microfugation for 5 minutes at 17,000 x g, 10 µL of 10X hot lysis buffer gel 
loading dye (1 M DTT, 1% Bromophenol blue) was added before a second boil 
at 95°C for 5 minutes. 
20 µL from each elution fraction within an observed UV peak was added to 5 
µL of 5X SDS-PAGE sample buffer before boiling at 95°C for 5 minutes.  
 
To check for successful enrichment and purity of the His-tagged 
RALA/proteins, 10 µL of each was run per lane on replicate 4-12% Bis-Tris 
NuPAGE gels using 1X MES running buffer. One gel was stained using 
SimplyBlue SafeStain and the other was transferred onto membrane for 
probing with an anti-His tag and RALA and RALB antibodies (see 2.4.5). 
2.5.4 Size-based purification using gel filtration 
Appropriate fractions were collected and pooled together before concentration 
in gel filtration buffer (40 mM Tris-HCl, pH 7.4, 50 mM NaCl, 5 mM MgCl2) 
using an Amicon Ultra 15 kDa MWCO filter column, under centrifugation at 
3000 x g until the total volume reached ~500 μL. 
Concentrated proteins were run through a Superdex 200 column previously 
equilibrated with 1.5 CVs of gel filtration buffer and collected in 1.25 CVs with 
an elution fraction size of 0.25 mL at a flow rate of 0.5 mL/min throughout. 
Again, 20 µL of each fraction of interest (based on the peak observed in UV 
trace) was taken and prepared as before to confirm purity using SDS-PAGE 






Table 2.23 1X M9 minimal media recipe. 




5X M9 media pH 7.4 
(autoclaved) 
120 mM Na2HPO4 
55 mM KH2PO4 
21.5 mM NaCl 
10 mM NH4Cl 
1X 
Hydrophobic amino 























Heavy (light for tests) 
L-Arginine and L-Lysine 




glucose glucose 0.4% 
Thiamine-HCl (1 
mg/mL) 
Thiamine HCl solution 1 μg/mL 
MgSO4 (1 M) MgSO4 solution 1 mM 
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CaCl2 (1M) CaCl2 solution 0.1 mM 
ZnSO4 (0.1 M) ZnSO4 solution 20 μM 
Trace metals mix Trace Metals A5 with Co 0.1% 
Ampicillin Ampicillin solution 100 μg/mL 
 
 
2.5.5 Storage and concentration determination of standards 
Desired gel filtration fractions were combined and concentrated using 10 kDa 
molecular weight cut-off 0.5 mL Centricon columns until the final volume of the 
protein standard is 150-400 µL. RAL isoform concentration was checked by 
BCA assay and the protein diluted using using 5X SDS-PAGE sample buffer 
to a final concentration of 1X sample buffer. Samples were boiled for 5 minutes 
at 95°C before being aliquoted into LoBind Eppendorfs and flash frozen in 
liquid nitrogen and stored at -80°C. 
The percentage of heavy labelling was determined using standard LC-MS or 
MRM by comparing heavy protein to a known concentration of light His-RALA 
and analysed using ProteinPilot5 software. 
2.5.6 Harvesting cells 
Cells were grown in 10 cm dishes to 80% confluence before dissociation with 
the appropriate reagent outlined in section 2.1.2. Cells were pelleted by 
centrifuging at 150 x g for 5 minutes and the supernatant aspirated off before 
resuspension of the cell pellet in 9 mL of medium supplemented with 10% 
FBS. A total of 9 mL was immediately transferred to a fresh 15 mL centrifuge 
tube for collecting the cell pellet (section 2.5.7). The remainder of the cell 
suspension was used for counting on a haemocytometer, with an average of 
two counts being within 5% of each other. 
2.5.7 Collecting cell pellets 
The 9 mL of cell suspension was centrifuged at 150 x g for 5 minutes at room 
temperature. The media was aspirated off and the cell pellet resuspended in 
10 mL of ice-cold PBS. Following a repeat centrifugation at 4°C, each cell 
pellet was resuspended in 300 μL of ice-cold PBS using a wide bore tip and 
transferred to a LoBind Eppendorf on ice. A fresh tip was used to add another 
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300 μL ice-cold PBS to the tube and the sample gently mixed before spinning 
at 150 x g for 5 minutes at 4°C. Each pellet was resuspended in 300 μL of ice-
cold PBS and transferred to a new LoBind Eppendorf before centrifugation. All 
PBS was removed using gel loading tips and either flash frozen in liquid 
nitrogen and store at -80°C or lysed on ice in NP40 lysis buffer. 
2.5.8 Cell lysis and spike-in 
Cell pellets were resuspended in 140-300 μL of NP40 lysis buffer and 
incubated on ice for 10 minutes. Following centrifugation at 17,000 x g for 15 
minutes at 4˚C, supernatant was collected and transferred to a new LoBind 
Eppendorf. 
Protein concentration was determined by BCA assay and final samples of 20 
μg of cell lysate with 2 ng of heavy His-RALA and His-RALB each were made 
and prepared for SDS-PAGE. 
Samples were separated by SDS-PAGE on a self-poured 15 well, 1 mm 10% 
gel at 100 V until all rainbow protein markers could just be visualised. 
Alternating lanes of rainbow marker and samples were run to aid in ease of 
gel extraction and reduce sample contamination. 
2.5.9 In-gel Digestion  
Once samples have been separated by SDS-PAGE, the gel was fixed with 
10% Acetic acid / 50% methanol for 10 minutes at room temperature with 
gentle rocking. Gels were washed in HPLC grade water 3 x 5 minutes, moved 
to a laminar flow hood and the region of interest (17-31 kDa) excised using 
sterile scalpel blades which were cut further into approximately 1 mm cubes 
and placed into a LoBind Eppendorf. 
Samples then underwent the following in-gel digestion steps: 
1. Dehydrate samples by adding 300 μL of 100% ACN to cover the gel pieces. 
Incubate at 37°C for 10 minutes, 900 rpm on a thermoshaker.  
2. Dry tubes completely using a SpeedVac for 5 minutes at 37°C. 
3. Reduce samples by adding 300 μL 10 mM DTT and incubate at 56 °C for 
1 hour at 900 rpm on a thermoshaker. Discard supernatant. 
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4. Alkylate samples by adding 300 μL of 50 mM IAM. Incubate in the dark for 
30 minutes, at room temperature, 900 rpm on a thermoshaker. Discard the 
supernatant. 
5. Wash samples by adding 300 μL of 100 mM Ambic. Incubate for 15 
minutes at room temperature, 900 rpm on a thermoshaker. Discard the 
supernatant. 
6. Wash samples by adding 300 μL of 50 mM Ambic / 50% ACN. Incubate for 
15 minutes at room temperature, 900 rpm on a thermoshaker. Discard the 
supernatant. 
7. Dehydrate the gel slices by adding 300 μL of 100% ACN. Incubate for 5 
minutes at room temperature, 900 rpm on a thermoshaker. Discard the 
supernatant. Repeat this step as many times as necessary until the pieces 
are small, hard and opaque white. 
8. Dry tube completely by SpeedVac for 5-10 minutes at 37°C. 
9. Make up a single stock of 2.5 ng/μL trypsin to cover all samples (typically 
60-90 μL per sample), plus excess, in reaction buffer.  
10. Add 1 volume trypsin to each tube and incubate for ~16 hours at 37°C. 
11. Add 1 volume of 100% ACN. Incubate for 30 minutes at 30°C, 900 rpm on 
a thermoshaker. 
12. Transfer the supernatant to a fresh LoBind Eppendorf. Repeat step 15 if 
pieces are not completely dehydrated. 
13. Add 1 volume of freshly prepared 1% formic acid to gel pieces. Incubate at 
room temperature for 20 minutes at 900 rpm on a thermoshaker. Transfer 
the supernatant to the same Eppendorf as in step 16. 
14. Repeat step 17. 
15. Add 1 volume of 100% ACN to the gel pieces. Incubate at room 
temperature for 10 minutes at 900 rpm on a thermoshaker. Transfer the 
supernatant to the same Eppendorf as in step 16. Repeat until gel pieces 
shrink and turn white. 
16. SpeedVac the peptides overnight at 37°C to dry them and store at -20°C. 
2.5.10 Desalting and clean-up 
Once peptides were dry, each sample was resuspended in 100 µL 0.1% TFA 
before microfugation at 12,000 x g for 5 minutes. Samples were transferred to 
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prelabelled glass vials and run on the Agilent 1260 to desalt. The peptides 
were then dried overnight at 37°C in the SpeedVac. 
2.5.11 Quantification of endogenous RAL levels in cell lysates 
Desalted samples were reconstituted in 11 µL of 0.1% formic acid and 
delivered into the mass spectrometer in 5 µL aliquots.  
The precise molecular weight (Mw) (in Daltons, Da) of the heavy standard 
(including His-tag) and was obtained by entering the protein sequence into 
ProtParam on the ExPasy webpage. The number of moles was then 
calculated by dividing the mass (g) by the molecular weight. A ratio of 
endogenous(light)/standard(heavy) AUC was calculated and multiplied by the 
number of moles to give the number of moles per lane. The calibration curve 
equation for each peptide can also be used to determine the number of moles 
of protein per lane. The following quantifications were then calculated: 
1. The number of moles per μg lysate (moles per lane divided by μg lysate 
per lane). 
2. The number of cells per μg lysate (number of cells in the pellet divided 
by the total μg lysate yielded). 
3. The number of moles per cell (step 1 divided by step 2). 
4. The number of molecules of RALA and RALB per cell by multiplying 












Chapter 3: Selecting cells for RAL biology 
analysis 
3.1 Introduction 
RAL is known to play a part in many cellular functions, including the exocyst 
and exocytosis (Moskalenko et al., 2002), actin organisation (Sugihara et al., 
2002) and gene transcription (Frankel et al., 2005). Studies like these have 
predominantly relied on the use protein overexpression to highlight the 
biological roles of RAL, with the caveat that overexpression perturbs cell 
signalling pathways. Furthermore, outside of its immediate effectors, the RAL 
pathway and its functions remains poorly understood in comparison to other 
RAS effector pathways.  
Endogenous RAL has been looked at using siRNA/shRNA and has provided 
evidence to support RAL’s participation in mitochondrial fission (Kashatus et 
al., 2011), invadopodia formation (Neel et al., 2012), autophagosome 
assembly (Bodemann et al., 2011), and the transformation and growth 
promoting activity of RAS (Chien and White, 2003; Kidd et al., 2010; Guin et 
al., 2013). However, knockdown experiments have their own limitations that 
include silencing of sequence specific non-target mRNAs and impairment of 
endogenous microRNA function (Boettcher and McManus, 2015). 
Protein overexpression has supported the idea that RAL plays a role in cancer. 
It has been demonstrated that the presence of a negative RALA mutant blocks 
overproduction of urokinase-type plasminogen activator and metalloproteases 
leading to v-Src and v-RAS induced tumourigenicity and an invasive, 
metastatic phenotype  (Aguirre-Ghiso et al., 1999). Activation of c-Src by EGF 
has been shown to occur through a RAL dependent mechanism with 
constitutively active RAL leading to phosphorylation of Stat3 and cortactin (Goi 
et al., 2000).  
However, these studies do not actually demonstrate the involvement of RAL 
in oncogenesis or metastasis development. Again, the use of ectopically 
expressed proteins in the experiments conducted, do not mimic those seen in 
physiological situations. The resulting protein overexpression used in these 
methods, may lead to improper subcellular localisation and in some cases 
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constitutively activated endogenous counterparts. Therefore, knockout cells 
that can be used to show that the loss of RAL expression reverts the 
transformed phenotype of tumour cells are highly beneficial. 
Together, the data currently available highlights the need for an appropriate 
model that can be utilised to study general RAL isoform function as well as 
any role the pathway plays in cell dysregulation and cancer progression. The 
generation of a panel of isoform-specific gene edited cell lines would 
overcome many of the problems associated with knockdown and 
overexpression studies and ultimately help elucidate the importance of RAL 
signalling downstream of oncogenic RAS. 
3.1.1 Suitable RAL relevant cell lines 
Since RAL primarily acts as an effector of active RAS, it seemed sensible to 
choose a RAS model focusing on one specific cell type to study RAL isoform 
biology. We also wanted to factor in RAL dependency on oncogenic RAS, 
particularly the most frequently mutated isoform, KRAS. With mutations in all 
three RAS oncogenes present in over 50% of colorectal carcinomas 
(Serebriiskii et al., 2019), colorectal cell lines are a suitable choice when 
studying RAL. 
RALA and RALB have also been shown to demonstrate antagonistic roles in 
colorectal cancer, with RALA activation required for anchorage-independent 
growth, whilst RALB suppression enhanced tumour survival (Martin et al., 
2011). This is an intriguing result that presents the idea of opposing roles for 
the RAL isoforms that might not just be confined to oncogenic RAS.  
Table 3.1 displays the panel of colorectal cell lines chosen for consideration. 
The fact there is mutant and wildtype RAS present in this cell panel, is an 
important feature for looking at normal and disease driven RAS biology. A 
recent study looking at RAS and RAL contributions to cell viability via 
knockdown (Lee et al., 2019), found a difference in terms of cell survival across 
this particular panel of colorectal cell lines. However, the reasons for the 
difference in RAL dependency between WT and mutant KRAS and even within 
various KRAS mutations remains unclear. Focusing on these colorectal cell 
lines, will provide the opportunity to discover new things about RAL function 
and its involvement in oncogenic RAS signalling. 
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Table 3.1 Mutational status of colorectal cancer cell lines considered. 
Cell 
Line 








WT RALA, RALB: WT Q1367* 
DLD-1 Colon, 
adenocarcinoma 

























WT RALA, RALB: WT R2714C 
SW403 Colon, 
adenocarcinoma 





G12V RALA, RALB: WT 
RALGAPA2: W620L 
Q1338* 
KRAS mutation status was obtained from Broad Institute Cancer Cell Line 
Encyclopaedia and verified on COSMIC. All heterozygous except SW620. 
Abbreviations: WT (wild type), *nonsense mutation. 
 
3.1.2 Aims and Objectives 
To screen a panel of colorectal cell lines to assess whether they would be 
potentially suitable for CRISPR/Cas9-mediated gene editing and subsequent 
study of RAL isoform biology. Assessment consisted of ease of handling 











3.2.1 Ease of handling 
Ease of handling is an important factor for selecting cells that are amenable to 
CRISPR/Cas9 gene editing. This focused on two key criteria: 
i) Transfection efficiency – this increases the likelihood of gene editing 
taking place. 




Transfection of a plasmid expressing GFP (Supplementary Supplementary 
Figure 7.7) using standard lipid transfection reagents was carried out to assess 
plasmid uptake efficiency. Although lentiviral particle production is an option 
for generating CRISPR/Cas9 edited cell lines, the large size of the Cas9 
enzyme leads to difficulties in viral particle packaging and additional steps 
would be required to aid transduction, lengthening the overall procedure time. 
Since the LentiCRISPR plasmid also contains an antibiotic selection marker, 
transfection using normal lipid transfection was deemed a sufficient technique 
for generating isoform specific RAL knockouts. Poor GFP expression was 
observed in CaCo2 and SW403 cell lines (Figure 3.1). Visible GFP expression 
was seen in the remaining colorectal cell lines tested with HCT116 cells 
showing GFP fluorescence levels similar to those observed in HEK293T cells. 
 
Amenability for single cell clonal selection 
Trypsin with 0.5% EDTA cell dissociation reagent was systematically profiled 
across the panel of cell lines to determine the ease of single cell isolation. As 
well as the laboratory standard, alternative dissociation reagents were 
investigated and StemPro Accutase was identified as a convenient and cost-
effective detachment solution, as well as being a direct substitute to trypsin, 
since it is made up of proteolytic and collagenolytic enzymes not derived from 
mammalian or bacterial products. 
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However, even with the use of these different reagents, some cell lines still 
didn’t dissociate. Several of the cell lines, most notably CaCo2, remained 
clumpy (upwards of 5 cells) following dissociation tests, as did DLD-1 and 
LoVo, although to a lesser extent. The inability to grow these cells from single 
cell clones meant that these were automatically excluded from final selection. 
Partial isolation, in which a mix of single cells and cell clumps is achieved, was 
observed in two cell lines, HCT116 and SW48. As a result, out of all cell lines 
described in Table 3.1, HCT116, SW48, SW403 and SW620 were the only 
ones that could be reliably cultured from single cell clones. These four cell 




Figure 3.1 GFP expression following lipid-based transfection. 
GFP expression following transfection of pEGFP-C1 using Lipofectamine LTX PLUS in a 
panel of colorectal cell lines plus HEK293T cells at 10X magnification. GFP fluorescence is 







3.2.2 Activation of the RAL pathway 
In order to achieve the primary aim of generating gene-edited cell models 
investigating isoform-specific RAL biology, it was important to select cell lines 
with RAL pathways that were demonstrably functional. An essential 
requirement for the selection of suitable cell lines was that RAL could be 
activated in response to upstream stimulation. An overview of the RAL activity 
assay is shown in Figure 3.2. Following stimulation of RAS through EGF at 
various timepoints, cells were lysed and incubated with a GST fusion protein 
containing the RAL binding domain of RAL effector RALBP1 (RLIP76) 
(Wolthuis et al., 1998a). Since this protein only binds to the GTP-bound active 
form of RAL, both isoforms were isolated and the activity of each determined 
by western blotting. Probing for phospho-ERK, a known RAS effector in the 





Figure 3.2 An overview of the RAL activity assay. 
Following stimulation of the RALGEF/RAL pathway with EGF, cell lysate is incubated with 
GST-tagged RALBD (RAL binding domain of RAL effector RALBP1) and sepharose beads. 
The beads are subsequently washed and resolved by SDS-PAGE before probing for RALA 
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Overall, all cell lines except one showed an increase in RALA and RALB 
activity (Figure 3.3 & Figure 3.4). In general, peak RAL activity was observed 
following 1-2 minutes of EGF treatment. No obvious difference was seen 
between the activity of one isoform compared to the other in any cell line. The 
total protein expression for RALA and RALB remained the same throughout 
the time course in all cell lines. 
Cell line HCT116 displayed the fastest but also the most short-lived activation 
of both isoforms following only 1-minute EGF treatment, before returning back 
to unstimulated levels (Figure 3.3). A clear and early activation of RALA and 
RALB was also observed in the SW48, peaking at 2 minutes and lasting a total 
of 5-10 minutes (Figure 3.3). SW403 cells also showed an early activation of 
RAL with just 1-minute EGF treatment (Figure 3.4). Unlike the HCT116 cell 
line, RAL activity was prolonged until 5 minutes stimulation. Only SW620 
showed no discernible increase in active RAL expression with EGF treatment 
(Figure 3.4). Instead, a constant level of active protein expression can be seen 
at all time points including untreated.  
HCT116 and SW48 cell lines displayed a clear and steady increase in 
phospho-ERK. This activation was later than that of RAL and started from 
around 5 minutes. A clear increase in phospho-ERK levels could also be seen 
in the SW403 line, peaking around 5-10 minutes after EGF treatment initiation. 
Only SW620 displayed a sharp increase of phospho-ERK at 1 minute, before 





Figure 3.3 RAL activity in parental HCT116 and SW48 cell lines.  
Following treatment with 50 ng/mL EGF at various time points (0-20 minutes), HCT116 cells 
displayed a clear increase in activity of both isoforms at 1 minute before quickly returning back 
to untreated levels. A clear and early activation of RALA and RALB was also observed in 
SW48 parental cells with peak activation around 2 minutes. RAL activity in the SW48 was 
longer lived, lasting 5-10 minutes in total. Phospho-ERK was also probed to confirm 
successful activation of RAS. n=1. 
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Figure 3.4 RAL activity in parental SW403 and SW620 cell lines.  
Following treatment with 50 ng/mL EGF at various time points (0-20 minutes), SW403 cells 
displayed a clear increase in activity of both isoforms at 1 minute that lasted up to 5 minutes. 
SW620 parental did not show any obvious activation of either isoform at any time point. 
Instead, steady expression levels could be seen throughout. Phospho-ERK was also probed 
to confirm successful activation of RAS. SW403 showed an increase in phospho-ERK over 
time, peaking around 5-10 minutes. SW620 displayed an increase in phospho-ERK at 1 



























CaCo2 NO NO NO NO - 
DLD-1 YES YES YES NO - 
HCT116 YES NO YES SOME YES 
LoVo YES YES YES NO - 
SW48 NO NO YES SOME YES 
SW403 YES YES NO YES YES 
SW620 YES YES YES YES NO 
 
Table 3.2 summarises the cell lines under consideration and their desirable 
feature scores to aid final cell selection. Four different cell lines were selected 
to undergo gene editing in an effort to reduce the dangers associated with cell 
line and clonal variability. The following ticked most of the boxes, HCT116, 
SW48, SW403 and SW620.  
 
3.3 Discussion 
In this chapter, an initial pre-screen of cell lines was performed to assess 
whether they would be potentially suitable for CRISPR/Cas9-mediated gene 
editing and subsequent study of RAL biology.  
Generating a panel of gene-edited cell lines from a particular cancer type 
provides more confidence into any insights that were generated. This is 
because signalling is often context-dependent and responses from a single 
cell line may not be representative of the general biology being investigated. 
Colorectal cancer was chosen as the model system because of its high 
relevance to RAS (~50% of colorectal cancer patients harbour mutations in 
KRAS (Serebriiskii et al., 2019)). A recent synthetic lethality study using the 
cell lines in this panel showed knockdown of RAL holds greater toxicity in 
mutant KRAS cell lines compared to WT KRAS (Lee et al., 2019). Here, KRAS 
oncoeffector nodes were determined by which effector knockdowns most 
closely phenocopied that of KRAS loss. RAL was identified as a key node in 
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the mutant cell lines, with ~50% decrease in cell viability observed in HCT116, 
and up to 25% decrease in viability in SW403 and SW620 cell lines. This gives 
confidence that RAL biology is relevant to these cells. However, the distinct 
requirements for RAL across the cell lines also show that there are still 
important aspects of RAL contributions to oncogenesis and RAS signalling 
that remain to be discovered. 
Arguably the most important factors to consider were ease of single cell 
isolation and transfection efficiency for the generation of isogenic cell lines. 
These were the initial cut-off points for cell selection. Once the panel was 
systematically profiled for these criteria and unsuitable cells excluded, the 
ability to display high/clear RAL activation was also deemed highly desirable.  
Although expected, it was difficult to acquire cell lines that satisfied every one 
of these criteria. Transfection using normal lipid-based reagents was variable 
across the whole panel of cell lines. Fortunately, with the inclusion of an 
antibiotic selection marker, even minimal transfection efficiency is more than 
sufficient for generating knockout cell lines. Very poor transfection efficiency 
combined with the inability to isolate single cells resulted in the exclusion of 
the cell lines CaCo2, DLD-1 and LoVo before the next step of testing. 
SW48 did not score highly for all desirable features, but since it was important 
to include a cell line that was WT for KRAS and they were easier to handle 
than CaCo2 cells, they were chosen for further investigation. The addition of 
a WT KRAS cell line gives us the option of exploring RAS-driven and RAS-
independent RAL biology. SW620 is the only line to contain a homozygous 
KRAS mutation. For this reason, as well as being the easiest to isolate single 
cells, it was also included in the final cell selection. Mutations in KRAS are 
recorded as being typically heterozygous, so the presence of a homozygous 
KRAS cell line might enhance RAL activity and therefore help clarify RAL 
mechanisms. It may also address any contribution RAL plays as a result of 
RAS mutant allele-specific imbalance (MASI), in which the mutant allele 
becomes dominant as a result of WT deletion or mutant copy number gain 





Utilising cell lines that have an easily activated RAL pathway or high RAL 
activity in general are optimal for isoform function analysis. High activity places 
a certain degree of dependency on a cell line, with changes in that pathway 
potentially leading to alterations in cell function and viability.  
EGF is a potent growth factor when it comes to activating RAS and the RAF 
pathway, with negligible RAS effector activation seen in serum starved cells 
regardless of RAS status (Hood et al., 2019). Indeed, stimulation of various 
growth factor receptors including EGF, results in rapid activation of RAL and 
a dominant negative RAS completely inhibits RAL activation induced by EGF 
(Wolthuis et al., 1998b). 
Although the activity assays in section 3.2.2 are n=1, the increase in both RAL 
isoforms at multiple time points gives me confidence that RAL was being 
engaged and these cell lines are responsive. Both the SW48 and the SW403 
cell lines have active RAL that is sustained for several minutes. There was no 
clear increase in activity observed in the SW620 cell line. This was repeated 
with my own beads as well as a commercial kit (data not shown) and it failed 
in both cases to see a response. Instead, the signal for protein expression at 
every time point is as strong as the peak activity recorded in the other cell 
lines. This could suggest the SW620 cell line has an active RAL pathway that 
remains high, regardless of stimulation or is faster/slower than the time points 
tested. The RALGEFs RALGPS1A, RALGPS1B and RALGPS2 are thought to 
activate RAL downstream from growth factor receptors independently of RAS 
activation (de Bruyn et al., 2000) and therefore the active RAL observed may 
in part be due to alternate growth factor signalling pathways.  
The duration of RAL activity in all the cell lines tested is relatively short in 
comparison to RAS activity and other RAS effectors. Transient activation of 
RAS has been observed for as long as 10 minutes in both HeLa and MEF cells 
following EGF stimulation (Hennig et al., 2016). Moreover, activity of RAS 
effector ERK was detected for 30 minutes in the same HeLa cells. This is in 
comparison to the average 1-2-minute activity of both RALA and RALB seen 
here, which agrees with the RAL activity duration observed in A14, Rat1 and 
CCL39 cells following growth factor stimulation (Wolthuis et al., 1998b). 
Interestingly, the SW620 cell line is also the only one to not have a gradual 
increase in phospho-ERK expression that is subsequently sustained for 
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several minutes. Rapid, transient activation of ERK by EGF has been reported 
in PC12 cells (Traverse et al., 1992). It is proposed that a mechanism exists 
for rapidly terminating EGF action on the MAPK cascade, even if the growth 
factor is still present, and that this rapid inactivation is likely to take place near 
or at the level of the EGF receptor. This could also explain why the RAL activity 
in the SW620 was not observable at the time points tested, even at 1 minute. 
Surprisingly few studies have recorded RAL activity in this way and in these 
particular cell lines. Usually as a result of RAL regulator alteration, activity has 
mainly focused on the overall activation state of individual RAL isoforms. 
Increased RALA activation after stimulation with 10% FBS for 5 minutes was 
observed in oral squamous cell carcinoma cell lines following knockdown of 
RALGAP (Gao et al., 2019). RALA activity has been shown to significantly 
decrease in HeLa cells following CCCP treatment to induce mitochondrial 
depolarisation (Pollock et al., 2019). Here, the RAL-GTP levels were 
determined over a time course lasting 80 minutes, with little insight into the 
activation status of both isoforms within the initial 30 minutes. Transfection of 
Cos7 cells with either WT or active RAL recorded approximately 8% of WT 
RAL was GTP bound, whilst over 85% of the active version contained GTP 
(Wolthuis et al., 1998a). Although the pulldown method used in all these 
studies was similar to the one used in section 3.2.2, none of them elucidate 
the initiation or duration of endogenous RAL activity in an appropriate RAS 
model.  
 
It is also unclear whether the additional mutations in key RAL regulators will 
interfere with data analysis and interpretation of normal RAL signalling. 
According to the COSMIC database, the RALGAPA2 missense mutation 
(W620L) present in the SW620 has a high pathogenic score of 0.98 (out of 1), 
as does the mutated RALGPS1 (P420L) in HCT116 cells (score 0.95) (Rogers 
et al., 2018). However, none of the resulting mutated proteins present are 
classed as tier 1 genes by COSMIC. This means no evidence of activity that 
may drive cancer has been provided and therefore these mutations are 
unlikely to impact any oncogenic role that RAL might play in the context of 
RAS. Nevertheless, mutational statuses of all RAL GEFs and GAPs will be 
taken into consideration when analysing activity data.  
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RAL itself has also been shown to be a critical regulator of Wnt signalling as 
well as the maintenance of the intestinal stem cell population in mice 
(Johansson et al., 2019). Genetic deletion of either isoform resulted in reduced 
stem cell function and hypersensitivity to Wnt inhibition. Whilst rapid crypt 
death was observed following ablation of both RALA and RALB. This offers up 
the idea of potential crosstalk between the RAS and Wnt signalling pathways 
through RAL activity. Therefore, it should be highlighted that dysregulation of 
the Wnt/β-catenin pathway plays a major role in colorectal carcinogenesis 
(Fodde, 2002). The presence of a mutation in the APC gene occurs more 
frequently than that of KRAS in sporadic colorectal cancer (Gerecke et al., 
2013). Indeed, many colorectal cancer cell lines available mirror this stance 
as they contain various mutations including the common R1450 nonsense 
mutation (Cheadle et al., 2002). This alteration in APCs mutation cluster region 
results in the truncated protein and subsequent Wnt signalling dysregulation. 
None of the cell lines included in this panel harbour mutations in this particular 
region and the missense mutations present in the final cell lines chosen, score 
low to 0 on the mutation “hotspot” scale (Broad institute CCLE, APC gene 
search). This could suggest minimal interference from potential aberrant APC 














Chapter 4: Editing RAL isoforms using the 
CRISPR/Cas9 System 
4.1 Introduction 
At the beginning of my project, there were no knockout or specific mutation 
knock-in human cancer cell models targeting RAL available to study 
endogenous isoform functions. As a result, our knowledge of RAL isoform 
specific biology is limited. With particular emphasis on RALA being the more 
dominant isoform, RAL isoform function has centred on specific subcellular 
interactions with little expansion into RAL isoform biology as a whole. 
Therefore, editing the gene locus and generating isoform specific knockout 
and RALG23V knock-in cell lines was desirable. This cannot be achieved 
through normal transfection methods and instead a programmable nuclease 
system is required. 
The use of programmable nucleases to edit the genome is a rapidly evolving 
field that enables the disruption of target genes in both an in vitro and in vivo 
context. Whilst nucleases such as Zinc-finger nucleases (ZFNs) and 
Transcription activator-like effector nucleases (TALENs) have been shown to 
be and still are an effective tool for genomic manipulation (Urnov et al., 2010; 
Bogdanove and Voytas, 2011), they are limited by the need to generate a 
specific protein for each DNA target site. Thus, due to its simplicity and 
efficiency in triggering site-specific DNA cleavage, it is the CRISPR/Cas9 
system that has become the preferred gene editing technique. 
Whilst several CRISPR/Cas9 systems have been characterised and 
developed for research purposes, it is the SpCas9 derived from Streptococcus 
pyogenes that was the first to be used successfully in humans and is the most 
commonly used Cas9 nuclease for gene editing (Jinek et al., 2013). 
This has been made possible through human codon optimisation of the Cas9 
nuclease as well as design of relevant and efficient guide RNA (gRNA) 
components. This includes a CRISPR RNA, which contains the gRNA, fused 
to a trans-activating CRISPR RNA through a linker loop region to form the final 
single gRNA (Kim and Kim, 2014). A protospacer adjacent motif (PAM) is a 
small base pair sequence directly upstream of the Cas9 nuclease binding site 
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on the target DNA strand. Following binding to the target sequence, Cas9 will 
cause a double stranded break in the DNA, three base pairs downstream of 
the PAM sequence. Subsequent repair of these breaks occurs through one of 
two pathways; non-homologous end joining (NHEJ), or homology directed 
repair (HDR). The former, NHEJ, is highly error prone and usually results in 
the introduction of an indel (insertion/deletion) mutation and a loss in function 
of the target gene. Conversely, HDR requires the addition of a homologous 
sequence template to allow precise repair and the option of knock-in gene 
editing (Chapman, Taylor and Boulton, 2012).  
Excluding CRISPR screens, RAL isoforms have only been targeted using the 
CRISPR/Cas9 system, with the intention for further experimental study, in 
HEK293T cells (Johansson et al., 2019). Although these knockouts were used 
to infer the involvement of RAL in Wnt signalling, it is not a suitable cell model 
to study RAL in the context of RAS biology. Therefore, a CRISPR/Cas9 
strategy to knockout separate RAL isoforms across the cell lines selected in 
chapter 3 needed to be established. This would also enable the generation of 
the tools required to insert a glycine to valine mutation in RAL at amino acid 
position 23 via a “knock-in” resulting in a constitutively activated RAL protein. 
Establishing a panel of RAL knockout and RALG23V cell lines will allow us to 
analyse the role of RAL isoforms in different cellular contexts. 
4.1.1 Aims and Objectives 
The aim of this chapter was to generate isoform specific RAL knockout lines 
in a panel of colorectal cancer cell lines, as well as optimise the tools needed 
to establish RALG23V knock-in cell lines. 
The following steps were taken to achieve this: 
• Validate the targeting efficiency of four different gRNAs per RAL 
isoform in HEK293T cells. 
• Optimise the double gRNA approach in HEK293T cells before applying 
to target cell lines. 
• Design and generate a construct containing a HDR DNA template with 
a G23V mutation for knock-in cell lines. 
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4.2 Knockout cell lines 
All target cell lines, initially underwent single cell isolation and expansion to 
generate parental clones to reduce clonal variability. These parental clones 
then underwent gene editing using CRISPR/Cas9.  
4.2.1 Double gRNA approach 
Using a single guide to target a gene of interest and generate knockout cells 
often results in small indels that are difficult to detect on a standard agarose 
gel and require assays such as the T7E1 to assess editing efficiency. By using 
a paired guide system that targets the same gene hundreds of bases apart, 
larger deletions can be detected on an agarose gel following amplification of 
the targeted region (Figure 4.1A). 
4.2.2 Guide RNA design 
All CRISPR/Cas9 components target the Exon 2 of each RAL gene, which is 
where the protein coding region initiates. Therefore, this region is 
subsequently referred to as Exon 1 from this point on. Guide RNAs (gRNAs) 
targeting Exon 1 of RALA/B (Figure 4.1B) were designed using the Synthego 
online tool https://design.synthego.com/#/validate. Guides were chosen for 
their low off-target effects but also for their proximity to the start codon in both 
RAL isoforms as well as amino acid G23. Exon 1 gRNAs were chosen as indel 
(insertion/deletion) mutations early on in a gene, as they are much more likely 




Figure 4.1 An overview of the generation of isoform specific RAL knockout cell lines 
using the CRISPR/Cas9 system. 
A) Outline of steps used to create isoform specific knockout cell lines using a LentiCRISPR 
construct containing two gRNAs and the Cas9 enzyme. B) gRNA sequences targeting Exon 
1 of RALA/B near G23 amino acid were designed using the Synthego online tool. 
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4.2.3 Design and construction of LentiCRISPR constructs 
For generation of knockout cell lines using the CRISPR/Cas9 system, delivery 
of the essential gRNA and Cas9 benefits from the use of a single plasmid. In 
this instance, all knockout cell lines utilised a modified form of the 
LentiCRISPR V2 plasmid https://addgene.org/52961/  (Addgene Boston USA) 
which was a kind gift from Dr Nicholas Harper (University of Liverpool, UK). 
This plasmid has had the minimal EFS promoter replaced with a Spleen 
Focus-Forming Virus (SFFV) promoter in order to enhance Cas9 expression. 
This plasmid contains an enhanced Streptococcus pyrogenes Cas9 
(eSpCas9) with a C-terminal Strep tag II motif fused to the PacI gene to confer 
Puromycin resistance (Supplementary Supplementary Figure 7.6). 
LentiCRISPR-SFFV was digested using BsmBI for 3h at 55°C. Digested 
plasmids were analysed on a 0.75% agarose gel to ensure removal of the non-
essential “stuffer” DNA, to allow insertion of the gRNAs and purified using the 
Wizard™ SV Gel and PCR clean up system. Each gRNA was ligated into 
individual LentiCRISPR-SFFV vectors. This resulted in 8 plasmids in total, 4 
with gRNAs targeting RALA and 4 targeting RALB. 
 
4.2.4 Optimising genotyping primers 
To screen for successful Cas9 cleavage, primers were designed outside the 
gRNAs in the Exon 1 region (Figure 4.2A & B). This should result in a full-
length PCR product in unedited cells and a shorter product in edited cells due 
to the loss of DNA between the target gRNAs. Amplification using all primer 
combinations was successful and produced a PCR product of ~600 bp on WT 
genomic DNA from HEK923Ts (Figure 4.2C). Genotyping primer 
combinations, Gen 1F + Gen1R for both RALA and RALB were chosen for 




Figure 4.2 Genotyping primers design and optimisation for generation of isoform 
specific RAL knockout cells.  
A) Genotyping primer pairs for RALA and RALB isoforms, forward and reverse. B) Example 
schematic of the position of genotyping primers in relation to RAL gRNAs and Exon 1. C) 1+3 
are gel mock-ups of predicted PCR amplification of RALA and RALB Exon 1. 2+4 are 
confirmed amplification of unedited (UT) RALA and RALB Exon 1 (PCR product ~600 bp) 





















































































Gen 2F Gen 2R
Gen 1RgRNA #1 gRNA #2 gRNA #4gRNA #3
200 400 600
Genotyping Primers RALA
Gen 1F 5'-GCT GAT ACC CCA TTA TTG TCA GC-3'
Gen 2F 5'-GTC AGC ATG CAG TTG TAC TGG G-3'
Gen 1R 5'-AAT CAA GTT ATG TAC AGA TGG CTC-3'
Gen 2R 5'-CCA TAA GTT CCT GAT TTG TAA AAT C-3'
Genotyping Primers RALB
Gen 1F 5'-GTG ACT TCC AGA GTT GTT GG-3'
Gen 2F 5'-GAG GGC TCG CAT GTC TGC-3'
Gen 1R 5'-CGA TGC AAG CAG AGA TCT CTC-3'
Gen 2R 5'-TAA CAA TGG AAA CGA TGC AAG-3'
3. 4.
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4.2.5 Single gRNA LentiCRISPR plasmids modify isoform specific RAL 
in HEK293Ts. 
To determine gRNA targeting and Cas9 cleavage efficiency, each single 
gRNA LentiCRISPR plasmid was validated in the easily transfectable cell line 
HEK293T. HEK293T cells were transfected with a paired combination of the 
four gRNAs specific to each isoform.  
Following amplification of Exon 1 using the genotyping primers specified in 
Figure 4.2A, untransfected (UT) cells produced a band of ~600 bp (Figure 
4.3A). Co-transfection of all gRNA combinations produced a smaller product 
for both RALA and RALB in around half of the cell population (Figure 4.3A) 
indicating DNA has been excised from Exon 1.  
Confirmation of Cas9 cleavage at the processing sites of each gRNA was 
verified by comparing the cut (lower band) sequence of DNA against the upper 
band of the unmodified wild type (WT) RALA/B (Figure 4.3B).  
Although all gRNAs resulted in cleavage and editing for both RAL isoforms, 
gRNA#2 and gRNA#4 for both RALA and RALB were chosen for future gene 
editing of selected cell lines, due to this gRNA combination having the highest 
population of edited cells. 
4.2.6 Duplexed gRNA LentiCRISPR plasmids modify RALA/B in HEK293T 
cells. 
Once each single gRNA construct had been validated in HEK293T cells, I 
modified each single LentiCRISPR containing the isoform specific gRNA#2 to 
also contain gRNA#4 and created a duplexed guide construct (Figure 4.4A). 
This allows transfection of a single plasmid that will express both gRNAs 
required to knockout its target RAL isoform. Three separate duplexed guide 
constructs were transfected into HEK293T cells alongside single guide 
transfections acting as a positive control for gene editing.  DNA was isolated 
and verified by PCR as previously described. All duplexed constructs targeting 
RALA resulted in cleavage of RALA Exon 1 (Figure 4.4B), whilst two out of 
three duplexed constructs targeting RALB also produced a smaller PCR 




Figure 4.3 All gRNA LentiCRISPR plasmids successfully cut target DNA in both RALA 
and RALB. 
A) Schematic of a single gRNA LentiCRISPR plasmid with PCR amplification of RALA and 
RALB Exon 1 in untransfected (UT) and two single gRNAs transfected HEK293T cells. B) 
Bands from the co-transfection of gRNAs #2 and #4 were extracted and sent for sequencing. 
Upper band represents the wild type Exon 1 of RALA/B (unmodified), whilst the lower band 







Figure 4.4 Duplexed gRNA LentiCRISPR plasmids successfully cut target DNA in both 
RALA and RALB. 
A) Schematic of a duplexed gRNA LentiCRISPR plasmid. B) PCR amplification of RALA and 
RALB Exon 1 in untransfected (UT), 1X separate gRNA transfection and 3X duplexed gRNA 
plasmid in HEK293T cells. 
 
 
4.2.7 Duplexed gRNA LentiCRISPR constructs modify RALA/B in target 
cell lines. 
As mentioned previously, all target cell lines underwent single cell clonal 
selection to produce parental (PAR) cell lines. This was carried out to reduce 
clonal variability and any gene-editing was conducted on these parental cell 
lines. 
For HCT116, SW403 and SW620, three separate parental cell lines were 
isolated and expanded (PAR1, PAR2 and PAR3). Only two parental lines were 
obtained for SW48 (PAR2 and PAR3). 
Following transfection of the duplexed gRNA LentiCRISPR-RALA/B 
constructs into every target parental cell line, cells underwent one round of 
puromycin treatment to select for positive editing. The remaining cells were 
left to grow and then transferred into 96-well plates at a seeding density of 0.5 
cells per well to obtain at least one plate per parental clone for each RAL 



































Duplexed (double) gRNA LentiCRISPR plasmid
U6 U6 EF-1αgRNA
EcoRI






Seeded plates were checked by eye for single cell colonies and a maximum 
of five colonies was picked from each plate and subsequently expanded for 
DNA extraction and PCR screening.  
 
Out of the picked SW620 clones transfected with gRNAs for RALA, four out of 
five (5th clone not shown) displayed a complete lower band shift in comparison 
to the untransfected (UT) (Figure 4.5A). No band shift was seen in the same 
genomic DNA screened with primers specific for RALB (Figure 4.5A). Four out 
of five SW620 clones transfected with gRNAs for RALB produced a smaller 
PCR product compared to UT (Figure 4.5A). Again, a band shift was not 
detected when using RALA specific primers. The second clone (BKO2) shows 
an incomplete band shift, with both the WT and edited band size products 
visible following PCR amplification. This cell line could be considered as a 
heterozygous population. An additional band was detected at ~400 bp in clone 
BKO3 as well as the predicted PCR product. 
All of the SW403 clones transfected with the duplexed gRNA plasmid for 
RALA, displayed a complete lower band shift in comparison to the UT (Figure 
4.6A). No band shift was seen in the same genomic DNA screened with 
primers specific for RALB. An additional band higher up than the predicted 
PCR product was also observed in clones AKO2 and AKO3 (Figure 4.6A). 
However, this was not the same size as the WT. Likewise, all SW403 clones 
transfected with gRNAs for RALB produced a smaller PCR product compared 
to UT (Figure 4.6A) with additional larger bands (~700 bp) present in clones 
BKO1 and BKO2. Again, a band shift was not detected when using RALA 








Figure 4.5 SW620 PCR screen and RALA/B knockout cell lines. 
(A) Following transfection with the duplexed gRNA LentiCRISPR plasmid and subsequent 
antibiotic selection, four out of five SW620 clones transfected with gRNAs for RALA, displayed 
a complete lower band shift in comparison to the untransfected (UT) (5th clone not shown). 
No band shift was seen in the same genomic DNA screened with primers specific for RALB. 
Four out of five SW620 clones transfected with gRNAs for RALB produced a smaller PCR 
product compared to UT with BKO2 presenting as a heterozygous population. Again, a band 
shift was not detected when using RALA specific primers. (B) Isoform specific protein 
expression was absent in all positive clones identified by PCR. The total RALB expression 
remained unaffected in the RAL KO clones, whilst BKO2 and BKO3 had noticeably reduced 
RALA expression. n=1 
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Figure 4.6 SW403 PCR screen and RALA/B knockout cell lines. 
(A) All SW403 clones transfected with gRNAs for RALA, displayed a complete lower band 
shift in comparison to the untransfected (UT). No band shift was seen in the same genomic 
DNA screened with primers specific for RALB. All SW403 clones transfected with gRNAs for 
RALB produced a smaller PCR product compared to UT. Again, a band shift was not detected 
when using RALA specific primers. (B) Isoform specific protein expression was absent in all 















































































































































4.2.8 Absence of RALA/B protein in selected cell lines. 
Given the results of the PCR, isoform specific RAL protein levels were 
expected to be reduced or completely absent.  
Analysis by western blot revealed an absence in protein production of the 
relevant RAL isoform in all SW620 clones (Figure 4.5B). A noticeable 
reduction but not complete absence of RALB was observed in clone BKO2 
(Figure 4.5B). This is consistent with results from the PCR data seen in Figure 
4.5A. Due to the presence of extra PCR products in BKO2 and BKO3 (Figure 
4.5A), clones AKO3, AKO4 and BKO1, BKO4 were selected as the final 
knockout clones for future experiments. For ease, these will now be referred 
to as clones AKO1, AKO2 and BKO1, BKO2. 
Probing for RALA and RALB in selected SW403 clones resulted in complete 
absence of the targeted RAL isoform for all clones (Figure 4.6B). PCR clones 
AKO1, AKO4 and BKO3 and BKO4 were chosen to go forward, excluding the 
other clones that had extra PCR products present during the screening. These 
are subsequently referred to as AKO1, AKO2 and BKO1, BKO2 respectively. 
Only two clones for each RAL isoform that had been confirmed by PCR 
screening (data not shown) were probed for RALA and RALB protein 
expression in HCT116 and SW48 cells (Figure 4.7). A clear absence of protein 
expression of the targeted RAL can be seen in all selected clones, whilst the 
other isoform remains unedited. All SW48 knockout clones come from a single 
parental cell line (Parental 3). The final knockout cell lines selected for study, 





Figure 4.7 HCT116 and SW48 RALA/B knockout cell lines. 
Isoform specific protein expression was absent in all positive clones identified by PCR, with 
protein expression of the non-target isoform unaffected in both HCT116 and SW48 cell lines. 
n=1 
 
Table 4.1 Knockout cell lines and their parental origin. 




RALA PAR2 HCT116 AKO1 
RALA PAR3 HCT116 AKO2 
HCT116 BKO RALB PAR1 HCT116 BKO1 RALB PAR3 HCT116 BKO2 
SW48 AKO RALA PAR3 SW48 AKO1 RALA PAR3 SW48 AKO2 
SW48 BKO RALB PAR3 SW48 BKO1 RALB PAR3 SW48 BKO2 
SW403 AKO RALA PAR1 SW403 AKO1 RALA PAR3 SW403 AKO2 
SW403 BKO RALB PAR2 SW403 BKO1 RALB PAR3 SW403 BKO2 
SW620 AKO RALA PAR2 SW620 AKO1 RALA PAR3 SW620 AKO2 
SW620 BKO RALB PAR1 SW620 BKO1 RALB PAR3 SW620 BKO2 
Final knockout clones selected for future experiments were given the updated name 
of KO1 and KO2. For three of the cell lines, all clones originated from 1 of 3 parental 
(PAR) clones with the intention of the two knockout clones for each RAL isoform 
descending from two different parental clones. SW48 KO clones were the only ones 
all with the same parental origin. 
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4.3 RALA/BG23V knock-in cell lines. 
The homology directed repair (HDR) pathway is used to create specific point 
mutations or modifications into the genome. This requires the presence of a 
homologous DNA sequence that acts as a template for DNA repair. For both 
RAL isoforms, the point mutation of a guanine to valine at amino acid position 
23 results in a constitutively active protein. 
 
Although polymer and lipid-based transfection reagents have been suitable for 
initial validation of all gRNAs and generation of isoform specific knockouts, the 
efficiency of these reagents is very low in my panel of colorectal cell lines 
(section 3.2.1). Given that the efficiency of CRISPR/Cas9 mediated HDR is 
less than 1% itself, a lentiviral system was selected as a more efficient method 
of delivery of the CRISPR components (Figure 4.8A). 
For the knockout cell strategy, the gRNAs and Cas9 endonuclease are 
contained within a single LentiCRISPR plasmid. Although the HDR DNA 
template can also be cloned into the same LentiCRISPR plasmid, all these 
components together would cause issues with packaging of the virus. For 
successful transduction to take place, the gRNA and HDR template need to 
be located within one plasmid without the Cas9. Instead, the Cas9 is integrated 
into the target cell genome and expressed separately within the cell. 
Here, the gRNA and HDR template were subcloned into a pLeGO-EGFP/2A-
Puro construct and inducible Cas9 cell lines were generated. The pLeGO was 
obtained from Addgene and modified by Dr Nicholas Harper, removing the Eu 
enhancer and replacing it with two multiple cloning sites to allow the gRNA 
and HDR template to be inserted into the same plasmid. The pLeGO construct 
also contains GFP and puromycin sequences for positive selection of 






Figure 4.8 Generation of constitutively active G23V isoform specific RAL cell lines. 
(A) Strategy used to create isoform specific knock-in cell lines using the CRISPR/Cas9 system 
and lentiviral transduction. (B) HDR DNA templates for each RAL isoform including G23V 
mutation and silent mutations (raised letters) to aid screening process. 
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Figure 4.9 pLeGO-EGFP/2A-Puro construct for G23V knock-in cell lines. 
A) Schematic of pLeGO construct containing both an enhanced GFP and puromycin selective 
markers. The G23V mutation HDR DNA templates for RALA and RALB were cloned in 
between NotI and NheI in the LH MCS, whilst the previously validated isoform specific 
gRNA#4 and a U6 promoter was cloned into the RH MCS. B) The efficiency of each gRNA#4 
in the new pLeGO construct was validated by co-transfection with the corresponding 
LentiCRISPR-gRNA#2 (to provide Cas9) and screened by PCR for Cas9 cleavage and lower 
band shift. C) Transfection of pLeGO-EGFP/2A-Puro with gRNA#4 into HEK293T cells to 
confirm GFP expression to be used as a positive selection marker. GFP = green fluorescent 
protein, HDR = homology directed repair, MCS = multiple cloning site, SFFV = spleen focus 
forming virus, 2A = 18-22 amino acid-long peptides. 
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4.3.1 HDR DNA template design and insertion into pLeGO-EGFP/2A-Puro 
For repair of the double strand break caused by Cas9 cleavage, a single 
stranded oligodeoxynucleotide (ssODN) containing the desired mutations was 
synthesised for each RAL isoform (Figure 4.8B). Both templates were 
designed to target the G23 amino acid and included changing bases of the 
RALA and RALB wild type sequence from a glycine to a valine. A number of 
silent mutations (Figure 4.8B) were also introduced into the HDR template that 
would aid in screening for positive knock-in cells via PCR as well as disrupting 
Cas9 PAM sequence binding and therefore prevent further gene editing 
following successful HDR. 
 
For the HDR template to be cloned into the pLeGO construct, it needs to be 
converted into a double stranded oligodeoxynucleotide (dsOND) and requires 
longer homology arms than is needed for ssOND delivery. To generate this 
larger HDR template, two overlapping regions of genomic DNA surrounding 
the G23 codon were amplified by PCR using the ssOND HDR template as a 
primer to introduce the required mutations into the final template sequence 
(section 2.3.7). 
4.3.2 Single gRNA#4 pLeGO plasmids modify RALA/B in HEK293T cells. 
To generate G23V knock-in cell lines, a gRNA that is close to the desired 
mutation is preferred. For both RALA and RALB, gRNA#4 used in creating 
knockout cell lines, is close to the G23 position and has already been 
validated. Therefore, each gRNA#4 was excised from the LentiCRISPR 
constructs and subcloned into its own pLeGO vector (section 2.3.6).  
 
Since the Cas9 gene is absent from the pLeGO constructs, 4 separate pLeGO-
gRNA#4 plasmids for each RAL isoform were co-transfected into HEK293T 
cells with the complimenting single LentiCRISPR-gRNA#2 to provide gRNA#2 
and Cas9 expression (Figure 4.9B). This allows the knockout screening 
method to be used to validate each gRNA#4 in the pLeGO construct. 
A lower band shift (smaller PCR product) was observed in all co-transfections 
involving the LentiCRISPR-gRNA#2 and pLeGO plasmids containing either 
the RALA or RALB gRNA#4 (Figure 4.9B) compared to the untransfected. Co-
 103 
transfection of separate LentiCRISPR-gRNA#2 and LentiCRISPR-gRNA#4 
was used as a control for successful Cas9 cleavage and deletion formation 
(Figure 4.9B). 
Finally, successful transfection of the pLeGO plasmids with relevant gRNAs 
and HDR template can be seen through EGFP expression (Figure 4.9C). 
4.3.3 Generation of doxycycline inducible Cas9 expressing SW403 and 
SW620 cells 
To generate Cas9 expressing cells, my target cell lines were transduced with 
the integrating Cas9 expression plasmid pCW-Cas9-Blast (section 2.3.5). This 
plasmid contains a Cas9 that is under a reverse tetracycline controlled 
transactivator, along with a blasticidin selectable marker (Figure 4.10A). 
Following stable integration into the genome, expression of Cas9 can be 
induced with doxycycline drug treatment (Figure 4.10B).  
Unfortunately, during antibiotic selection with blasticidin, in conjunction with 
single cell isolation, no viable HCT116 and SW48 clones were isolated. Only 
SW403 and SW620 cells survived treatment and were isolated and expanded. 
Following 48-hour treatment with doxycycline, several clones from each cell 
line were positive for Cas9 expression. Three clones in total from each cell line 




Figure 4.10 Generation of Cas9 inducible SW620 and SW403 cell lines. 
A) Schematic of pCW-Cas9-Blast construct containing SpCas9 under a reverse tetracycline 
controlled transactivator with a blasticidin selectable marker. B) Expression of doxycycline 
inducible Cas9 following stable integration of the reverse tetracycline controlled transactivator 
(rtTA) dependent system. C) Expression of Cas9 can be seen in all transduced SW620 and 
SW403 clones following 48-hour treatment with doxycycline. Blast = blasticin, hPGK = human 
phosphoglycerate kinase, rTetR = reverse Tet repressor, SpCas9 = Streptococcus pyogenes 





4.3.4 PCR screening for identification of HDR. 
Unfortunately, due to time constraints, RALA/BG23V knock-in cell lines were not 
generated. If time permitted, the following protocol would be carried out to 
screen for successful HDR. 
 
Once the SW403 and SW620 Cas9 inducible cells have been treated with 
doxycycline to induce enzyme expression, as well as transduced with either 
the pLeGO-EGFP/2A-Puro-gRNA#4-RALA or pLeGO-EGFP/2A-Puro-
gRNA#4-RALB, positive cells will be selected through puromycin treatment 
and isolated as single cells into 96-well plates. Once the single clones have 
expanded, genomic DNA will be extracted from each well and will be screened 
by PCR to identify knock-in cells. 
To screen for a successful knock-in of the desired HDR template, isolated DNA 
will undergo genotyping PCR using primers situated in Exon 1 in combination 
with primers designed to bind to the mutated sequence only. All primers were 
checked for specificity using NCBI Blast with the primer binding locations are 
shown in (Figure 4.11). The resulting PCR products for RALA using Primer 
Pair 1 (Gen 1F + Gen1R) and Primer Pair 2 (Gen2F + Gen2R) is 428 bp and 
216 bp respectively. The resulting PCR products for RALB using Primer Pair 
1 (Gen 1F + Gen1R) and Primer Pair 2 (Gen2F + Gen2R) is 292 bp and 294 
bp respectively. Once knock-in cells have been identified they will be sent off 







Figure 4.11 Genotyping primers for identification of knock-in mutations.  
A) Genotyping primers were designed to bind to the mutated sequence (mutated bases 
underlined) to enable amplification of the inserted HDR template only, allowing for 
identification of knock-in clones. B) Position of genotyping primers required for identification 
of knock-in mutations. One primer is situated outside of the mutated region and the other 
designed to bind to the mutated knock-in sequence situated in exon 1 for both RALA and 
RALB. The resulting PCR products for RALA using Primer Pair 1 (Gen 1F + Gen1R) and 
Primer Pair 2 (Gen2F + Gen2R) is 428 bp and 216 bp respectively. The resulting PCR 
products for RALB using Primer Pair 1 (Gen 1F + Gen1R) and Primer Pair 2 (Gen2F + Gen2R) 
























The aim of this chapter was to initially establish individual RALA and RALB 
knockout cell lines in the colorectal cells selected in chapter 3. This was done 
by validation of a CRISPR/Cas9-based strategy in HEK293T cells. Using 
multiple gRNAs for knockout generation resulted in larger DNA deletions 
compared to using a single gRNA. This has the advantage that larger 
sequence deletions can be easily detected through standard PCR instead of 
the more time consuming T7 endonuclease I assay, that recognises 
mismatched dsDNA. Due to the high transfection rate of HEK293T cells, 
validation of each gRNA was carried out before transfection into the target cell 
lines, as well as allowing subsequent identification of the most efficient gRNAs 
to generate separate RALA/BG23V knock-in cell lines. 
Four gRNA sequences per isoform were successfully cloned into separate 
modified LentiCRISPR plasmids, containing a functional Cas9 nuclease. 
Transfection of these constructs showed successful DNA cleavage by Cas9 
in HEK293T cells (Figure 4.3). All Cas9 orthologues available for CRISPR 
gene editing are often limited by the placement of the PAM site required for 
gene targeting. This can be a problem for generating knockout cell lines but 
even more so for knock-ins, as gRNAs need to be designed adjacent to a PAM 
sequence. The SpCas9 used here relies on the more frequently appearing 
5'NGG PAM site, increasing the likelihood of one being present in close 
proximity to our specific target sequence. Indeed, all gRNAs designed (4 for 
RALA, 4 for RALB), were able to target Exon 1 of their specific RAL isoform 
and resulted in a double stranded break which was detected by genotyping 
PCR (Figure 4.3). It has been shown that CRISPR/Cas9 editing efficiency 
decreases as the mutation to DNA cut distance increases (Paquet et al., 
2016). This means gRNA#4 for both RAL isoforms are expected to be the most 
efficient for knock-ins but gRNA efficiency can be tested by selecting positively 
transfected cells and performing quantitative PCR. 
 
The different methods used to deliver the CRISPR/Cas9 system components 
into a cell population have their own advantages and disadvantages. The main 
strategies involve delivery of the Cas9 mRNA and gRNA as separate RNA 
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components, a plasmid-based system and finally, the delivery of the gRNA 
and Cas9 protein (Liu et al., 2017). Here, only the plasmid-based system was 
used for both knockout and knock-in cell line generation. 
The delivery of in vitro transcribed gRNAs, rather than through plasmid 
expression, reduces the risk of unwanted indels due to the short life of small 
RNA sequences. This method can be improved further by combining the 
gRNA delivery with either a Cas9 mRNA or Cas9 protein to bypass the use of 
DNA completely (Liu et al., 2017). The synthesis of “ready-to-go” gRNAs has 
the advantage of avoiding time consuming cloning steps and cellular in vitro 
transcription. However, plasmid free delivery does not benefit from the addition 
of selection markers and is therefore not recommended for difficult to transfect 
cell lines such as these. 
Using plasmids, like the lentiviral vectors used here, is limited due to 
restrictions in virus packaging capacity. Cas9 variants such as the saCas9 and 
St1Cas9 are smaller than the more popular SpCas9 and can help overcome 
this problem (Murovec, Pirc and Yang, 2017). However, with the HDR DNA 
template required for knock-in cell lines in addition to the 4.2 kb SpCas9 
endonuclease, delivery into my panel of cell lines presents a major challenge 
when using the CRISPR/Cas9 system. Consequently, using a lentiviral vector 
for the gRNA and HDR template along with separate Cas9 expressing cells 
ensures a higher transduction efficiency of the colorectal cell lines. 
A disadvantage to the stable integration and expression of Cas9 in target cells 
is the occurrence of off-target gene editing. It has been shown that Cas9 can 
induce mutations that differ from the target site (Chew et al., 2016; Fu et al., 
2013) and that an increase in off-site Cas9 cleavage correlates with high Cas9 
expression levels (Fu et al., 2013). To avoid continuous Cas9 expression, a 
plasmid containing an inducible promoter was used to control expression and 
keep levels down.  
The tetracycline regulation system used here, is very sensitive and commonly 
used in mammalian cell culture, mice as well as other species (Howe et al., 
1995). Whilst inducible gene expression plasmids allow temporal and 
quantitative control over gene expression, they can be limited by a number of 
factors such as the toxicity of the inducing agent and low induction expression 
depending on the expression system used. However, the doxycycline 
 109 
concentration of 8 µg/mL used here was sufficient at inducing Cas9 expression 
with no toxic or detrimental effects seen on cell health. Alternatively, a self-
limiting SpCas9 that removes the nuclease from edited cells, preventing the 
incidence of further off-target modifications could also be used (Petris et al., 
2017). 
For introducing small mutations such as the ones required here, an HDR DNA 
template in the form of a ssODN is preferable to larger donor plasmids (Ran 
et al., 2013b). The HDR DNA templates used to introduce the G23V point 
mutation in both RAL isoforms were originally designed as a 138 bp and 139 
bp ssODN respectively. For small mutations, a ssODN should be around 100-
150 bp total homology with the mutation introduced in the middle and flanking 
sequences of at least 40 bp on each side (Chen et al., 2011a; Ran et al., 
2013b). Silent mutations were included around the G23 target site to allow for 
positive identification by PCR using mutation specific primers. The addition of 
silent mutations also destroys the PAM sequence, preventing any further Cas9 
cleavage following the occurrence HDR mediated editing.  
Homology arm length, symmetry and chemical modifications of the HDR DNA 
template can affect the efficiency of the HDR pathway. Using an unmodified 
template with asymmetrical homology arms has been shown to increase HDR 
efficiency (Richardson et al., 2016). However, the use of a phosphorothioate 
modified template with symmetric arms has been shown to improve knock-in 
efficiency more so than an unmodified template (Renaud et al., 2016) and may 
be worth consideration.  
Whilst these optimisations are suitable for transfection involving a 
Cas9/gRNA-expressing plasmid and separate ssODN DNA template, as 
previously mentioned, the transfection efficiency of these colorectal cell lines 
is poor and therefore delivery of components through viral transduction is 
preferred. With that in mind, delivery of the gRNA, as well as the HDR template 
required a separate pLeGO plasmid that contained an additional selection 
marker. A selection marker is not necessary when an introduced mutation 
changes the cell phenotype, as the edited subpopulation can easily be isolated 
via flow cytometry. Since this is not known to be the case for the introduction 
of the RALA/BG23V mutation, a GFP selection marker was used for easy 
monitoring of transduction efficiency and positive cell selection.  
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An integrase defective lentiviral vector (IDLV) was used to package the gRNA 
and HDR template. Most IDLVs have mutations introduced in the catalytic triad 
of the integrase region, such as a residue D64 mutation seen here, that results 
in the inactivation of the integrase enzyme. The use of IDLVs compared to 
standard lentiviral vectors has been shown to have transient expression with 
a decreased capacity to induce off-target mutations (Ortinski et al., 2017). In 
this instance it was also used to prevent integration of the GFP sequence into 
the cell genome preventing the future use of fluorescent analysis. 
If the transduction efficiency of the integrase deficient virus is very low, the 
GFP selection marker can be used to sort cells by fluorescence-activated cell 
sorting (FACS). However, whilst this will result in an enrichment of transduced 
cells, along with puromycin selection, it may increase the stress on the cells 
and affect overall viability. Furthermore, it increases post-selection recovery 
time which may lead to contamination and loss of cells. Therefore, for future 
experiments, if the viral transduction efficiency is too low, the IDLV will be 
exchanged for a standard packaging vector such as psPAX2 and the GFP 
selection marker removed from the pLeGO plasmid to prevent integration of 
the fluorescent marker into the host genome. 
Knock-in efficiency via the HDR pathway is reported as being as low as 1% 
(Wang et al., 2015) meaning that only a small percentage of transduced cells 
will contain the RALA/BG23V mutation. HDR can be enhanced by suppressing 
key proteins in the NHEJ repair pathway. Inhibition of Ku70, Ku80 and DNA 
ligase IV can increase HDR efficiency by up to 4-5-fold (Chu et al., 2015). 
Exogenous expression of the homologous recombination protein Rad52 can 
also increase HDR and when combined with DNA ligase IV inhibition, using 
the small molecule inhibitor Scr7, it can improve repair efficiency up to 40% 
(Shao et al., 2017). However, these strategies have been tested using small 
inserts on few gene loci, so it is not clear whether they would enhance a 
RALA/BG23V knock-in. Furthermore, inhibition of the NHEJ pathway alone may 
cause toxicity. Another strategy to increase HDR efficiency would be to use 
double nicking. This method involves a Cas9 D10A nickase that creates a 
single-strand rather than double-strand DNA break. When used with two 
gRNAs that target opposite DNA strands, each gRNA pair has been shown to 
successfully induce HDR at frequencies higher than those of single gRNA with 
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WT Cas9 (Ran et al., 2013a). This method has also been shown to reduce off-
target activity. 
Finally, once RALA/BG23V knock-in clones have been generated, the whole 
RAL isoform gene will be sequenced to determine if any additional mutations 
surrounding Exon1 have been inserted. Any additional mutations could result 
in changes in protein conformation and activity affecting functional analysis. 


























Chapter 5: Phenotypic profiling of cell lines 
5.1 Introduction 
Generation of a panel of isoform specific knockouts now allows us to look at 
RAL isoform signalling. It has been demonstrated that signalling responses 
vary between the different RAL isoforms in both normal biological functions as 
well as tumour cell progression. RALB but not RALA has been shown to act 
as a regulatory switch, promoting biogenesis of autophagosomes through 
direct engagement of the Exo84 effector, following cellular starvation in 
HEK293T cells (White et al. 2011). Knockdown of RALA and RALB leads to 
opposing effects on the development of tight junction barrier function in MDCK 
II dog cells (Hazelett et al. 2011). Constitutively active RALA but not RALB 
promoted basolateral delivery of secretory vesicles (Shipitsin & Feig. 2004). 
Knockdown of RALA but not RALB affects mitochondrial fission and 
morphology in human HEK-TtH cells (Kashatus et al. 2011). Different RAL 
requirements have also been seen in embryo development, where RALB null 
mice are viable but RALA null leads to exencephaly and embryonic lethality  
(Peschard et al., 2012). 
The idea that these two highly related proteins could also serve opposing 
functions in oncogenic RAS processes has been previously described. 
Knockdown of RALA expression impeded and, in some cases, prevented 
tumourigenesis of human cancer cells (Lim et al. 2005). Interfering RNA stable 
suppression of RALA has also been shown to reduce anchorage-independent 
growth in colorectal cancer cell lines, whilst suppression of RALB had a 
contrasting effect of enhancing soft agar colony size and frequency (Martin et 
al. 2012). Despite these opposing activities, both RAL isoforms required 
interaction with the effector RALBP1 (RLIP76), as well as members of the 
exocyst complex. However, it was determined that RALA required exocyst 
component Sec5 but not Exo84 and vice versa for RALB, highlighting the 
differences in the direct protein-protein interactions involved in RAL signalling. 
Again, RALA but not RALB is required for anchorage-independent growth in 
vitro and tumourigenic growth in vivo, in human pancreatic carcinoma cells 
(Lim et al. 2006), whereas lung metastasis was more RALB dependent (Lim 
et al. 2006). 
 113 
Any divergent functional roles are thought to be due, in part, to the differences 
in subcellular location of each isoform (Gentry et al., 2015). Furthermore, even 
though RALA and RALB share a high degree of amino acid sequence identity 
(Gentry et al., 2014), distinct biological roles have also been largely attributed 
to their differing C-terminal hypervariable regions (Shipitsin and Feig, 2004; 
Lim et al., 2005). The varied posttranslational modifications of the C-terminal 
of RALA and RALB, also result in different RAL isoform regulation and 
therefore function (Gentry et al., 2015). 
Although these observations suggest a contrast in RAL isoform functionality, 
many in an appropriate cell model, these studies rely on temporary 
suppression or overexpression of RAL proteins. Additionally, whilst RALA 
induced anchorage independent growth was found to be independent of KRAS 
mutation status (Martin et al. 2012), somewhat surprisingly, the influence of 
RAS status and whether it presents as a cofounding factor in RAL signalling 
has been largely ignored. Potentially due to insufficient cell model availability 
and lack of knowledge of RAL signalling in general, studies have focused on 
understanding interactions downstream of RAL and not its regulation by RAS. 
Ultimately, whether the status of RAS is important in RAL function or whether 
RAL is even involved in oncogenic RAS signalling is still unclear.  
The RAL knockout cells generated in chapter 4 allow us to address RAL 
isoform activity and function at an endogenous level in an appropriate model 
for RAL study. Unlike other RAL studies, profiling a larger panel of knockout 
cell lines will not only account for clonal differences but also any variations 
between cell lines. Furthermore, since RAS is expected to be engaged in RAL 
signalling, this panel of colorectal cell lines includes different KRAS mutation 
statuses, allowing for direct comparison and therefore collection of a more 
robust profile of RAL biology. 
With the recent development of various omic tools, it is possible to 
systematically characterise RAL signalling networks without altering location 
or protein structure/activity through modifications. There are a variety of omic 
techniques that can be used to cover gene expression right through to protein 
analysis, each with their own benefits.  
Various microarray techniques can be used to profile the genome. In fact, gene 
expression profiling via microarray following separate RALA and RALB 
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knockdown in the UMUC-3 bladder cancer cell line has already revealed 
RREB-1 as a novel transcriptional RAL effector (Oxford et al. 2007). However, 
RNA sequencing (RNAseq) is a more sensitive method in detecting gene 
expression changes especially when at very low levels. It is also more 
accurate at detecting extremely abundant genes and has a wider dynamic 
range than microarray (Zhao et al. 2014). RNA samples can be easily obtained 
and reproducibly measured in a high-throughput manner using a variety of 
sequencing technologies (Marioni et al. 2008 and Elliot et al. 2009). Indeed, 
the advent of next generation sequencing has revolutionised transcriptomics 
and established RNAseq as the preferred method for the study of gene 
expression (Finotello et al. 2014). The expression levels of RNA can be used 
as a proxy for protein abundance, but due to various regulation stages, the 
presence of specific RNA products does not necessarily guarantee a 
functional end product. Therefore, the use of additional omic tools looking at 
the proteome, to see if any gene expression changes generate meaningful 
protein changes, is desirable. 
Whilst whole proteome investigation provides direct insight into actual protein 
level changes, analysis of large volume of data can be time consuming. 
Moreover, protein levels in themselves don’t necessarily tell you if something 
is changing or address any post translational modifications. Signalling status 
can be determined by lower throughput methods such as western blot but a 
more useful approach is to focus on families of proteins using an assay such 
as Reverse Phase Protein Arrays (RPPA) (Spurrier, Ramalingam and 
Nishizuka, 2008; Baldelli et al., 2017). RPPA is not only relevant for cancer 
pathway study, but it also provides the ability to infer protein network 
responses of hundreds of proteins/phospho-proteins and capture the state of 
key signalling transduction pathways. 
By conducting unbiased large-scale screens on these new RAL knockout cell 
models, a larger data set of RAL signalling networks can be collected. This will 
provide a broad understanding of the changes that have occurred in these cell 
lines due to gene knockout and pin any changes, where possible, onto direct 




5.1.1 Aims and Objectives 
The aim of this chapter is to determine the effect of single RAL isoform deletion 
on the RAL pathway and wider cell signalling networks. 
Objectives: 
• Determine activity changes in the remaining RAL isoform using the 
active RAL pulldown assay used in chapter 3. 
• Profile the transcriptome of parental and RAL knockout lines using RNA 
sequencing to determine changes in mRNA expression. 
• Profile the proteome of the same cell lines using RPPA to see if 
changes extend to the protein level. 
• Validate proteins of interest by western blotting. 
 
5.2 Results 
5.2.1 Isoform specific RAL KO activity assays 
Following pulldown of endogenous active RAL in the unedited parental cell 
lines in chapter 3, I wanted to see what effect knockout of each RAL had on 
the activity of the remaining RAL isoform. The same commercial pulldown 
method for isolating active RAL was used as outlined in chapter 3. To profile 
RAL isoform activity in the KO vs PAR cell lines, I used 2 minutes of EGF 
stimulation since this corresponds to the average peak RAL activity (Figures 
3.2-3.3). Probing for phospho-ERK was also carried out to confirm stimulation 
of RAS by EGF. RAL activity assays were repeated 3 times (individual repeats 
in supplementary material) and the RAL activity for each clone was quantified.  
 
The results for individual cell lines are shown in Figures 5.1-5.4 and a 
summary is shown in Figure 5.5. Activity of the remaining RAL isoform was 
recorded in all edited clones, across all cell lines, and no visible activity of the 
“knocked-out” RAL could be seen (Figure 5.1A-5.4A). Whilst activity varied 
between RAL KO clones within cell lines, activity of the remaining isoform 
always trended in the same increased direction. For RALA, a small increase 
was observed in some of the BKO samples, whereas RALB activity was 
significantly increased in the RALA KOs, across all cell lines except SW48. 
When looking at individual cell lines, the increase in RALA activity in the SW48 
and SW620 RALB KO clones was not as pronounced as the HCT116 and 
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SW403 cell lines (Figure 5.2 and 5.4) but could still be seen clearly for clone 
BKO2 in the SW620 cell line. Overall, a clear compensatory increase in the 
other isoform was seen in all cases except the SW48 cell line (Figure 5.2A). 
No change in overall protein expression of either RALA or RALB was detected 
in any of the cell lines (Figure 5.1A-5.4A). Therefore, it is inferred that loss of 






Figure 5.1 RAL activity in HCT116 isoform specific knockout cell lines. 
A) Following treatment with 50 ng/mL EGF for 2 minute, HCT116 RALB KO clones, BKO1 
and BKO2, displayed a small increase in RALA activity compared to the parental (PAR1 and 
PAR3). An obvious increase in RALB activity was observed in both RALA KO clones (AKO1 
and AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 
which were run on SDS-PAGE along with 10 µg total lysate. B) Quantification of RAL activity 
confirmed a significant increase (p < 0.05) in RALB activity vs PAR in the RALA KO clones. 
Data is presented as a fold change and represents an increase or decrease in activity 































































































* p < 0.05
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Figure 5.2 RAL activity in SW48 isoform specific knockout cell lines. 
A) Following treatment with 50 ng/mL EGF for 2 minute, SW48 RALB KO clones, BKO1 and 
BKO2, displayed similar RALA activity compared to the parental (PAR2 and PAR3). An 
obvious increase in RALB activity was observed in both RALA KO clones (AKO1 and AKO2). 
Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads which were 
run on SDS-PAGE along with 10 µg total lysate. B) Quantification of RAL activity confirmed 
no significant increase in activity in the KO clones. Data is presented as a fold change and 




























































































Figure 5.3 RAL activity in SW403 isoform specific knockout cell lines. 
A) Following treatment with 50 ng/mL EGF for 2 minute, SW403 RALB KO clones, BKO1 and 
BKO2, displayed a small increase in RALA activity compared to the parental (PAR1 and 
PAR3). An obvious increase in RALB activity was observed in both RALA KO clones (AKO1 
and AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 
which were run on SDS-PAGE along with 10 µg total lysate. B) Quantification of RAL activity 
confirmed a significant increase in RALA activity vs PAR in the RALB KO clones (p < 0.05) 
and a significant increase in RALB activity vs PAR in the RALA KO clones (p < 0.001). Data 
is presented as a fold change and represents an increase or decrease in activity compared to 




































































































* p < 0.05
*** p < 0.001
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Figure 5.4 RAL activity in SW620 isoform specific knockout cell lines. 
A) Following treatment with 50 ng/mL EGF for 2 minute, SW620 RALB KO clone BKO2, 
displayed a small increase in RALA activity compared to the parental (PAR2 and PAR3). A 
significant increase in RALB activity was observed in both RALA KO clones (AKO1 and 
AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 
which were run on SDS-PAGE along with 10 µg total lysate. B) Quantification of RAL activity 
confirmed a significant increase in RALB activity vs PAR in the RALA KO clones (p < 0.05). 
Data is presented as a fold change and represents an increase or decrease in activity 



























































































* p < 0.05
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Figure 5.5 RAL activity in RAL knockout cell lines vs PAR across all cell types. 
A) Quantification of RALA activity across all PAR and RAL KO cell types. The RALA activity 
varies across all cell types in the BKO clones and parental. SW403 display the highest RALA 
activity out of the cell types. B) Quantification of RALB activity across all parental and RAL 
KO cell types. Again, RALB activity is varied between cell types in the AKO clones with the 
highest activity observed in the HCT116 RALA KO clones. Data is presented as a fold change 
and represents an increase or decrease in activity compared to PAR; fold change ± SE of n = 




















































5.2.2 Transcriptome analysis of PAR and RAL Knockout cell lines using 
RNA sequencing 
Since RAL isoform specific knockouts were first generated in the SW403 and 
SW620 colorectal cell lines, these were selected to undergo RNA sequencing. 
This included two parental (PAR), two RALA KO and two RALB KO clones for 
each cell type, giving a total of twelve samples. 
 
5.2.2.1 Gene expression profiles  
In order to reflect the correlation of gene expression between all twelve 
samples, the Pearson correlation coefficient of expression levels was 
calculated between each two samples. RNAseq gene expression profiles are 
different between cell types regardless of RAL status (Figure 5.6A). 
All RNAseq samples then underwent hierarchical clustering by the expression 
level of all genes (Figure 5.6B). This directly reflects the relationship between 
each two samples, where the closer the samples are to each other, the more 
similar the expression level. For the RNAseq, the two cell lines remain as 
distinct branches separate from each other, whether they be parental or 
knockout. For SW403, RAL KO samples had a more similar expression profile 
with each other than compared with the parental, regardless of RAL isoform 
targeted. The parental cell lines can be seen grouped together in both cell 
types, with the RALA KO clones paired off in SW620, with RALB KO2 
branching off the main knockout branch. Only RALB KO1 from the SW620 cell 
type was clustered with the parental clones. This could reflect the similar levels 




Figure 5.6 Correlation between samples and comparison of Differentially Expressed 
Genes (DEGs) from RNAseq data analysis. 
A) Pearson correlation coefficient values for all gene expression levels between each two 
samples. B) Hierarchical clustering of the expression level of all genes between each sample. 
C) Number of DEGs between RAL status in SW403 and SW620 cell lines. D) Number of DEGs 
within two samples of the same cell type with the same RAL status for SW403 and SW620 
cell lines. E) Total number of DEGs in single RAL knockout (RAL KO) cell lines compared to 
the parental (PAR). Only six genes are shared between the two cell types (SW403 and 
SW620) that are significantly different. F) Breakdown of DEGs into RALA KO, RALB KO and 
shared within each cell type. Breakdown of RALA KO and RALB KO DEGs according to 
































































































































































1 0.985 0.983 0.980 0.984 0.966 0.897 0.901 0.898 0.892 0.887 0.902
0.985 1 0.980 0.971 0.981 0.963 0.888 0.889 0.894 0.885 0.877 0.889
0.983 0.980 1 0.996 0.998 0.987 0.897 0.898 0.900 0.896 0.889 0.899
0.980 0.971 0.996 1 0.996 0.995 0.896 0.899 0.893 0.894 0.890 0.902
0.984 0.981 0.998 0.996 1 0.991 0.895 0.896 0.897 0.894 0.887 0.897
0.966 0.963 0.987 0.995 0.991 1 0.888 0.891 0.882 0.885 0.882 0.894
0.897 0.888 0.897 0.896 0.895 0.888 1 0.998 0.989 0.993 0.995 0.985
0.901 0.889 0.898 0.899 0.896 0.891 0.998 1 0.985 0.990 0.996 0.990
0.898 0.894 0.900 0.893 0.897 0.882 0.989 0.985 1 0.991 0.986 0.975
0.892 0.885 0.896 0.894 0.894 0.885 0.993 0.990 0.991 1 0.991 0.986
0.887 0.877 0.889 0.890 0.887 0.882 0.995 0.996 0.986 0.991 1 0.984
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5.2.2.2 Identification of shared differentially expressed genes (DEGs) 
Based on the gene expression level and the parameters previously mentioned 
(fold change ≥2.00 and adjusted P value ≤0.05), the differentially expressed 
genes (DEGs) between RALA/B KO and PAR samples can be identified.  
Overall, more DEGs were identified in SW403s, with a total of 513 DEGs 
present in the RAL KOs vs PAR, than in the SW620 cell line, which had a total 
of 206 DEGs (Figure 5.6E). Although the number of total DEGs differs between 
the SW403 and SW620 clones (Figure 5.6E), more differentially expressed 
genes were detected in the RALA KOs for both cell types, suggesting it is the 
more dominant of the two RAL isoforms when it comes to RAL network 
signalling and potentially function. For most of the DEGs in the SW403 cell 
line, gene expression was decreased in both RAL KOs in comparison to the 
parental, whilst a more even distribution of increased and decreased DEGs 
was observed in the SW620 samples (Figure 5.6C and Figure 5.6F). This 
suggests that different cell types might have different preferences for RAL 
isoform signalling. The small number of differentially expressed genes 
between RAL isoform samples, implies the two isoforms are involved in similar 
gene interactions and same signalling networks. Very few if any genes were 
identified where they increased in one isoform KO and decreased in the other 
(Figure 5.7). Again, this highlights the idea that there is some functional 
compensation within the two RAL isoforms. 
Although DEG identification between RAL status did not include genes that 
were only differentially expressed in one of the two knockout clones, it is still 
important to consider any gene expression differences within the two RAL KO 
samples. For the SW403s, PAR had the most DEGs present between the two 
clones (Figure 5.6D). In comparison, the knockout clones for SW620 have 
more DEGs present between isoform specific KO clones than the PAR clones 
(Figure 5.6D). This might explain the discrepancy between the higher total of 
DEGs identified in the SW403 cell type compared to the lower numbers 
recorded for SW620. Significant changes in gene expression between two 
samples with the same RAL status, emphasises the presence of clonal 
variation and how two samples can have different expression profiles and 
consequently differing cell signalling networks, regardless of gene editing. This 
is an important consideration when it comes to future data analysis and 
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interpreting RAL isoform specific function from clones with varied gene 
expression. 
 
Only 12 DEGs are shared between SW403 and SW620 (Figure 5.7A), with 
different expression trends seen in genes PTHLH (parathyroid hormone like 
hormone), PLXNA2 (plexin A2), IGFBP2 (insulin like growth factor binding 
protein 2) and PLAU (plasminogen activator, urokinase). The enzyme CHST3 
(carbohydrate sulfotransferase 3), is the only shared gene that is increased 
across all KO samples vs PAR and is the only shared gene that is classified 
as a DEG under a different RAL status (SW620 AKOs and SW403 BKOs), 
whilst trending in the other RALKO. Surprisingly, only 6 DEGs displayed 
decreased expression between the two cell lines (Figure 5.6E and 5.7A). PLK2 
(polo-like kinase 2), MYZAP (myocardial zonula adherens protein), EREG 
(epiregulin), GJB3 (gap junction protein, beta-3), ETS1 (ETS proto-oncogene 
1) and PRSS3 (serine protease 3) are all downregulated in the RAL KO 
samples (Figure 5.7A). This reflects the lack of gene expression correlation as 
a whole seen in Figure 5.5 and how different these two cell lines are at the 
genome level. 
To determine if the top DEGs for one cell type also trended in the other cell 
type, heatmaps were generated comparing RALA specific, RALB specific and 
RALA and RALB specific DEGs between SW403 and SW620 samples (Figure 
5.7B). It should be pointed out that although the DEGs from both cell lines 
were selected for comparison against each other, the higher total number of 
DEGs for the SW403 mean a lack of expression change is observed on the 
SW620 side. In fact, no DEGs were present in both AKO and BKO clones in 
the SW620 cell line. Overall, there was little similarity in the expression trends 
between the two cell lines. Many of the DEGs for one cell line, were either 
absent, showed no change or even showed an opposite trend in expression 
for the other type (Figure 5.7B). This lack of trending gene expression further 






Figure 5.7 Differentially Expressed Gene (DEGs) trends. 
Comparison of RALA specific, RALB specific and both RALA and RALB DEGs between 
SW403 and SW620 cell lines displayed little similarities between the two cell lines. DEGs in 
both the AKOs and the BKOs were only present in the SW403 cell line. The difference in gene 
expression profiles between the two cell lines is highlighted by the lack of expression change 
for many genes in one cell line but are significant for the other. Total lack of expression (grey) 
for some DEGs can also be seen in both cell lines. The few shared DEGs are highlighted on 











5.2.3 Proteome analysis of PAR and RAL Knockout cell lines using RPPA 
Although, RNAseq data allowed us to comprehensively profile changes at the 
genome level, assessing changes on the level of protein expression is also 
required. RPPA not only determines protein expression levels but also 
phosphorylation, cleavage and fatty acid alteration modifications. Over 400 
antibodies are utilised in this assay, that specifically recognise proteins in the 
PI3K-AKT and MAPK cascades and receptor tyrosine kinases, as well as 
components involved in cell cycle, DNA repair and apoptosis pathways. The 
same SW403 and SW620 clones (different lysates) used for RNAseq 
underwent RPPA analysis for comparison.  
Again, the Pearson correlation coefficient of RPPA expression between each 
two samples within the same cell line was calculated (Figure 5.8A). Overall, 
the RPPA expression profiles of the RAL KO samples differ to the parental 
(PAR) samples in both SW403 and SW620. Whilst SW620 clone BKO2 was 
the most similar to the PAR samples, correlation of all KO clone trends in the 
same direction. All RPPA samples then underwent hierarchical clustering by 
the expression level of all protein and phospho-protein (Figure 5.8B). For 
SW403, RAL KO samples had expression profiles that were distinct from the 
parental cell lines. However, expression profiles varied between RALKO 
clones and were not isoform specific. The parental clones were also clustered 
together in the SW620s (Figure 5.8B), with only the SW620 clone BKO2 
having a similar expression profile to the parental rather than the other RALKO 
samples.  
Whilst a fold change cut off value for ±2.00 was used in the RNA sequencing 
analysis, very few proteins reached this level of expression difference and 
none were deemed to be significantly different following statistical analysis. 
Furthermore, RPPA analysis covers less of the proteome than the RNA 
sequencing analysis does of the transcriptome, therefore a higher cut off value 
may result in the loss of too many proteins/phospho-proteins. It was decided 
a ±0.5 cut off for defining a differentially expressed protein (DEP) would be 
more appropriate to reduce the risk of missing interesting and relevant proteins 
that could be investigated further at a later stage. 
More differentially expressed proteins (DEPs) were identified in the SW620 
RALKO samples than SW403 (Figure 5.9 and 5.10). The RPPA expression 
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values of the top RPPA hits in both cell lines, trend in the same direction as 
their corresponding gene expression obtained from the RNAseq data (Figure 
5.9A and 5.10A). Only three DEPs in the SW403 had opposing gene 
expression (LDHA, PCNA and EphA2) (Figure 5.9A). This implies that 
expression trends at the gene level translates to the resulting protein, although 
it is important to note that RPPA expression values in individual clones may 
not be as strong as the other (Figure 5.9B and 5.10B). 
As with the RNAseq data, the RPPA expression values for proteins and 
phospho-proteins trended in the same direction for both RALA and RALB KO 
samples in SW403s and SW620s (Figure 5.9 and 5.10). This supports the idea 
of the RAL isoforms carrying out similar functions. Only co-receptor CD4 and 
phospho-EphA2 had contrasting expression levels between RALKO status in 
the SW620s, with a decrease observed in the RALA KOs, and an increase in 
expression in the RALB KOs. Comparison of top proteins/phospho-proteins 
between cell types revealed very few trends in expression (Figure 5.11). 
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Figure 5.8 Negative correlation of protein expression between parental vs knockout 
clones in RPPA data analysis. 
A) Pearson correlation coefficient values for all RPPA expression levels between each two 
samples. A negative correlation between all knockout clones (KO) and the parental (PAR) can 
be seen in both cell types. B) Hierarchical clustering of the expression level of all RPPA 
between each sample. All KO samples are displayed as distinct branches compares to the 
parental clones. Only SW620 clone BKO2 displayed the least change vs PAR in proteome 
expression compared to the rest of the knockout clones. 
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Figure 5.9 RNA expression matches top DEPs in SW403 when comparing RNAseq and 
RPPA data. 
A) Differentially expressed (phospho-)proteins (DEPs) in the RAL KO vs PAR SW403 samples 
with the corresponding Log2 RNA expression. B) Individual Log2 expression values of all the 
RPPA data collected, with top hits (DEPs) highlighted. DEPs = Log2 fold change ≥ 0.5. 
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Figure 5.10 RNA expression matches top DEPs in SW620 when comparing RNAseq and 
RPPA data. 
A) Differentially expressed (phospho-)proteins (DEPs) in the RAL KO vs PAR SW620 samples 
with the corresponding Log2 RNA expression. B) Individual Log2 expression values of all the 




Figure 5.11 Comparison of top RPPA hits between SW403 and SW620 samples. 
A) Comparison of top DEPs in RALA KOs vs PAR between SW403 (x axis) and SW620 (y 
axis) samples. B) Comparison of top DEPs in RALB KOs vs PAR between SW403 (x axis) 
and SW620 (y axis) samples. Differentially expressed (phospho-)proteins (DEPs) = Log2 fold 







DEPs were separated into RALKO status vs PAR (Figure 5.11) and the 
majority of hits for one cell line did not have a significant expression fold 
change in the other or did not change at all. Once again, this highlights the 
overall different profiles of protein expression between cell lines that was also 
seen at the genome level. Only a few hits could be classified as DEPs for both 
SW403 and SW620 samples (highlighted in the red boxes), although 
expression did not always trend in the same direction between cell lines. 
Notable RPPA hits for both cell lines were the increased expression of JNK2 
(MAPK9), phospho-S6 and phospho-PEA15, as well as increased and 
decreased expression of phospho-ERK1/2 in SW620s and SW403s 
respectively. 
 
5.2.4 Pathway Trends and Gene Ontology (GO) Analysis  
An overview of the RAS pathway (Figure 5.12) including key nodes across the 
RNAseq and RPPA data sets allows individual gene level with corresponding 
protein and phospho-protein expression values where available to be seen. In 
addition to this, GO analysis was carried out to gain an idea of the overall 
trends within both sets of data (Figure 5.13).  
Gene Ontology (GO) analysis assigns enriched genes to predefined groups 
based on their functional characteristics, helping to build a more detailed gene 
expression profile and understand RAL isoform knockout effect on biological 
processes. Since the SW403 cell line had more DEGs compared with the 
SW620 in the RNAseq data set, GO analysis was performed on the SW403 
DEGs and any enriched pathways were assessed for trends in the SW620 
samples (Figure 5.13A). Individual genes that map to the processes 
highlighted in Figure 5.13A can be found in Supplementary Table 7.1. 
Many different GO terms were associated with the DEGs provided, with the 
processes outlined in Figure 5.13 involving the largest groups of significant 
genes. The majority of processes are significantly decreased following either 
RALA or RALB knockout, with only DNA Replication, G1/S Transition of Mitotic 
Cell Cycle and Cell Mobility displaying an increase in related gene expression. 
Although these processes are presented as distinct functions, many of them 
involve crossover into different signalling pathways. The decrease in “EGFR  
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Figure 5.12 RAS signalling and cancer pathways. 
An overview of the RAS pathways including the three main nodes; RAF-MAPK, PI3K-AKT and 
RALGEF-RAL pathways. Corresponding protein/phospho-protein expression is included from 
the RPPA data analysis where available. Expression is represented as a Log2 fold change vs 





Signalling Pathway” could impact Cell Proliferation and Apoptotic Processes, 
which themselves involve Transcription Factor Binding, Inactivation of the 
MAPK Pathway and Small GTPase Mediated Signal Transduction. 
Many of the phenotypes identified in the GO analysis are well known to be 
driven by RAS signalling, although in many cases it is the MAPK/ERK and 
PI3K-AKT pathways that are generally considered to be the key regulators. 
The fact that they are enriched in the RAL KO cells suggests that there may 
be crosstalk with these other RAS effector pathways. The extent to which RAL 
isoforms might directly or indirectly regulate canonical RAS effector pathways 
is currently poorly understood and so this was selected as a line of 
investigation in our subsequent analysis.  
Whilst the RNAseq data highlighted some interesting trends for future 
validation, changes in mRNA levels do not necessarily mean that there will be 
meaningful changes in protein levels of signalling wiring relevant to the targets 
of interest. To address this, protein and phospho-protein changes collected in 
the RPPA analysis were utilised and the corresponding genes also underwent 
GO analysis to determine if similar biological processes were affected (Figure 
5.13B and 5.13C) 
Together, the detailed RNAseq and RPPA data, along with the broader GO 
analysis, provides evidence of crosstalk between the RALGEF-RAL and 
MAPK pathways. The RAL regulators and effectors themselves, as well as 
possible RAL involvement in RAS-driven processes such as cell cycle are also 














Figure 5.13 Gene Ontology (GO) Analysis highlights MAPK activity as well as 
proliferation and cell cycle pathways. 
A) Go analysis of the SW403 DEGs collected from the RNAseq analysis. B) GO analysis of 
the top RPPA hits in SW403. C) GO analysis of the top RPPA hits in SW620. GO analysis for 
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RAL signalling and cancer pathway trends – RNAseq and RPPA 
 
RAL regulators/RAL pathway 
RAL isoforms are regulated by a panel of GEFs and GAPs and in an isoform-
specific manner by Aurora A kinases and Protein Kinase C. Once activated, 
RAL engages pathways regulating the exocyst, the actin cytoskeleton, 
phospholipase D. Surprisingly, analysis of the two datasets focusing on 
components of these known regulatory or effector functions, showed very few 
significant changes in gene expression (Figure 5.14A). In fact, only one DEG 
was identified in the SW403 cell line and that was a decrease in the RALGEF, 
RALGDS. Likewise, an increase in Interferon Regulatory Factor 3 (IRF3) gene 
expression in the SW620 RALA KO was the only DEG present in this cell line. 
Although few genes reached the high bar for differential expression there are 
some clear trends within the RAL regulators; RALGEFs and RALGAPs across 
the KO samples (Figure 5.14A). Even though no RPPA data is available for 
these RAL regulators, all four of the RAS-dependent RALGEFs RGL1-4 have 
increased expression in the RAL KOs compared to the parental, whilst 
RALGDS and the RAS-independent RALGEFs, RALGPS1 and RALGPS2 
display a predominantly decreased expression. Similarly, all the RALGAP 
genes have decreased expression in the SW403 knockouts and are 
predominately increased in SW620s. Adding to these regulation changes, both 
RALA and RALB are also known to be phosphorylated by Aurora A kinase 
(AURKA) and Protein kinase C (PRKCA/B) respectively. Whilst RNA 
expression did not trend in the same direction between cell lines, it did 
translate to the protein and phospho-protein levels in both RALA and RALB 
KOs. However, this could not be confirmed by western blot (Figure 5.14B). 
Overall, knockout of one isoform seems to result in changes in RAL regulation 
but further validation is required. 
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Figure 5.14 RNAseq and RPPA analysis of the RALGEF-RAL pathway. 
A) An overview of the RALGEF-RAL pathway including RAL regulators and effectors. This 
includes components of known RAL functions such as the exocyst, filamin and cytoskeleton 
changes, endocytosis. Corresponding protein/phospho-protein expression is included from 
the RPPA data analysis where available. Expression is represented as a Log2 fold change vs 
the parental (PAR). B) Validation of key RAL effectors and regulators by western blot revealed 











Potential crosstalk with the other key RAS pathways was seen in many of the 
GO terms (Figure 5.13), including regulation of the MAP Kinases (MAPK). 
When looking at crosstalk, MAP Kinases involved in the JNK pathway were 
also considered. 
The well-described MAPK/ERK pathway is centred on the activation of RAS 
and the subsequent activation of a kinase cascade involving RAF, MEK and 
finally ERK proteins. Knockout of either RAL isoform resulted in an overall 
gene expression decrease in the ERK regulators, DUSPs (Figure 5.15A). 
DUSPs are dual specificity phosphatases that dephosphorylate MAPK 
proteins. Therefore, a decrease in DUSP activity should lead to an increase in 
ERK activity. However, whilst the gene expression data collected suggests 
there may be a change in DUSPs, RPPA data was only available for DUSP4 
and DUSP6 which didn’t always translate from the mRNA level. As a result, 
DUSP5 expression was checked by immunoblotting with an increase in protein 
levels seen in the SW403 KO clones (Figure 5.15B). This is in contrast to the 
decrease in expression seen at the transcript level. Another but lesser known 
ERK regulator, PEA-15 is significantly increased at the protein and phospho-
protein level in both the SW620 RALA and RALB KOs (Figure 5.15A). A 
smaller increase in phosphorylated PEA-15 is displayed in SW403, with a 
decrease at the gene and protein level.  
Changes in ERK itself can be seen at the gene level (Figure 5.15A), right 
through to protein and phospho-protein. For the SW403 RAL KOs, there was 
a strong increase in phosphorylated ERK, yet the actual protein levels mimic 
those of the mRNA with a decrease in expression for RALA and RALB KOs. 
On the other hand, SW620s, have an increase in mRNA and total protein 
expression but a decrease in phospho-ERK1/2. However, just because the 
regulation of MAP kinases is different, doesn’t mean the signalling of the 
pathway has also changed. 
Although the gene expression trends differ between all the known ERK 
effectors, changes in these ERK related components suggest that there is 
evidence of MAP Kinase pathway regulation by RAL. Several transcription 
factors downstream of ERK were significantly decreased at the gene level. 
This included JUN (SW403), FOS (SW403 and SW620 RALA KO) and the 
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shared DEG, ETS1 highlighted in section 5.3.2. However only protein 
expression was available for ETS1 which actual displayed an overall opposite 
increase in expression and could not be validated by western blot (data not 
shown). Phosphorylation data was also obtained for JUN, which also 
contrasted to the gene expression, but it is important to remember mRNA 
status does not directly influence phospho-protein levels. The most consistent 
change in the MAPK/ERK downstream effectors was an increase in the 
ribosomal S6 kinase (RSK) family, particularly RSK1 an RSK3 (Figure 5.15A). 
These serine/threonine protein kinases are involved in cell growth, 
proliferation and survival. Similar gene expression data was observed for other 
MAPK pathways, including a decrease in DUSPs in both cell lines with a 
general increase in JNK MAP Kinases, but a lack of RPPA data covering these 
kinases and their effectors meant I was unable to perform a comprehensive 
analysis.  
Finally, looking at receptors that are known to activate RAS, the receptor 
tyrosine kinase (RTK) EphA2 was found to be a DEG in SW403 RALA KOs 
(Figure 5.15A), as was EphA4 (data not shown). This translated to an increase 
in EphA2 protein and phospho-protein expression that was subsequently 
confirmed by western blot (Figure 5.15B and Supplementary Figure 7.12). 
However, re-expression of the knocked-out RAL isoform did not always 
restore p-EphA2 expression to that recorded in the parental (Figure 5.15B). 
Together, this RNAseq and RPPA data hints at both RAL isoform involvement 
in the regulation of all the MAPK pathways but these points need further 




Figure 5.15 RNAseq and RPPA analysis of the RTK/MAPK pathway. 
A) Overview of the RTK/MAPK pathway including receptor tyrosine kinases (RTKs). This 
pathway is predominantly involved in cell growth and proliferation. Corresponding 
protein/phospho-protein expression is included from the RPPA data analysis where available. 
Expression is represented as a Log2 fold change vs the parental (PAR). B) Validation of RPPA 
hits phospho-EphA2 (ser897) and DUSP5 in SW403 PAR, RALKO and RALKO + WT RAL. 
An expression increase in both proteins can be seen in the RALA and RALB knockout clones 
(KO). Transduction of WT RALA/B back into KO clones did not restore expression levels back 
to parental. Although re-expression of RAL was not to the levels seen in the PAR clones. C) 
Quantification of DUSP5 and p-EphA2 expression. A significant (*) increase in DUSP5 
expression is present in the BKO clones. Data is presented as a fold change and represents 
an increase or decrease in expression compared to PAR; fold change ± SE of n = 3 biological 
replicates. 
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Cell cycle  
GO analysis highlighted cell cycle as being a significant process affected by 
knockout of RAL in both cell lines (Figure 5.13). The cell cycle is a 4-stage 
process consisting of a Gap 1 (G1), Synthesis (S), Gap 2 (G2) and mitosis (M) 
(Figure 5.16A). Each phase is regulated by the formation of cyclin (Cyclin A, 
B, D, E) and cyclin dependant kinases (CDK 1, 2, 4, 6) heterodimers (Figure 
5.16A), which in turn are regulated by cyclin dependent kinase inhibitors 
(CDKN1A/B and CDKN2A/B/C).  
Whilst gene expression changes between the different cyclins and CDKs is 
not consistent within each cell line, there appears to be an overall increase in 
related transcription factors and an overall decrease in cell cycle regulators 
(Figure 5.16B), albeit this is mostly centred on RNAseq. The most visible 
expression trends are in the various cell cycle regulators. The CAK complex 
genes (CCNH and CDK7) that activate the cyclin/CDK heterodimers are 
decreased in the RAL KOs compared to the parental in both cell lines, as well 
as cyclin B1 (CCNB1) and CDK1 negative regulator WEE1 (Figure 5.16B). 
The decrease in WEE1 has been validated by western blot in SW403 KOs and 
was found to be significant in both the RAL AKO and BKO clones (Figure 
5.16D), although expression levels did not fully return to those of the PAR 
clones following re-expression of WT RALA or RALB (Figure 5.16D). There is 
also a decrease in cyclin B1 (CCNB1) and CDK1 regulator PLK1 in SW620 
and an increase in SW403. Cyclin B1 itself, strongly reflects this expression 
pattern and is increased in SW403 and decreased in SW620 at the gene level 
right through to protein expression. The previously mentioned PEA-15 also 
plays a role in the cell cycle, regulating CDK6 and CDC25 directly. Both mirror 
the PEA-15 expression in each cell line, with an increase in the SW620 and a 
decrease in SW403, although RPPA data is absent for CDK6. 
Like members of the MAPK pathways, analysis suggests that RAL has 
involvement in regulating the cell cycle. Whether this is through independent 
mechanisms or the previously mentioned MAPK pathways, which is heavily 






Figure 5.16 Changes in expression within the cell cycle. 
A) The four distinct phases of the cell cycle; Gap 1 (G1), DNA synthesis (S), Gap 2 (G2) and 
Mitosis (M). Cell cycle regulation is carried out by the formation of cyclin (Cyclin A, B, D, E) 
and cyclin dependant kinases (CDK 1, 2, 4, 6) heterodimers. Cell cycle checkpoints are 
regulated by cyclin dependent kinase inhibitors (CDKN1A, CDKN1B). Cell cycle progression 
occurs from Cyclin D + CDK4/6 induced phosphorylation of Rb, which enables E2F-mediated 
transcription of S-phase genes. B) Cell cycle signalling network illustrating the fold change of 
RNA/protein/phospho-protein expression in SW403/SW620 RALA and RALB knockout cell 
lines. Red indicates a positive Log2 fold change and an increase in expression compared to 
PAR (parental), whilst blue represents a negative fold change and a decrease in expression. 
C) Validation of RPPA hit WEE1 in SW403 PAR, RALKO and RALKO + WT RAL. A decrease 
in WEE1 protein expression can be seen in both RALA and RALB knockouts (KO). 
Transduction of WT RALA/B back into KO clones did not fully restore expression levels back 
to parental. Although re-expression of the RAL isoforms themselves was not to the 
endogenous levels seen in the PAR clones. D) Quantification of WEE1 expression. 
Quantification confirmed a significant (*) decrease in WEE1 expression (p < 0.05) in both AKO 
and BKO vs PAR. Data is presented as a fold change and represents an increase or decrease 




In this chapter I report the first large-scale analysis of RAL GTPases in a 
colorectal cancer cell model using a multi-omic approach. This involved 
profiling the network of outputs influenced by each RAL isoform using 
genome-wide and protein expression/activity analysis. Integrating the isoform 
activity and multi-omic data has revealed the unique RAL signalling signatures 
of different CRC cells. 
 
When it comes to changes in RAL isoform activity, previous work has mainly 
focused on activation as a consequence of a non-RAL loss/gain of function. 
The activity of RALA has been found to increase significantly in PI3Kɣ 
knockout mice (Sim et al., 2013), knockdown of RASGAP RASA1 leads to an 
increase in RALA activity via R-RAS (Sung et al., 2016) and RAB10 increases 
the GTP binding of RALA through the recruitment of Rgl2 (Karunanithi et al., 
2014). 
Here, the effects on activity of each RAL isoform following gene knockout of 
RAL itself have been determined. Our data shows that upon deletion of one 
RAL ortholog, the activity levels of the remaining isoform increase, whilst total 
protein levels remain similar to the parental. This was observed across all four 
cell lines with a significant increase in RALB activity detected in all cell lines 
except SW48. This could suggest that the mutant RAS proteins present in the 
HCT116, SW403 and SW620 cell lines impact RAL activity, as the WT RAS in 
the SW48 cell lines does not increase RAL activity to significant levels. The 
idea that there is compensatory activation of one RAL isoform in the absence 
of the other was highlighted in isoform specific null MEFs (Peschard et al., 
2012). Activity levels of GTP-RALB were found to be significantly increased in 
RALA null MEFs and GTP-RALA was increased in RALB null MEFs. The 
increased activation was also reported to occur without any apparent changes 
in RAL protein levels. This data from a mouse model study supported these 
findings and in fact, a significant increase in GTP-RALA in the BKOs, in one 
of the cell lines investigated was found. 
The reasons for how this compensatory increase occur remain unclear but it 
is not unreasonable to believe this is due to the removal of competition through 
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an increase in availability of RALGEFs and RALGAPs. A deficiency of 
RALGAP, RALGAPA1 has been found to cause constitutive activation of 
RALA (Wagner et al., 2020), RALGAP suppression caused RALB activation 
and the suppression of autophagy (Martin et al., 2014) and aberrant 
overexpression of the RALGEF Rgl2, promotes RAL-dependent pancreatic 
cancer growth (Vigil et al., 2010). Therefore, if RAL regulator availability 
directly affects RAL activity, it is not unlikely that the availability of RAL itself, 
say the lack of one isoform, can affect the activity levels of the other.  
Why compensation occurs is likely linked with the functional redundancy of the 
two isoforms. It also highlights the question of RAL isoform abundance and 
how much of each is present that consequently determines the level to which 
one isoform can compensate for the other. Likewise, the different RAL 
regulator abundances in different cell lines will also impact the levels of RAL 
activity compensation and therefore RAL-dependent functions. The idea of 
RAL isoform abundance will be addressed in the next chapter but varying RAL 
quantities across cell lines will ultimately influence RAL function and 
dependency on this particular pathway. 
 
The idea that one isoform compensates for the other is supported by a highly 
similar response at the mRNA level for RALA and RALB in both cell lines 
tested. Only a few genes showed opposite expression changes between RAL 
status upholding the premise of similar effector interactions. This could also 
explain why known effectors and interactors of the RAL pathway appear to 
show little to no change at the mRNA and protein level.  
Despite the same trend response between RALA and RALB KOs for most 
genes within a cell line, there was very little correlation between the expression 
profiles across the two cell lines at the transcript level. Since both SW403 and 
SW620 cell lines harbour G12V KRAS mutations, it was thought that their RAL 
signalling responses, at least in terms of RAS activity, might be more 
comparable. This highlights how different the signalling networks between cell 
lines can be and that their genetic background can be extremely varied 
regardless of the fact they have the same tissue origin. This is likely due to 
variations and mutations in other signalling pathway proteins. One example of 
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this is the fact that SW620 is homozygous for mutant KRAS and the SW403 
cell line only has a single mutated copy.  
With this in mind, it was surprising that the SW403 KOs had a higher number 
of changes at the transcript level when compared to the parental, rather than 
the SW620 KOs. Studies have shown that increased copy number of mutant 
KRAS is present in a significant portion of human tumours (Soh et al., 2009). 
This suggests that multiple copies of mutant KRAS may impart a stronger 
signalling effect than a single mutant copy. However when it comes to KRAS 
mutant colorectal cell lines and their dependency on RAL, it has been 
previously shown that knockdown of both isoforms decreased cell viability in 
the SW403 cell line more than SW620 with survival of the remaining population 
being ~50% and 75% respectively (Lee et al., 2019). Therefore, the increased 
dependency on RAL for cell viability in the SW403 cell line, seems to be 
unrelated to mutant KRAS copy number and therefore may not contribute to 
the larger response seen in our RNAseq data following RALA or RALB 
knockout. 
Only twelve genes were identified as being differentially expressed in both cell 
lines and only seven of those genes trended in the same direction (PLK2, 
MYZAP, EREG, GJB3, ETS1, PRSS3 and CHST3). Studies focusing on RAL 
and these genes is severely limited. Only a link between RAL and ETS Like-1 
protein (ELK1) has been reported, in which growth hormone stimulated RALA-
PLD formation was required for ERK activation and ELK1 transcription (Zhu, 
Ling and Lobie, 2002). Additionally, although displaying contrasting 
expression profiles between SW403 and SW620, IGFBP2 could potentially be 
a gene of interest. The IGFBP2 counterpart IGFBP1 was found to activate 
ERK and RAL in an oligodendrocyte precursor cell line (Chesik et al., 2010). 
It’s worth noting that IGFBP2 was also identified from the RPPA data as being 
differentially expressed at the protein level in SW403 KOs. In spite of the lack 
of research, several of these genes are either involved in MAPK pathways 
(EREG and ETS1) (Tetsu and McCormick, 2017; Kohsaka et al., 2014; Draper 
et al., 2003) or cellular processes linked to RAS signalling (PLK2) (Lee, Hoe 
and Pak, 2011; Lee et al., 2011; Walkup et al., 2018). Together with the RAL-
dependent activation of ELK1, this data supports the idea of crossover 
between RAL and the other main pathways of RAS. 
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Unfortunately, apart from IGFBP2 and ETS1, these genes were not covered 
in the RPPA analysis to see if expression changes at the mRNA level 
translated to the protein level. Furthermore, western blot analysis of EREG, 
ETS1 and PLK2 expression did not match that seen in the RNAseq data. This 
lack of translational efficiency could be explained by modifications such as 
methylation of the mRNA affecting their stability (Mauer et al., 2017; Zaccara, 
Ries and Jaffrey, 2019). The protein stability itself may also be a factor, as 
proteins have different half-lives (Eden et al., 2011) with some proteins 
needing to be quickly degraded for proper function (Toyama and Hetzer, 
2013). Indeed, the ETS1 ortholog ETS2 is known to have a half-life of 
approximately 20 minutes (Papas et al., 1990), which is considered a very 
short half-life with the majority of proteins lasting between 8 and 10 hours 
(Chen, Smeekens and Wu, 2016). 
Like the RNAseq, the RPPA data displayed different protein expression 
profiles between the SW403 and SW620 cell lines. However, there was still a 
high correlation of expression change between RALA and RALB, again 
reinforcing the idea that isoform compensation does not just involve activity 
levels but extends to functionality. As previously mentioned, there were very 
few DEGs that matched up with proteins that were differentially expressed, 
however clear trends could be seen throughout the two datasets supporting 
the change from mRNA to protein. 
By comparing transcriptomic, proteomic and phospho-proteomic datasets, 
likely protein expression/activity changes and the potential participation of RAL 
in novel signalling pathways were identified. A high correlation between mRNA 
and protein levels indicated that protein abundance was likely to be 
determined by transcript abundance and that the RPPA dataset was reporting 
differential protein expression across both RAL knockout cell lines.  
For this reason, focus was turned to proteins involved in the RTK/MAPK and 
PI3K pathways, as well as processes highlighted in the GO analysis that are 
known to be activated by RAS, such as cell proliferation and growth including 
the cell cycle. Although multi-omic analysis was only carried out on two out of 
the four knockout cell lines generated, potential hits were also validated in the 
HCT116 an SW48 cell lines where appropriate.  
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Unfortunately, some of these proteins that were highlighted by the RPPA and 
had corresponding RNAseq data, could not be validated by western blot. 
Probing for phospho-RSK, PEA15, phospho-PEA15 and phospho-ERK did not 
display any significant expression changes. Whilst this does mean further 
validation is required to establish a link with RAL, it should be noted that RPPA 
is a more robust form of quantification and has a higher degree of sensitivity 
compared to western blot (Boellner and Becker, 2015). This could explain why 
small changes in protein expression were detected in RPPA but not western 
blot.  
From our initial activity studies, activation of both RAL isoforms was found on 
average to peak around one minute, extending to two minutes in HCT116. 
Whether or not the duration of the remaining RAL isoform also increases 
following isoform specific knockout has not been determined, it seems unlikely 
that it would extend far beyond those seen in the parental cell lines. With this 
in mind, any involvement of RAL in the activity of these proteins could be short-
lived and provide the initial activation before other pathways become more 
dominant and any differences in expression are lost. 
Finally, rewiring and compensation in the RAS pathways has been shown to 
occur in a matter of days. Phospho-ERK levels returned to control levels after 
only 24 hours treatment with a G12C-specific KRAS inhibitor (Hallin et al., 
2020), and work conducted in our lab has shown drug resistant signalling 
pathways emerge after only 2-4 days with KRAS inhibitor treatment (Warren 
et al, unpublished). Therefore, the expression changes seen in both the 
RNAseq and RPPA may have already been adjusted back to parental levels 
due to alternate pathway activation. Carrying out western blot validation on 
knock-in cell lines or even double RAL knockout might help address this issue 
by either enhancing protein interaction and activity changes via a constitutively 
active RAL or preventing potential compensation through the remaining RAL 
isoform. 
 
Our studies provide evidence of a link between several DUSPs and both RAL 
isoforms. There was a clear downward trend of nearly all the DUSP mRNA 
levels in both the SW403 and SW620 cell lines, with DUSP4 and DUSP5 being 
significantly downregulated. Only data covering DUSP4 protein levels was 
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available from the RPPA and this was seen to have an inverse relationship 
with mRNA expression with a small increase in protein levels detected in the 
SW403 KOs.  
Western blot analysis confirmed an increase in the nuclear protein DUSP5 in 
SW403 RALA and RALB KOs which again, is opposite to that reported at the 
transcript level. It should be noted that validation of a link between RAL and 
DUSP5 was not always successful, as this DUSP5 expression increase in 
SW403 KOs was not consistently restored to levels seen in the parental 
clones, following re-expression of the knocked-out isoform. This is most likely 
due to the re-expression levels of RAL itself being noticeably lower than that 
of the endogenous RAL. Future re-expression attempts, whether that be stable 
or transient expression, would benefit from having a stronger expression 
promoter, such as a CMV promoter, present in the transfer plasmid. Moreover, 
isolation and expansion of a positive re-expression cell population would also 
ensure RAL levels were as close as possible to those recorded in the parental 
clones and eliminate interference from any remaining knockout cells present 
in a heterogenous population.  
Further validation efforts through RALA or RALB knockdown in the parental 
clones (data in supplementary material), did not show an increase in DUSP4 
or DUSP5 expression. However, it is likely that the knockdown period was not 
sufficient for RAL to exert any effect. Additionally, knockdown did not fully 
eliminate isoform expression and therefore may also explain the lack of 
differential DUSP protein expression. 
The MAPK pathway is subject to a large number of negative feedback loops 
that includes the dephosphorylation and inactivation by DUSPs (Caunt and 
Keyse, 2013). DUSP4 and DUSP5 display nuclear localisation and have a 
preference for different MAPK proteins, with DUSP4 inactivating ERK, p38 and 
JNK, whereas DUSP5 is ERK specific (Lake, Corrêa and Müller, 2016). Upon 
MAPK pathway stimulation, DUSP expression levels increase. Moreover, 
DUSPs can be directly phosphorylated by MAPKs, leading to increased 
stabilisation and prolonged activation, which in turn inactivates MAPK 
proteins. However, studying DUSP activity and MAPK regulation is difficult due 
to the presence of this feedback mechanism, short protein half-lives and low 
basal expression levels. Indeed, a DUSP2 deficiency was found to not cause 
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enhanced ERK phosphorylation (Jeffrey et al., 2006). Similarly, DUSP10 
knockdown does not induce p38 hyperphosphorylation (Zhang et al., 
2004).This inconsistency of DUSP regulation of MAPK proteins may be 
attributed to the use of overexpression systems in an effort to combat the low 
basal levels of DUSP expression.  
By measuring the endogenous expression of DUSP5 mRNA levels after MEK 
inhibitor treatment, the molecular mechanisms underlying the induction of 
DUSP5 transcription by the MAPK pathway were finally revealed. These 
involved promoter binding sites for a ternary complex involving ETS binding 
sites for transcription factor ELK1, serum response factor (SRF) and a serum 
response element, with subsequent depletion of SRF or ELK1 leading to a 
decrease in DUSP5 mRNA following serum stimulation (Buffet et al., 2015). 
This study also found that the mRNA of DUSP5 is rapidly induced by ERK 
activation but unlike DUSP6, its stability is independent from the activation of 
the MAPK pathway. 
There is currently no available data connecting RAL activity and DUSP 
proteins. However, considering the link between RAL and ELK1 (Zhu, Ling 
and Lobie, 2002), DUSP5 and ELK1, as well as transcription factor ETS1 
presenting in our data as a DEG in both SW403 and SW620, crosstalk 
between RAL and the MAPK pathway through DUSPs looks promising. Since 
DUSP5 stability seems unaffected by the MEK/ERK pathway, taking mRNA 
measurements by RT-qPCR following the combined use of a MAPK and PI3K 
inhibitor would assist in determining the potential role RAL plays in DUSP5 
regulation. This inhibitor approach would also help deduce other interactions 
between RAL and RAS pathway kinases, such as p-ERK, RSK and AKT, that 
we were unable to fully validate by western blot. 
 
One kinase that displayed evidence of RAL dependency was receptor tyrosine 
kinase EphA2. In the SW403 RAL KO cells, a downregulation of EphA2 mRNA 
and an increase in protein and phospho-protein expression was observed, 
which was subsequently confirmed by western blot. EphA2 is generally 
thought of as a tumour promoter and is overexpressed in a variety of different 
cancers including and colorectal cancer (Kou and Kandpal, 2018). EphA2 
displays significantly higher expression levels in colorectal tumours leading to 
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an increase in cell migration and invasion and correlates with poor survival in 
stage II/III cancer tissues (Dunne et al., 2016). Importantly, this study found 
that EphA2 levels were regulated by KRAS-driven RALGDS-RALA and MAPK 
pathways. Further analysis revealed that RNAi-mediated silencing of RALA 
but not RALB significantly decreased EphA2 protein levels in HCT116 and 
DLD-1 cells. Furthermore, examination of a large colorectal cancer cell panel 
revealed a link between high EphA2 expression and an activating mutation in 
KRAS. Like DUSPs, a negative feedback loop exists between RAS and 
EphA2. It has been shown that whilst RAS-MAPK signalling induces EphA2 
expression, EphA2 stimulation through ligand interaction, downregulates 
MAPK signalling (Macrae et al., 2005). This may explain why the EphA2 
mRNA and protein expression levels reported in the SW403 cells are 
differentially expressed. 
Whilst a link between RAL and EphA2 has already been established, the data 
reports the opposite expression profiles to those seen in our data. This could 
simply be due to different cell lines used or the fact that the association 
between the two proteins was detected as a result of RNAi not full gene 
knockout. Since our data has demonstrated a compensatory effect in RAL 
isoform activity, not only does this suggest that EphA2 regulation may be a 
PAN-RAL response, but our knockout cells have had a longer time to adjust 
and alter this pathway. Regardless, collectively these data provide evidence 
that EphA2 is an important mediator in colorectal cancer progression and that 
this RAL-dependent function may be a consequence of oncogenic RAS. 
Finally, several cell cycle proteins were identified from our two datasets as 
being differentially expressed in both cell types including an overall 
downregulation of CyclinD1 and WEE1 mRNA and protein levels, as well as 
changes in CyclinB1 expression that translates from mRNA to protein. RAS 
activity is known to promote cellular proliferation or differentiation through 
growth factor stimulation and ultimate activation of MAPK proteins. MAPK 
induced phosphorylation of transcription factors such as FOS, JUN and ETS 
(identified as DEGs in our data) results in the expression of immediate-early 
response genes required for progression through early phases of the cell cycle 
(Zhang and Liu, 2002). Whilst RAL has not been shown to contribute to cell 
proliferation in the absence of RAS (Drosten et al., 2010), RAL has been 
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implicated in cell cycle progression. Notably, RAL GTPases have been found 
to enhance cell detachment and motility through Cyclin D1 (Fernández et al., 
2011) and the regulation of Cyclin D1 by RAL occurs through activation of 
NFκB (Henry et al., 2000). One study has also shown that activation of RAS 
during the mid-G1 phase of the cell cycle does not result in ERK activation and 
that RAS may target an alternative effector pathway during cell cycle 
progression (Taylor and Shalloway, 1996). Could RAL be responsible for the 
passage through multiple points during the cell cycle? Indeed, WEE1 is a 
protein kinase that regulates the G2 checkpoint and prevents entry into mitosis 
by inhibiting phosphorylation of CyclinB1/Cdc2 complexes (Geenen and 
Schellens, 2017). Activation of RAL by RAS has been found to interfere with 
this phosphorylation process and decrease CyclinB1/Cdc2 activity (Agapova 
et al., 2004). The reduced expression of WEE1 collected from the omic 
analysis was validated by western blot, providing evidence for a link between 
RAL and cell cycle progression through WEE1 regulation. 
 
The combination of techniques was applied to obtain an insight into protein 
interactions and signalling pathway adaptations to isoform specific RAL 
knockout. Importantly it highlights how varied the signalling networks of 
different cell lines can be and that an appropriate cell line with robust 
dependency on the target protein pathway, making it capable of highlighting 
novel interactions, is crucial in determining its role in cellular physiology. 
Together, these data provide evidence for crosstalk between RAL and other 
pathways of RAS as well as highlights involvement with novel regulators of 






Chapter 6: Protein Standard Absolute 
Quantification of RAL Isoforms 
6.1 Introduction 
Despite studies spanning over three decades, a complete understanding of 
RAL GTPase function and dysfunction, particularly in cancer, is yet to be 
realised. Indeed, one part of RAL biology that has not been fully addressed is 
protein abundance. Specifically, how much RAL, as well as how many 
molecules of each RAL isoform are present in cell lines commonly used in cell 
signalling cancer research. Protein abundance is a critical parameter in cell 
signalling, especially since research is becoming less focused on identifying 
and characterising individual proteins and instead shifting to a more holistic 
approach that seeks to understand how proteins work together in complex 
signalling networks (Aldridge et al., 2006; Bordbar et al., 2014). Therefore, 
utilising a method that can serve to quantify proteins of interest is highly 
desirable. 
Although the utilisation of immunoblotting to quantify small GTPase protein 
abundance and activation is a well-established technique (Omerovic et al., 
2008; Chapman and Hall, 2005; Kim et al., 1997), in this instance it fails to 
provide a larger, more detailed picture of RAL biology that is required. Whilst 
it would enable the identification of RALA and RALB and their expression in 
cells or tissue samples, immunoblotting is highly variable and would not allow 
sufficient quantification and therefore comparison between isoforms. 
Furthermore, due to the lack of PAN RAL antibody availability, the overall RAL 
expression across a panel of cell lines would not be accurately determined. 
Therefore, a more robust method to measure the abundance of RAL isoforms 
is preferred. 
The emergence of Liquid Chromatography with tandem mass spectrometry 
(LC-MS/MS)-based proteomics has provided a more effective method for 
studying complex proteomes. This approach involves the enzymatic digestion 
of a proteome to generate peptides that are subsequently acidified to give 
them a positive charge before separation through LC and analysis by MS. Due 
to its ability to identify thousands of peptides/proteins, this techniques is often 
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referred to as shotgun proteomics (Aebersold and Mann, 2003; Domon and 
Aebersold, 2006). Unfortunately this approach has limited sensitivity and most 
often only provides relative quantification of the most abundant components 
(Gallien, Duriez and Domon, 2011). 
Thus, alternative targeted proteomic approaches such as selected reaction 
monitoring (SRM)-based LC-MS have been developed to quantitatively and 
precisely analyse complex samples (Anderson and Hunter, 2006). This assay 
usually involves the initial ionisation of a sample followed by two stages of 
mass selection: first selecting the mass of the intact “parent” ion, and then that 
of a specific fragment ion following collision-induced dissociation. Collectively, 
this generates a SRM assay, or multiple reaction monitoring (MRM) if more 
than one parent/fragment ion pair is monitored (Gallien, Duriez and Domon, 
2011). Furthermore, this MS-based approach in combination with an 
appropriate isotope-labelled standard can provide absolute quantitation of 
endogenous protein concentration. 
Since RAL has currently not been quantified in this way but both RAL isoforms 
share similar (46-51%) sequence identity and domain architecture to that of 
RAS small GTPases (Nicely et al., 2004), studies that have attempted to 
quantify cellular RAS abundance using this technique were looked into. By 
adding isotopic RAS reference peptides as standards ahead of SRM analysis, 
a number of groups directly measured RAS protein abundance but with highly 
variable results, ranging from <100 to >5,000,000 molecules of RAS per cell 
(Schwanhäusser et al., 2011; Halvey, Ferrone and Liebler, 2012; Wang et al., 
2011). 
The significant divergence in RAS abundance estimates recorded in these 
studies is likely due to the use of enrichment steps and relative quantitation 
strategies. All these targeted approaches involved the labelled RAS peptide 
standards being spiked-in immediately prior to injection of the sample into the 
mass spectrometer. This means that any differences acquired during sample 
preparation, proteolysis and/or peptide gel extraction were not factored into 
the final quantitation (Lowenthal et al., 2014). To avoid these problems, 
Mageean et al. optimised a methodology known as Protein Standard Absolute 
Quantitation (PSAQ) (Mageean et al., 2015). Instead of adding individual 
peptides, PSAQ involves the addition of full-length isotope-labelled protein 
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standards into the sample cell lysate before processing and importantly does 
not require any antibody enrichment steps (Brun et al., 2009; Dupuis et al., 
2008). By adding the stable recombinant protein standard at the beginning of 
the procedure, it will be subjected to the same potential errors and losses as 
the endogenous protein, enabling a more accurate approach to protein 
quantification. 
Mass spectrometry analysis performed by SRM-based quantification, in 
combination with a protein standard, paves the way for quantifying 
endogenous levels of specific proteins and their isoforms. Importantly, 
because expression of both RAL isoforms is not a result of ectopic over-
expression, data across any cell line of interest can be accurately collected. 
 
6.1.1 Aims and Objectives 
The aim of this chapter is to precisely quantify RAL isoform abundance across 
a large panel of colorectal cell lines. The objectives of this process involved 
the establishment of the PSAQ method in the lab. This required the following 
stages of optimisation: 
• Produce isotope-labelled His-tagged recombinant RAL proteins. 
• Optimise sample processing through in-gel digest. 














6.2.1 Production of PSAQ RAL standards 
As mentioned previously, the generation of full-length, isotope-labelled protein 
standards forms the basis of the PSAQ strategy and is required for the 
successful quantification of a target protein(s) (Figure 6.1). Since the 
proteotypic RAL peptides selected later on will contain a C-terminal lysine 









N4 L-arginine (+10 Da). To 
express these proteins, AT713 bacteria deficient for the biosynthetic genes 
ArgA and LysA were used, since they are suitable for generating uniformly 
labelled proteins with arginine and lysine isotopes. 
Following sequence cloning of WT RALA and RALB into the pTrcHis A vector, 
AT713 E. coli were transformed with these plasmids and grown under different 
conditions in M9 minimal media which had been supplemented with heavy 
arginine and lysine. Culture samples taken and run on SDS-PAGE revealed 
His-RALA was stable at 37°C and 21°C but an overnight incubation at the 
lower temperature increased the yield. On the contrary, His-RALB seemed 




Figure 6.1 Protein Standard Absolute Quantification (PSAQ) for measurement of 
cellular RAL abundance. 
Isotopically labelled RALA and RALB recombinant proteins are spiked into cell lysates at a 
known concentration before fractionation, proteolysis and quantification of pre-determined 















Figure 6.2 Elution profiles for His-tag and size exclusion-based chromatography of 
RALA (light) and RALA (heavy) purifications. 
Nickel-based enrichment of His-tagged proteins typically retains contaminating proteins that 
require further purification steps to achieve sufficient purity for use as an isotope-labelled 
protein standard for use in protein quantitation. Blue = UV absorbance (mAU), Green = 
percentage concentration of Buffer B (%). 
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Figure 6.3 Elution profiles for His-tag and size exclusion-based chromatography of 
RALB (light) and RALB (heavy) purifications. 
Nickel-based enrichment of His-tagged proteins typically retains contaminating proteins that 
require further purification steps to achieve sufficient purity for use as an isotope-labelled 
protein standard for use in protein quantitation. Blue = UV absorbance (mAU), Green = 
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were produced at 37°C with only a 3-hour incubation to prevent possible 
degradation and His-tag cleavage (Supplementary Figure 7.15). The His-
tagged RAL isoforms were subsequently purified using His-Trap HP columns 
before relevant fractions were collected and subjected to gel filtration using 
Superdex Increase 200 10/300 GL and AKTA purifier equipped with Frac950 
and UPC900 (Figure 6.2 & Figure 6.3). Further details of purification are in the 
supplementary material (Supplementary Figure 7.16-7.19). 
Following this last step of purification, coomassie staining of fractions 
containing the RAL PSAQ standards revealed there was no contaminations 
with any other proteins (Figure 6.4A). The concentration of the RAL PSAQ 
standards was determined by generating an isotopically light labelled His-
RALA protein. The concentration of this light version was measured using a 
bicinchoninic acid (BCA) assay (Figure 6.4D). Once an accurate concentration 
was determined, a known amount of the light His-RALA was mixed 1:1 with 
the heavy RAL PSAQ standards, before in-gel digestion and SRM analysis of 
the light and heavy versions of the PAN RAL peptides (Figure 6.4C). Accurate 
measurement of the PSAQ standards was resolved through comparison of the 
intensities of the respective isotope signals. 
Finally, 15 µg of SW48 cell lysate with and without 100 ng of PSAQ standards 
was run on a self-poured 15 well, 1 mm, 10% BisTris SDS-PAGE gel with 
alternating lanes of rainbow marker to determine the migration of the 
endogenous and His-tagged RAL proteins and which segment is required for 
processing (Figure 6.4B).  
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Figure 6.4 High-purity His-RAL protein standards.  
A) Coomassie staining showed no contaminating proteins. 200 ng of each protein loaded per 
lane. B) Determining gel migration for accurate excision of target protein and standards. The 
His-tag results in a band shift that must be accounted for when determining where to cut the 
gel. For the western blots, 5 ng His-RAL and 15 µg SW48 lysate are loaded in the indicated 
lanes. Note all recombinant proteins run at different band sizes depending on gel composition. 
C) A known amount of accurately quantified His-RALA light (100 ng) was mixed BCA reported 
100 ng worth of isotope-labelled RAL standards to accurately determine heavy-labelled 
protein concentration. D) Concentration of His-RAL proteins determined by BCA and then by 
mass spectrometry analysis. 
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6.2.2 Identification of proteotypic RAL peptides and their transitions 
To be able to accurately quantify protein abundance, it is first necessary to 
identify peptides that are unique to the protein(s) of interest. Identifying these 
peptides, known as proteotypic peptides (Mallick et al., 2007), can present a 
significant challenge with small GTPases such as RAL, as the two isoforms 
share an 82% overall sequence identity (Gentry et al., 2014). This limits the 
number of isoform specific peptides that can be generated following 
proteolysis as a high proportion of those peptides generated will be shared 
between both isoforms.  
That said, only a few representative peptides are needed to confirm the 
presence of a protein in a biological sample (Lange et al., 2008). However, 
due to the considerable amount of time and resources required to produce 
quantitative standards, such as these recombinant proteins, the selection of 
the best peptides for each protein is a crucial step in the development of SRM 
assays (Deutsch, Lam and Aebersold, 2008). Therefore, peptides were 
carefully selected and the following criteria were used to decide which ones 
were most suitable to measure RAL abundance: (1) peptides must be unique 
to both RAL isoforms or isoform specific, (2) ideally peptides must be between 
8-25 amino acids in length, (3) a peptide must have limited chemically 
modifiable residues, such as asparagine, glutamine and methionine (4) a 
peptide must be devoid of known post-translational modification sites e.g. not 
be from the HRV region of RAL, (5) exclusion of peptides generated as a result 
of missed cleavages is preferred and (6) peptides with multiple mid-chain 
basic residues should be discounted. 
The majority of large-scale proteomic studies utilise trypsin to digest proteins 
into analysable peptides (Gallien, Duriez and Domon, 2011). A similar protein 
quantification study carried out in our laboratory, found that trypsin generated 
the most information regarding RAS abundance from a single digestion. 
Trypsin is a stable protease that displays high cleavage specificity at arginine 
(R) and lysine (K) residues and can act under a wide range of conditions 
(Olsen and Mann, 2004). Since trypsin cuts after a K or R, it means that the 
peptides should always be labelled with a heavy isotope, either 8 or 10 Da 
respectively. The presence of a C-terminal basic residue in tryptic peptides 
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means they are typically multiply charged, making them highly suitable for 
fragmentation under low energy collision induced dissociation (CID) conditions 
(Paizs and Suhai, 2001). For these reasons, trypsin was selected as the 
enzyme of choice for digestion of the samples collected. 
Tryptic digestion of both RAL isoforms was first performed in silico using the 
Expasy PeptideMass calculator. To ensure specificity to RAL, all selected 
peptides were subjected to BLAST analysis (Basic Local Alignment Search 
Tool, National Library of Medicine) using a non-redundant protein sequences 
database and blastp (protein-protein BLAST) algorithm. The predicted 
peptides that agreed with most of the criteria outlined above, were selected as 
potential candidates (Figure 6.5). Although, it should be noted that it was 
difficult to find any PAN RAL or isoform specific peptides that did not include 
at least one modifiable residue.  
To discover if these peptides were detectable under our experimental 
conditions, the recombinant proteins underwent in-gel digestion and analysis 
on the mass spectrometer at different concentrations with and without cell 
lysate. After selection of suitable transitions (Figure 6.6 & Figure 6.7), initial 
analysis of a high concentration (100 ng) of either His-RALA/B alone (without 
cell lysate) included detection of all candidate peptides (Supplementary Figure 
7.20 and Supplementary Figure 7.21). However, the levels of RALB specific 
peptide IPLLVVGNK were found to be lower than that of the others and RALA 





















Figure 6.5 Proteotypic RAL peptides. 
All peptides are tryptic-derived. The candidate peptides describe total RAL as well as isoform 
specific peptides. Only RALA specific peptide EDENVPFLLVGNK was consistently detected 





































This missed cleavage site is likely due to the presence of a glutamic acid (E) 
at the start of the desired peptide sequence (Šlechtová et al., 2015). 
Although detection of all peptides under these conditions seemed promising, 
identification of the same peptides in subsequent runs in which a range of 
lower concentrations of heavy recombinant RALA/B (0.5 – 5 ng), with and 
without lysate, proved to be more challenging (Figure 6.8A). The RALA 
specific peptide EDENVPFLLVGNK, was again detected with a miscleavage 
at both the light and heavy levels and instead was detected as 
VKEDENVPFLLVGNK. Whilst detection of the heavy version of the other 
RALA specific peptide ADQWNVNYVETSAK was clear, when looking at the 
light (endogenous) levels, this peptide seemed to increase in a linear manner 
similar to that of the heavy (data not shown). Combined with the unreliable 
detection of one RALA specific peptide but the consistent detection of the 
miscleaved peptide in all samples and subsequent repeat runs, 
VKEDENVPFLLVGNK was deemed the preferred peptide for future 
quantification analysis.  
Again, identification of the RALB specific peptide IPLLVVGNK was difficult and 
in fact was undetectable at all lower concentrations as either the light or heavy 
version. The other RALB specific peptide AEEWGVQYVETSAK was also 
difficult to identify due to interfering peaks but was the more reliable of the two. 
Both PAN-RAL candidates were clearly visible in the 100 ng samples but the 
linearity of each peptide was variable at lower concentrations, in and out of 
cell lysate. The lack of an identifiable peak for both the light and heavy versions 
of VIMGSGGVGK and SALTLQFMYDEFVEDYEPTK, in different 
experimental runs, suggests the peptides may be unstable or that they are 
being oxidised due to the presence of a methionine in both. Since other runs 
displayed these heavy peptides as increasing in a linear manner (Figure 6.8A), 
both peptides were selected to be included in the final calculations and 
compared to RALA + RALB peptides to provide a level of confidence in peptide 
detection. Overall, whilst identification of the peptides at these lower 
concentrations proved to be problematic, the following peptides: 
VKEDENVPFLLVGNK (RALA), AEEWGVQYVETSAK (RALB), 
SALTLQFMYDEFVEDYEPTK and VIMGSGGVGK (both PAN RAL) were 
selected for use in quantifying RAL abundance in my final cell samples. 
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Figure 6.6 MS/MS transition spectra for PAN RAL peptides. 
100 ng of His-tagged RAL isoforms were subjected to LC-MS/MS analysis for detection of 
candidate peptides. Both PAN RAL peptides were detected for RALA and RALB. Precursor 
(Q1) and fragment (Q3) ions are indicated for both the heavy and light peptides. Transitions 
are chosen based on signal-to-noise and sensitivity to allow robust discrimination versus other 
peptides with similar mass/charge in the cell lysate. Generally, higher mass range transitions 
are preferred due to the higher likelihood that they will be selective for the parent peptide. 
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Figure 6.7 MS/MS transition spectra for RALA and RALB peptides. 
100 ng of His-tagged RAL isoforms were subjected to LC-MS/MS analysis for detection of 
candidate peptides. All isoform specific peptides were detected at this concentration with 
VKEDENVPFLLVGNK (RALA) and AEEWGVQYVETSAK (RALB) selected for future 
analysis. RALB peptide AEEWGVQYVETSAK was presented with a 2+ and 3+ charge. The 
2+ ions were used for data analysis as they displayed less interference. 
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6.2.3 Calibration Curves and determining spike-in concentration 
During the selection of the most appropriate peptides for use in quantification, 
adding a range of standard concentrations (0.5 – 5 ng) into 20 µg cell lysate, 
allowed rough determination of how much His-RALA/B to spike into the final 
samples. Using the calibration curve generated from the heavy standards 
(Figure 6.8A) endogenous peptide readouts from the cell lysate could be 
compared. Across the five samples analysed in the first run, the average RALA 
concentration was less than 1 ng, RALB was 3 ng. However, since the PAN 
RAL (based on SALTLQFMYDEFVEDYEPTK) readout was 1 ng, this 
concentration was selected for both RALA and RALB for future samples in 
case the RALB levels in this cell type were higher than average. Following the 
processing of three batches (21 samples each), it was decided that since the 
average readout for both the endogenous RALA and RALB in the colorectal 
cells lines was 2 ng each, future batches would have a spike-in concentration 
that matched this increase. 
 
6.2.4 Recombinant protein labelling efficiency 
In addition to selecting appropriate peptides, the protein standards were also 
tested to confirm efficiency of incorporated heavy amino acids (arginine and 
lysine). Following SDS-PAGE and in-gel digestion, analysis was performed on 
the mass spectrometer to determine the presence of “light” peptides that would 
indicate incomplete incorporation (Figure 6.8B). Analysis using LC-MS 
revealed the percentage of heavy labelling to be 95.7% and 96.3% for the PAN 
RAL peptides for His-RALA, 95% and 99.2% for the PAN RAL peptides from 
His-RALB and 99.7 and 99.3% for RALA and RALB specific peptides 
respectively (Figure 6.8C). Since the percentage of unlabelled standard is low, 




Figure 6.8 Protein labelling efficiency and linearity between RAL peptide abundance 
and MS response. 
A) 20 µg HEK293T lysate was mixed with isotope-labelled RALA and RALB at concentration 
ranging from 0.5, 1, 2, and 5 ng each before being subjected to in-gel digestion. B) 
Representative analysis graph of light and heavy versions of RAL peptides to determine the 
extent of isotope labelling of full-length PSAQ RAL standards. Low light AUC value in 
comparison to heavy AUC, indicates high levels of heavy amino acid incorporation. C) AUC 



































































PAN RAL - SALTLQFMYDEFVEDYEPTK















PAN RAL - VIMGSGGVGK
isoform peptide sequence light heavy % heavy a.a incorporation
PAN RAL SALTLQFMYDEFVEDYEPTK 9.66E+05 2.26E+07 95.7
PAN RAL VIMVGSGGVGK 3.97E+07 1.06E+09 96.3
RALA
RALB
VKEDENVPFLLVGNK 1.56E+06 5.68E+08 99.7
PAN RAL SALTLQFMYDEFVEDYEPTK 4.59E+05 9.19E+06 95.0
PAN RAL VIMVGSGGVGK 1.09E+07 1.34E+09 99.2






6.2.5 Quantification of endogenous RAL levels in colorectal cell lines 
The measurement of cellular RAL abundance covered a range of colorectal 
cancer cell lines (Table 6.1), including an isogenic panel of SW48 cell lines 
harbouring a range of RAS mutations. Unlike the other colorectal cell lines in 
this analysis, these isogenic cell lines were generated through targeted 
homologous repair in which the endogenous WT RAS allele was exchanged 
for a mutant RAS sequence. The RAS mutation status of each cell line is also 
included in Table 6.1 and represents the KRAS mutations present in over 75% 
of colon tumours (G12D, G12V and G13D), as well as other less prevalent 
KRAS mutations (G12A, G12C, G12R and G12S) (Prior, Lewis and Mattos, 
2012; Vaughn et al., 2011). The SW48 panel of cell lines also included HRAS 
G12V and NRAS G12V mutations. All mutant cell lines except SW620 were 
heterozygous for their respective RAS mutations (COSMIC database). 
 
 
Table 6.1 Panel of colorectal cell lines for PSAQ. 
Cell type RAS mutation status 
CaCo2 WT 
DLD1 KRAS G13D 
HCT116 KRAS G13D 
LoVo KRAS G13D 
SW48 WT 
SW48 HRAS G12V 
SW48 KRAS G12A 
SW48 KRAS G12C 
SW48 KRAS G12D 
SW48 KRAS G12R 
SW48 KRAS G12V 
SW48 KRAS G13D 
SW403 KRAS G12V 




Since the cells from each sample were counted and the cell lysate volume 
measured, it was possible to calculate the number of RAL molecules per cell. 
The total number of RAL molecules was calculated from the PAN RAL peptide 
VIMGSGGVGK and varied across the different cell lines (Figure 6.9A). The 
SW403 cell line had the most RAL out of all the colorectal cell lines tested, 
with 451,792 ± 114,110 RAL molecules. Comparison with other cell lines 
containing an active KRAS G12V mutation (SW48 and SW620) revealed 
noticeably lower values for total RAL with 256,197 ± 52,041 and 169,051 ± 
22,328 respectively. This suggests that the difference in RAL expression is not 
necessarily impacted by KRAS mutation. This is supported by the fact that the 
second highest RAL total was see in the KRAS WT, CaCo2 cell line with 
422,637 ± 99,117 and 349,497 ± 36,899 copies calculated in KRAS G13D 
HCT116 cells. Although it should be pointed out that the variability between 
CaCo2 repeats was highly variable, which could be due to the difficulties in 
handling and counting of this cell line.  
That being said, whilst the SW48 WT, SW48 HRAS G12V and SW48 KRAS 
G13D all display similar levels of total RAL, there was an observable decrease 
in total RAL in SW48 cell lines harbouring a mutation at codon 12 (Figure 
6.9A). Adding to this observation is the fact that the cell line with the lowest 
number of total RAL molecules, SW620, is also the only cell line within the 
panel tested to harbour a homozygous KRAS G12V mutation (Figure 6.9A). 
This decrease in RAL was not associated with a decrease in a particular RAL 
isoform (Figure 6.9B). This suggests that a KRAS specific codon 12 mutation 
may impact both RAL isoforms and RAL expression in general. 
The overall RAL isoform percentage varies between cell line and RAS 
mutation (Figure 6.9B). This again implies that RAS is not the main cause of 
RAL expression level differences. However, a relationship between total RAL 
expression and RAL isoform % expression was visible (Figure 6.10A). On the 
whole, those cell lines with higher numbers of total RAL molecules per cell had 
more RALB expression. Whereas lower total RAL expression correlated with 
equal RAL expression or in the case of SW620 and LoVo, RALA expression 
was dominant (Figure 6.10A). 
Since there were difficulties in identifying certain peaks during sample 
analysis, the sum of RALA and RALB molecules was also calculated for 
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comparison against the PAN RAL values (Figure 6.10B). On the whole these 
two values were similar, providing some confidence in the reliability of all four 
peptides in the quantification of RAL. Again, CaCo2 had noticeable variability 
between PAN RAL and RALA+RALB values (Figure 6.10B). This is likely a 
result of the cell line handling issues mentioned earlier, as well as difficulties 








Figure 6.9 Cellular RAL abundance in colorectal cell lines. 
A) Total number of RAL molecules per cell (PAN RAL) in different colorectal cell lines including 
a panel of SW48 isogenic cell lines with various RAS mutations. B) RAL isoform percentage 
within each cell line. C) Total number of RAL molecules per cell (PAN RAL) across a panel of 
SW48 isogenic cell lines with knock-in RAS mutations. A decrease in RAL expression was 
seen in cell lines harbouring a KRAS mutation at codon 12 vs SW48 WT. KRAS G12A, G12D 
and G12R were significantly decreased (p < 0.05). All bars represent mean ± SE of 3 biological 




Figure 6.10 RAL isoform abundance in colorectal cancer cell lines. 
A) Percentage of RAL isoforms present in colorectal cancer cell lines, in relation to total 
number of molecules per cell (RALA + RALB), ordered highest to lowest RAL abundance. All 
data represent mean ± SE of 3 biological repeats, except SW48 NRAS G12V that is n=1. 
B) number of molecules of RALA and RALB across a panel of colorectal cell lines including 
SW48 isogenic knock-in mutants. Total RAL abundance per cell is also included, along with 






































































































































































The PSAQ method is based on the inclusion of full-length recombinant 
proteins that can be cleaved to produce proteotypic peptides that uniquely 
identify the protein(s) of interest. Candidate peptides are selected based on 
several factors including sequence length, likely charge states, known 
posttranslational modifications (PTM) and the presence of modifiable 
residues. Since many proteomic studies are based on tryptic peptide 
identification, in this instance trypsin was also utilised to proteolyse the 
standards and generate both PAN RAL and isoform specific RAL peptides. 
Whilst this was sufficient in generating peptides that were then successfully 
used to calculate RAL abundance, there were factors associated with each 
peptide, especially the PAN RAL peptides, that hindered the overall process. 
Any PTMs on RAL must be taken into account when selecting appropriate 
peptides for quantification. Both RAL isoforms undergo geranylgeranylation in 
order for proper membrane localisation to take place (Falsetti et al., 2007). In 
addition to these lipid modifications, both RAL isoforms can undergo 
phosphorylation at differing serine residues to allow for subcellular relocation 
and function (Wu et al., 2005; Wang et al., 2010; Sablina et al., 2007; Kashatus 
et al., 2011; Martin et al., 2012). All of these modifications occur in the 
hypervariable region of RAL and therefore any peptides covering this region 
were discounted. RAL isoforms can also be modified on residues outside of 
this region and have both been found to be monoubiquitinated in a 
nondegradative manner (Neyraud et al., 2012). Several lysine (K) residues are 
viable sites for ubiquitination. In particular ubiquitination of K47 in RALB 
determines effector binding and subsequent functionality (Simicek et al., 
2013). This lysine residue is situated at the end of the PAN RAL peptide 
SALTLQFMYDEFVEDYEPTK. The extent of RALB ubiquitination at K47 is 
unclear, although arginine substitution markedly reduced RALB ubiquitination 
levels, so addition of the second PAN RAL peptide VIMGSGGVGK was useful 
in validating PAN RAL levels. Ubiquitination of RALB has also been detected 
at K129 and K160 residues at the end of both RALB specific peptides 
IPLLVVGNK and AEEWGVQYVETSAK (Simicek et al., 2013). Unfortunately, 
these were the only two candidates produced following trypsin digestion that 
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were deemed suitable. Therefore, other proteases may be able to provide 
alternative peptides that can complement the tryptic digest and be utilised for 
future sample analysis if necessary. 
Nearly all the peptides generated included additional residues that can be 
chemically modified, which presents a problem for SRM-based strategies. 
Both PAN RAL peptides included a methionine (M) residue and one also 
contained a glutamine (Q). Both RALA peptides included an asparagine (N) 
residue and one RALA and one RALB-specific peptide also included a 
glutamine. Methionine can undergo modification in the form of oxidation, 
generating methionine sulfoxide or sulfone, resulting in a mass increase of 
15.99 or 31.99 respectively (Ghesquière and Gevaert, 2014). Glutamine and 
asparagine residues can undergo deamidation and be converted into 
glutamate and isoaspartate/aspartate respectively (Geiger and Clarke, 1987; 
Lange et al., 2008; Piszkiewicz, Landon and Smith, 1970), causing an 
increase in mass of almost 1 Da. Changes in mass such as this are 
problematic, since modified peptides will be ejected if not specifically selected 
for in SRM. Chemical modifications will also act to spread the signal of a 
peptide, reducing the sensitivity of the assay, which in this instance is already 
utilising low concentrations of protein standards.  
The use of the PSAQ strategy ought to compensate for any of these acquired 
modifications, since the isotope-labelled standard is added to the sample at 
the earliest possible point in the workflow and therefore should be equally 
affected as the endogenous proteins. However, other common proteases such 
as LysC, elastase and GluC might be worth consideration for their ability to 
generate proteotypic peptide that overcome these problems. In fact, a 
simulated digestion with GluC, which cleaves at the C-terminal end of glutamic 
acid (E) residues, revealed two alternative PAN RAL peptides 
(DYEPTKADSYRKKVVLDGEE, TSAKTRANVDKVFFDLMRE) and two RALB 
specific peptides (DKIPLLVVGNKSDLEE, GFLLVFSITE). However, these 
PAN RAL peptides contain multiple mid-chain highly basic residues that may 
limit their fragmentation and dilute the response signal. Furthermore, one of 
the RALB specific peptides includes the problematic tryptic peptide 
IPLLVVGNK that was completely undetectable under the conditions used in 
this assay. 
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Besides further optimisation of peptide generation and selection, other steps 
could be taken to enhance peptide detection and increase reliability in peptide 
peak presence. It was highlighted early on in the PSAQ process that 
contamination from residual Triton X-100 lysis buffer and/or acrylamide within 
the gel was interfering with data acquisition on the mass spectrometer. This 
meant that optimisation steps to reduce the volume of gel excised, whilst still 
having sufficient material for MS analysis was required. In addition to using an 
alternative NP40 based lysis buffer, lowering the acrylamide percentage, 
running the gel just far enough to get clear resolution of the protein ladder, as 
well as using small, narrow lanes, reduced the size of the gel piece excised 
eliminated the problems initially seen when processing samples. As such only 
20 µg of cell lysate with ng volumes of standards were used in the final sample 
preparations. Using lower concentrations also reduces the visibility of peptide 
peaks and increases background noise. During data analysis the parameters 
can be adjusted to display the retention times for lower intensity peaks. Whilst 
this was necessary to detect the low concentration of standards and 
endogenous protein levels involved, it should be pointed out that quantifying 
peaks below the limit of quantification is not advisable. This limitation is defined 
in various ways, with the most common one being the lowest calibration 
standard with a percentage coefficient of variation (CV) less than 20. Whilst 
almost all the intensity peaks were clear enough to provide a certain degree 
of confidence during peptide identification, upscaling the amount of cell lysate 
and spike-in standard concentration to those above the normal detection 
values, in combination with an in-solution digest protocol to eliminate gel 
contaminants would be desirable. 
 
Regardless of any issues in peptide detection and sample preparation, the 
presented data represents the most accurate quantification of cellular RAL 
isoform abundance to date. By calculating RAL protein expression across a 
variety of relevant human cancer cell lines, insight was gained into the factors 
that may impact RAL-dependent signalling and oncogenic RAS. 
Overall, the total RAL expression differed greatly from line to line, with over 
500,000 copies per cell difference calculated between the highest and lowest 
recorded values. Excluding the CaCo2 cell line, the two cell lines with the 
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highest RAL abundance were SW403 and HCT116. This implies the presence 
of highly active RAL signalling in these cell lines, as well as placing a certain 
degree of dependency on the RALGEF/RAL pathway in carrying out various 
functions. Indeed, out of a panel of colorectal cell lines including the same 
ones analysed in this study, HCT116 and SW403 displayed the strongest 
decrease in cell viability following RAL knockdown (Lee et al., 2019). As well 
as high total RAL expression, these cell lines reported high RALB levels as 
well as RALB being the dominant isoform expressed. This link between cell 
viability, high total RAL and high RALB abundance is consistent with the 
findings that RALB was found to be more important for cell survival, with 
transformed cell lines undergoing apoptotic cell death following RALB 
knockdown (Chien and White, 2003). In addition to HCT116 and SW403, 
RALB was found to be the dominant isoform across the cell lines tested or was 
in equal abundance to RALA. Indeed, the RAL activity assay performed in the 
previous chapter support the notion that a certain level of both RALA and 
RALB is required in these cells, since activity increases in the remaining RAL 
were detected following isoform specific knockout, across all cell lines tested. 
This is in contrast to RAL expression in pancreatic cell lines, in which RALA 
was found to be the dominant isoform expressed and RALB was in fact 
undetectable in pancreatic islets (Ljubicic et al., 2009). This highlights the 
differences in RAL requirements between cell types and needs to be taken 
into consideration when investigating any role that RAL might play in the 
dysregulation of cellular processes.  
The inclusion of the SW48 isogenic cell lines allowed us to determine the 
effect, if any, of different RAS mutations on RAL protein abundance. The first 
and second most abundant KRAS mutation in colorectal cancer are G13D and 
G12V respectively (Vaughn et al., 2011). As previously mentioned, cell lines 
SW403 and HCT116 that carry these mutations, displayed high RAL 
abundance supporting a link between mutant RAS and increased RAL 
expression levels. Interestingly, SW48 cell lines harbouring these same 
mutations did not induce significant changes in RAL expression. However, it 
is important to point out that the SW48 cell line is not dependent on RAS to be 
viable and therefore may not be a true representation of RAS driven signalling. 
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In relation to mutant RAS and oncogenic activity, HRAS G12V mutants that 
activate different RAS effector pathways, have shown that it is the RALGEF 
pathway that is sufficient for RAS transformation in human cells (Hamad et al., 
2002). Additionally, early RAS research shows HRAS G12V mutation have the 
greatest potency compared to other HRAS mutations (Der, Finkel and Cooper, 
1986; Seeburg et al., 1984; Sloan, Newcomb and Pellicer, 1990).  
Furthermore, similar protein abundance studies currently being conducted in 
our lab found that the SW48 HRAS G12V cell line had more total RAS than 
the SW48 parental and other mutation cell lines (Hood et al. unpublished). 
Therefore, it is perhaps surprising that the overall RAL expression in the SW48 
HRAS G12V cell line has not deviated from that recorded in the SW48 
parental, neither is there one RAL isoform whose expression dominates the 
other. Again, this lack of change in RAL abundance suggests that mutant RAS 
does not impact RAL expression and consequently does not contribute to RAS 
oncogenicity. However, as well as the limitations associated with this cell lines, 
it is important to remember that this assay is only indictive of protein 
expression not activity. Therefore, it is beneficial to refer to the activity assays 
performed in the previous chapter that showed the RAL knockout cell lines 
with mutant RAS had significant activity compensation compared to SW48 
RAS WT. Since mutant RAS expression is associated with oncogenic 
transformation, any involvement of the RALGEF/RAL pathway may be due to 
changes in activity, not expression. Moreover, the transformation potential of 
different RAS effectors reportedly varies in rodents depending on cell type 
(Cowley et al., 1994; Mansour et al., 1994; Oldham et al., 1996). It is possible 
that transformation of human cells seen using RALGEF specific RAS effector 
mutants may be restricted to specific cell types and determining RAL 
abundance and activity levels in cancer cell lines with alternative tissue origins 
is desirable. Again, focusing on the SW48 isogenic cell lines, with the 
exception of HRAS G12V and KRAS G12V, those with a mutation at codon 12 
displayed reduced RAL expression compared to SW48 parental. This implies 
that G12 RAS mutations may actively effect RAL abundance and in fact 
suppress RAL-driven processes. 
In relation to G12V mutations, even though cell lines harbouring a KRAS G12V 
mutation were found to have some of the highest levels of RAL expression, 
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SW620 cells that also have this mutation contain the lowest RAL abundance 
out of any of the cell lines tested. This is despite SW620 being homozygous 
for mutant KRAS. However, since RAS mutations induce cellular stress 
(Grabocka and Bar-Sagi, 2016), a homozygous KRAS G12V mutation could 
produce such a prolific oncogenic signal that the cells actively limit its cellular 
abundance and consequently RAL expression. 
In general, this analysis of RAL isoform abundance suggests that regardless 
of RAS status, high RAL abundance contributes to a strong RAL signalling 
response and varying RAL expression levels is determined by the overall 
expression profile of the cell. Nevertheless, the data collected here indicates 
that mutant RAS can influence RAL, although it appears that this is not solely 
confined to changes in expression but may present as a change in RAL activity 
instead. It seems that for the most part, colorectal cancer cell lines are reliant 
on both RAL isoforms, with a small bias towards RALB expression. This is 
reflected in the activity assays. Indeed, when combined with the RAL activity 
data collected, it is likely that abundance and activity work together to carry 

















Chapter 7: Outlook and future work 
The small GTPase RAL is known to have a role in many different cellular 
functions (Feig, 2003; Gentry et al., 2014). That being said, the majority of our 
understanding of RAL signalling has been inferred from knockdown/ectopic 
expression studies, often in mouse or human cell lines that are not RAS 
addicted or prone to RAS-dependent malignancies. Furthermore, whilst 
several distinct functions can be associated with each RAL isoforms, isoform 
specific RAL biology remains a relatively unexplored area and outside of its 
immediate effectors, the RAL pathway is still poorly understood in comparison 
to other RAS effector pathways. Therefore, this study focused on investigating 
isoform specific RAL signalling at the endogenous level in an appropriate 
human cell model. 
 
In the initial stages of this project, I successfully generated isoform-specific 
RAL knockout clones across several colorectal cancer cell lines using the 
CRISPR/Cas9 system, as well as optimised the tools necessary to establish 
gain-of-function knock-in cell lines.  
The discovery of the CRISPR/Cas9 system has revolutionised gene editing 
across many areas of biomedical research including model cell line 
development. Its increasing popularity and widespread use can be explained 
through its simplicity and flexibility to target nearly any location within the 
genome. Although there are many advantages to other gene editing tools, 
such as ZFNs and TALENs, they lack the versatility associated with CRISPR 
and can often require more complex expertise in molecular biology. However, 
the CRISPR/Cas9 system suffers from its own set of drawbacks, particularly 
those focusing on its efficacy that remain to be fully addressed. These factors 
include on- and off-target cleavage, guide design, DNA repair (NHEJ and 
HDR) efficiency and delivery of the required components. These last two 
points in particular were challenges faced in this project when trying to 
establish knock-in cell lines. As well as working with the low knock-in efficiency 
associated with HDR, low transfectability of target cell lines hindered this 
process and steps were taken to optimise this strategy to aid component 
delivery into cells that are hard to transfect. As a result of these technical 
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issues and subsequent time constraints, RAL G23V knock-in cells were not 
generated. In addition to complementing the data obtained from the knockout 
cell panel, establishing gain-of-function cell lines would enable the 
investigation of constitutively active RAL at endogenous levels and any part it 
may play in the role of oncogenic RAS. Nevertheless, the capability of the 
CRISPR/Cas9 system to precisely edit RAL gene sequences and halt gene 
expression by generating RAL knockouts has been demonstrated. Studying 
protein function through CRISPR/Cas9 generated gene knockouts is 
advantageous over RNAi-based knockdowns, as it is a permanent change that 
guarantees 100% knockout efficiency due to the selection of a single clone. 
Currently, these clones are the first to be created for the use of investigating 
endogenous RAL isoform signalling in a cancer relevant panel of human cell 
lines. 
 
A combination of methodologies was applied to this cell panel, in order to 
obtain an insight into cellular RAL isoform signalling under different oncogenic 
RAS mutations. Determining RAL activity through pulldown of GTP-bound 
RAL revealed a compensatory increase in activity (significant RALB activity 
increase in RALA KO clones harbouring mutant RAS) in the remaining RAL 
isoform in the knockout clones compared to the parental clones. This is in 
concordance with a study conducted in mice cells, that also showed activity 
compensation following single RAL isoform deletion (Peschard et al., 2012). 
This compensatory increase raises the question of whether there is functional 
redundancy between the two isoforms. Indeed, this same study demonstrated 
deletion of both RAL GTPases impaired cell proliferation, whilst single gene 
knockout did not. Hence, isoform activity compensation suggests that the 
overall level of RAL activity is a crucial factor in RAL signalling response, not 
just the expression levels of a specific isoform. Going forward it would be 
beneficial to extend these findings to the SW48 isogenic cell lines to determine 
the direct impact of RAS mutational status on RAL activity. It would also be 
beneficial to test these functional implications through proliferation assays in 
our panel of cell lines to confirm this redundancy in a human model. Moreover, 
these assays could be applied to knock-in cell lines to help characterise 
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functional responses associated with constitutively active RAL which mimics 
signalling dysregulation. 
The observation of isoform compensation was subsequently also seen in the 
cell lines that underwent omic profiling. Whilst the expression of genes and 
proteins in the KO clones compared to the parental were often different 
between the two cell lines, changes in expression nearly always trended in the 
same direction between RAL isoforms. An interesting observation was the lack 
of responses within the immediate RAL network. Whilst the RPPA assay did 
not cover many of the interactors involved in the RAL pathway, the RNAseq 
data and immunoblotting validation failed to highlight any significant changes 
in known RAL effector proteins. Since the RAL isoforms interact with many of 
the same set of proteins, it’s likely that the compensation in activity carries 
over into effector interactions and therefore little change in expression of 
effectors is not surprising. 
Nevertheless, this unbiased multi-omic approach has allowed us to study RAL 
isoform specific signalling in a wider context. Indeed, RNA sequencing and 
RPPA analyses revealed a subset of RAL responsive proteins that were 
suggestive of crosstalk between the RALGEF/RAL pathway and the other 
main pathways downstream of RAS (MAPK and PI3K). Out of the several 
proteins shortlisted for further investigation, differential expression of DUSP5, 
EphA2 and WEE1 was confirmed by immunoblotting. However, further 
validation is needed to characterise these proteins as part of RAL signalling. 
Of these, only a link between RAL and EphA2 has been recorded in previous 
studies. It seems likely that RAS signalling is based on a complex network of 
nodes rather than just the classical linear pathways that are more familiar. 
Potential crosstalk between pathways also presents the idea of signalling fail 
safes that ensure RAS-driven functionality, that could be taken advantage of 
by oncogenic RAS especially following therapy-induced resistance. Therefore, 
it would be desirable to subject knock-in RAL mutant cells to assays (with and 
without RAS pathway inhibitors) that would determine invasiveness, 
proliferation and cell viability, to ascertain the impact of RAL dysregulation. 
However, analysis at both the transcriptome and proteome level also revealed 
how different the expression profiles of cell lines can be, even if they have the 
same tissue origin. Both cell lines appeared to activate distinct sets of proteins, 
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suggesting differential signalling occurs downstream of RAS and therefore 
RAL, depending on the overall profile of the cell. This highlights how important 
it is to choose the right cell lines when investigating cell signalling proteins 
such as these. It also shows how regardless of the similarities in mutation 
status of direct RAL regulators, the overall expression of the proteome is the 
overriding factor that impacts the signalling response of RAL and how this 
pathway interacts as part of a larger network. Future studies in this field need 
to be aware of these concepts and not extrapolate from an observation in a 
single cell line. Indeed, large-scale studies looking at endogenous mutant 
KRAS signalling dependencies showed significant heterogeneity in effector 
requirements between cell lines with each line requiring a unique combination 
of effector interactions (Yuan et al., 2018). This is also an important 
consideration when inferring a role for RAL in the oncogenicity of RAS. 
Although RAL can be implicated in a variety of RAS-driven functions such as 
cell proliferation and survival, the contribution and dependency of RAL 
signalling is likely to differ on a case by case basis. 
Finally, the SRM-based quantification method in combination with PSAQ 
standards has enabled the most accurate measurement of cellular RAL 
isoforms to date. Following adaptation and optimisation of this technique for 
use against RAL, it reliably detected both RALA and RALB at endogenous 
levels, as well as peptides shared between both isoforms to verify the isoform-
specific quantification. Moreover, the PSAQ method accounted for variations 
in the recovery of peptides due to gel excision difference and incomplete 
proteolysis. Importantly, this technique is easily implementable in most 
biological laboratories due to the familiarity with SDS-PAGE fractionation and 
lack of specialist knowledge required for the in-gel digestion steps. As a result, 
this technique would easily enable the quantification of cellular RAL 
abundance across any cell line and even tissue samples.  
In this instance, abundance was calculated in a variety of different colorectal 
cancer cell lines, as well as in an isogenic panel of SW48 cells. It seems that 
for the most part, colorectal cancer cell lines require sufficient levels of both 
RAL isoforms for proper signalling, with a small bias towards RALB 
expression. This again supports the idea of high levels of functional 
compensation between the two isoforms in colorectal cancer, with any 
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differences in RAL isoform function resulting from changes in location and 
posttranslational modifications. Finally, looking at the abundance dataset in 
conjunction with the isoform activity analysis, it seems that the mutation status 
of RAS may directly influence RAL, affecting a combination of abundance and 
activity levels. 
Together, the data presented in this thesis allows us to build knowledge of the 
specific set of requirements needed in both normal and pathophysiological 
RAL signalling. Knowing how these different factors combine together, helps 



























































Supplementary Figure 7.1 psPAX2-D64V plasmid map. 
The psPAX2-D64V plasmid was obtained from Addgene (#63586) and is a packaging plasmid 
used for generating integrase deficient lentiviral vectors due to a point mutation in the 
integrase gene. This stops any fluorescent markers from the transfer plasmid, such as the 
EGFP present in the pLeGO plasmid, from inserting into the target genome which would 






Supplementary Figure 7.2 pBABE-puro plasmid map.  
All the WT and mutant RAL constructs were derived from the pBABE-puro plasmid (Addgene 





Supplementary Figure 7.3 ptrcHisA plasmid map.  
The ptrcHisA plasmid was used to generate His-tagged WT RALA and WT RALB recombinant 
proteins for PSAQ. Importantly, this plasmid contains the sequence for the LacI gene that is 
required for successful IPTG induction and subsequent production of T7 RNA polymerase for 




Supplementary Figure 7.4 LentiCRISPR V2 plasmid map. 
This plasmid is a lentiviral SpCas9 expressing plasmid purchased from Addgene (#52961). 
The EF-1ɑ core promoter in the original plasmid was replaced with a SFFV promoter. To allow 
cloning of gRNAs, the plasmid was digested with BsmBI to remove the stuffer region before 




Supplementary Figure 7.5 pCW-Cas9 plasmid map. 
This plasmid expresses a doxycycline inducible lentiviral SpCas9 with a blasticidin antibiotic 
selection marker. The Cas9 enzyme is under the control of a Tet-ON promoter. Purchased 








Supplementary Figure 7.6 pLeGO plasmid map. 
The pLeGO lentiviral plasmid was initially purchased from Addgene (#27341) and expresses 
EGFP under the control of an SFFV promoter. For CRISPR use, this plasmid was modified to 
contain two multiple cloning sites (MCS, RH and LH depicted in red) that sit either side of the 
EGFP selection marker. The additional cloning sites allowed cloning of gRNA#4 into the RH 







Supplementary Figure 7.7 pEGFP-C1 plasmid map. 
The pEGFP-C1 plasmid expresses an EGFP fluorescent marker under the control of a CMV 
promoter. This plasmid was used to assess transfection efficiency and plasmid uptake. 
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Supplementary Figure 7.8 RAL isoform activity in HCT116 PAR and KO repeats. 
Following treatment with 50 ng/mL EGF for 2 minute, HCT116 RALB KO clones, BKO1 and 
BKO2, displayed a small increase in RALA activity compared to the parental (PAR1 and 
PAR3). An obvious increase in RALB activity was observed in both RALA KO clones (AKO1 
and AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 








Supplementary Figure 7.9 RAL isoform activity in SW48 PAR and KO repeats. 
Following treatment with 50 ng/mL EGF for 2 minutes, a clear increase in RALB activity was 
observed in both RALA KO clones (AKO1 and AKO2) vs PAR2 and PAR3 in SW48. Whole 
lysates were prepared, and 400 µg was incubated with GST-RALBD beads which were run 








Supplementary Figure 7.10 RAL isoform activity in SW403 PAR and KO repeats. 
Following treatment with 50 ng/mL EGF for 2 minute, SW403 RALB KO clones, BKO1 and 
BKO2, displayed a small increase in RALA activity compared to the parental (PAR1 and 
PAR3). An obvious increase in RALB activity was observed in both RALA KO clones (AKO1 
and AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 






Supplementary Figure 7.11 RAL isoform activity in SW620 PAR and KO repeats. 
Following treatment with 50 ng/mL EGF for 2 minute, SW620 RALB KO clones, BKO2 in 
particular, displayed a small increase in RALA activity compared to the parental (PAR1 and 
PAR3). An obvious increase in RALB activity was observed in both RALA KO clones (AKO1 
and AKO2). Whole lysates were prepared, and 400 µg was incubated with GST-RALBD beads 




Supplementary Table 7.1. GO analysis for SW403 DEGs collected from RNAseq. 
 
GO code Description Gene list
GO:0006260 DNA replication
LIG1, RMI2, MCM2, RNASEH2A, MCM3,
MCM4, MCM5, MCM6, RPA1, POLD4, POLE2,
CHTF18, RBM14, EGF, ORC1
GO:0001525 angiogenesis
COL18A1, NRP1, TNFRSF12A, NOX1, CSPG4,
JAG1, MMRN2, TGFB2, EREG, SRPX2,
UNC5B, ID1, PTK2B, DLL4, PLCD3, ADM2,
EGF, PLXND1
GO:0000082 G1/S transition of mitoticcell cycle
RPA1, CDKN1A, PLK3, POLE2, PLK2, MCM2,
MCM3, MCM4, ORC1, MCM5, MCM6
GO:0000188 inactivation of MAPKactivity
DUSP5, DUSP4, DUSP18, DUSP1, RGS3,
DUSP8
GO:0008134 transcription factorbinding
BCL10, ARHGEF2, CEBPB, FOXA3, FHL2,
SMAD3, HES6, IFI16, FOSB, DDIT3, TRIB1,
MED19, GATA2, FOS, ID1, ETS1, GPX3, BCL3,
PITX2
GO:0016266 O-glycan processing ST3GAL1, MUC2, ST6GAL1, GALNT6,GALNT5, B3GNT6, GCNT1, MUC4
GO:0031581 hemidesmosomeassembly COL17A1, LAMB3, LAMA3, LAMC2
GO:0006915 apoptotic process
STEAP3, DPF2, KRT20, ZC3H8, UNC5B,
PTK2B, PCSK9, INPP5D, PHLDA2, IL1A,
PHLDA1, BCL10, BCL2L14, PTPRH, MCM2,
DAPK2, DDIT3, WDR92, RNF130, RASSF5,
PLK3, RASSF6, BBC3, CSRNP1, GADD45A,
DRAM1, PPP1R15A, TRIM39
GO:0007173 EGFR signalling pathway EREG, PLCG1, PTK2B, GAREM1, HBEGF,AREG, EGF
GO:0034976 response to endoplasmicreticulum stress
CEBPB, WFS1, BBC3, ERN1, TRIB3,
FAM129A, PPP1R15A, DDIT3
GO:0008284 positive regulation of cellproliferation
COL18A1, FGF19, NOX1, GAREM1, EFNB2,
IL6R, PROX1, PLAC8, TGFB2, PTHLH,
AKR1C2, ATF3, EREG, ETS1, PTK2B, CLCF1,
ADRA2A, HBEGF, CEACAM6, CHRNA7,
LAMC2, AREG, EGF, FOSL1
GO:0009612 response to mechanicalstimulus
TXNIP, ETS1, PTK2B, FOSB, IGFBP2, FOSL1,
KALRN
GO:0003779 actin binding
CAP2, CNN3, MYO7B, BAIAP2L1, MICAL2,
ABLIM3, FSCN1, SPIRE1, FMN1, CORO1A,
SYNE1, TNS1, EPB41L1, CGN, GSN, FHOD1
GO:0008285 negative regulation of cellproliferation
COL18A1, KLF10, TIMP2, PROX1, TGFB2,
PTHLH, RASSF5, CDKN1A, SERPINE2, EREG,
CDKN2B, NME1, ETS1, PTK2B, DLL4, FOSL1,
SMARCA2, IL1A, KLF4, NEURL1
GO:0022617 extracellular matrixdisassembly
LAMB3, LAMA3, GSN, MMP7, LAMC2, TIMP2,
SPP1
GO:0007264 small GTPase mediatedsignal transduction
RAB3B, RAB7B, RALGDS, RND3, RAB32,
ARHGAP32, SH2D3A, RAB30, RAB43, ARL14,
RASL10B, RAB14, RAPGEF1, RASD2
GO:0048870 cell motility SRPX2, ETS1, FSCN1, EPHA2
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Supplementary Figure 7.12 Validation of key hits from RNAseq and RPPA data in 
SW403 KOs repeats. 
Immunoblotting of EphA2 and WEE1 confirmed the changes in protein expression detected 
in the RPPA analysis, with an increase in EphA2 and a decrease in WEE1 levels in the RAL 
AKO and BKO clones versus parental. An increase in DUSP5 expression was seen in the KO 




Supplementary Figure 7.13 Validation of key hits from RNAseq and RPPA data in 
SW403 parental, isoform specific RAL knockout clones and knockout clones stably re-
expressing WT RAL repeats. 
SW403 RALA knockout clones were transduced with retrovirus to re-express WT RALA and 
RALB knockout clones were transduced with retrovirus to re-express WT RALB. Expression 
of WT RAL partially restored WEE1, DUSP5 and p-EphA2 (Ser897) expression to that of the 
parental clones in some cases. Expression levels of transduced WT RAL do not reach those 
of the endogenous levels seen in the parental clones. 
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Supplementary Figure 7.14 Expression of known and potential RAL interactors in 
SW403 PAR clones following isoform specific knockdown. 
No expression changes were observed in known RAL effectors following isoform specific 
knockdown of RAL in SW403 parental clones (PAR1 and PAR3). There were also no clear 
expression changes in potential hits identified from the RNAseq and RPPA analysis following 











Supplementary Figure 7.15 Test induction of recombinant His-RALB protein. 
The optimal induction conditions of His-RalB were determined using increasing IPTG 
concentrations (0.5-5 mM), combined with either a 3-hour incubation at 37°C or overnight at 
room temperature. Note 3 hours at the higher temperature is sufficient for His-RalB induction 
as a longer incubation leads to degradation of the protein. 
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Supplementary Figure 7.16 Protein purification of WT His-RALA (Light) using the AKTA 
purifier system. 
(A) Elutions collected after initial purification on the AKTA purifier system using HisTrap HP 
following loading of AT713 bacterial supernatant. Induced WT His-RALA (light) protein was 
present in fractions D6-C8. (B) WT His-RALA (light) protein was present in elutions E8-F8 
following gel filtration. Fractions E2-E12 show contamination with different protein. (C) 
Western blot of gel filtration elutions E8-F9 confirm the presence of RALA and the co-
localisation of the His-tag. 
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Supplementary Figure 7.17 Protein purification of WT His-RALA (Heavy) using the 
AKTA purifier system. 
(A) Elutions collected after initial purification on the AKTA purifier system using HisTrap HP 
following loading of AT713 bacterial supernatant. Induced WT His-RALA (heavy) protein was 
present in fractions C5-C12. (B) WT His-RALA (heavy) protein was present in elutions E8-F9 
following gel filtration. Fractions E8-E9 show contamination with different protein. (C) Western 






Supplementary Figure 7.18 Protein purification of WT His-RALB (Light) using the 
AKTA purifier system. 
(A) Elutions collected after initial purification on the AKTA purifier system using HisTrap HP 
following loading of AT713 bacterial supernatant. Induced WT His-RALB (light) protein was 
present in fractions B2-B12. (B) WT His-RALB (light) protein was present in elutions E2-E12 
following gel filtration. Fractions E2-E9 show contamination with different protein. (C) Western 




Supplementary Figure 7.19 Protein purification of WT His-RALB (Heavy) using the 
AKTA purifier system. 
(A) Elutions collected after initial purification on the AKTA purifier system using HisTrap HP 
following loading of AT713 bacterial supernatant. Induced His-RALB (heavy) protein was 
present in fractions C7-D8. (B) His-RALB (heavy) protein was present in elutions E8-F10 
following gel filtration. Fractions E8-E9 show contamination with different protein. (C) Western 




Supplementary Figure 7.20 MS/MS transition spectra for RALA peptides. 
100 ng of His-tagged RAL isoforms were subjected to LC-MS/MS analysis for detection of 
candidate peptides. Both RALA specific peptides were detected. Despite 
VKEDENVPFLLVGNK including a miscleavage, the more consistent readings meant it was 




Supplementary Figure 7.21 MS/MS transition spectra for RALB peptides. 
100 ng of His-tagged RAL isoforms were subjected to LC-MS/MS analysis for detection of 
candidate peptides. Both RALB specific peptides were detected at this concentration. 
However, when repeated at lower concentrations required for sample processing, peptide 
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